var title_f35_15_36080="Mometasone: Drug information";
var content_f35_15_36080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mometasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/23/38261?source=see_link\">",
"       Mometasone (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/11/34998?source=see_link\">",
"       Mometasone (oral inhalation): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/46/43748?source=see_link\">",
"       Mometasone (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9663 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36080=[""].join("\n");
var outline_f35_15_36080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/23/38261?source=related_link\">",
"      Mometasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/11/34998?source=related_link\">",
"      Mometasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/46/43748?source=related_link\">",
"      Mometasone (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36081="M-mode echocardiogram in cardiac tamponade";
var content_f35_15_36081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram in cardiac tamponade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode echocardiogram showing respiratory motion of the interventricular septum in cardiac tamponade such that during inspiration, the right ventricle enlarges, and the left ventricle becomes smaller.",
"    <div class=\"footnotes\">",
"     RV-I: right ventricle in inspiration; RV-E: right ventricle in expiration; LV-I: left ventricle in inspiration; LV-E: left ventricle in expiration.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission of the American Heart Association from Settle, et al. Circulation 1977; 56:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36081=[""].join("\n");
var outline_f35_15_36081=null;
var title_f35_15_36082="Sore throat in adults";
var content_f35_15_36082=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sore throat in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/15/36082/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36082/contributors\" id=\"au3749\">",
"       Wendy Stead, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/15/36082/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36082/contributors\" id=\"se6334\">",
"       Mark D Aronson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/15/36082/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36082/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/15/36082?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     A sore throat (pharyngitis) is a common problem and usually is caused by a viral or bacterial infection. Sore throat usually resolves on its own without complications in adults, although it is important to know when to seek medical attention.",
"    </p>",
"    <p>",
"     Viruses can cause a sore throat and other upper respiratory infections, such as the common cold. Sore throat caused by a virus is not treated with antibiotics, but instead may be treated with rest, pain medication, and other therapies aimed at relieving symptoms.",
"    </p>",
"    <p>",
"     Strep throat is a particular kind of pharyngitis that is caused by a bacterium known as group A streptococcus (GAS). Strep throat is treated with a course of antibiotics.",
"    </p>",
"    <p>",
"     A topic that discusses sore throat in children is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/22/3427?source=see_link\">",
"      \"Patient information: Sore throat in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SORE THROAT SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Viral pharyngitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with a sore throat have a virus. The most common viruses are those that cause upper respiratory infections, such as the common cold. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44210?source=see_link\">",
"      \"Patient information: The common cold in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Symptoms of a viral infection can include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A runny or congested nose",
"      </li>",
"      <li>",
"       Irritation or redness of the eyes",
"      </li>",
"      <li>",
"       Cough, hoarseness, or soreness in the roof of the mouth",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some viruses cause a fever and can make you feel quite ill.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Strep throat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 10 percent of adults with a sore throat have strep throat. Signs and symptoms of strep throat include the following (",
"     <a class=\"graphic graphic_figure graphicRef78761 \" href=\"mobipreview.htm?8/28/8641\">",
"      figure 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pain in the throat",
"      </li>",
"      <li>",
"       Fever (temperature greater than 100.4&ordm;F or 38&ordm;C)",
"      </li>",
"      <li>",
"       Enlarged lymph glands in the neck",
"      </li>",
"      <li>",
"       White patches of pus on the side or back of the throat",
"      </li>",
"      <li>",
"       No cough, runny nose, or",
"       <span class=\"nowrap\">",
"        irritation/redness",
"       </span>",
"       of the eyes",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Other infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many other less common but more serious infections can cause a sore throat, including mononucleosis (mono), influenza (the flu), N. gonococcus (gonorrhea), human immunodeficiency virus (HIV), and others. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/0/7170?source=see_link\">",
"      \"Patient information: Symptoms of HIV infection (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"      \"Patient information: Gonorrhea (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/11/176?source=see_link\">",
"      \"Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      When to seek urgent help",
"     </span>",
"     &nbsp;&mdash;&nbsp;See your doctor or nurse immediately if you have a sore throat along with any of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Difficulty breathing",
"      </li>",
"      <li>",
"       Skin rash",
"      </li>",
"      <li>",
"       Drooling because you cannot swallow",
"      </li>",
"      <li>",
"       Swelling of the neck or tongue",
"      </li>",
"      <li>",
"       Stiff neck or difficulty opening the mouth",
"      </li>",
"      <li>",
"       Underlying chronic",
"       <span class=\"nowrap\">",
"        illness/medication",
"       </span>",
"       that may impair your immune system",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      SORE THROAT DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Most people with a sore throat get better without treatment. There is no specific treatment for a sore throat caused by usual cold viruses.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Is it strep or not?",
"     </span>",
"     &nbsp;&mdash;&nbsp;A combination of symptoms (fever, enlarged glands in the neck, white patches on your tonsils, and no cough) can help in determining if you have strep. If you have two or more symptoms, a rapid test or throat culture may be done. People with fewer than two symptoms usually do not need testing or treatment for strep throat, though they may benefit from treatment with modalities for symptom reduction.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Rapid test",
"     </span>",
"     &nbsp;&mdash;&nbsp;The rapid test determines if there are streptococcus bacteria on a throat swab. The test may be done in a clinician's office and the results are available within a few minutes. The test is accurate in most cases, although a small percentage of tests are falsely negative (the bacteria are present but the test is negative) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/15/36082/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Throat culture",
"     </span>",
"     &nbsp;&mdash;&nbsp;A throat culture involves swabbing the throat, sending the swab to a laboratory, and waiting 24 to 48 hours for the results. Throat cultures are slightly more accurate than the rapid test.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      TREATMENT OF SORE THROAT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Sore throat treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics do not help throat pain caused by a virus and are not recommended. Inappropriate use of antibiotics for viral illness can unnecessarily expose patients to side effects like diarrhea, rash, or more serious allergic reactions. Sore throat caused by viral infections usually lasts four to five days. During this time, treatments to reduce pain may be helpful. Several therapies can help to relieve throat pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Pain medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;You can treat your throat pain with a mild pain reliever such as acetaminophen (Tylenol&reg;) or a non-steroidal anti-inflammatory agent such as ibuprofen or naproxen (Motrin&reg; or Aleve&reg;). Both have been shown to provide fast and effective relief of sore throat pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Oral rinses",
"     </span>",
"     &nbsp;&mdash;&nbsp;Salt-water gargles are an old stand-by for throat pain. It is not clear that salt water works to relieve pain, but it is unlikely to be harmful. Most recipes suggest",
"     <span class=\"nowrap\">",
"      1/4",
"     </span>",
"     to",
"     <span class=\"nowrap\">",
"      1/2",
"     </span>",
"     teaspoon (1.5 to 3.0 g) of salt per one cup (8 ounces or 250 mL) of warm water.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Sprays",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sprays containing topical anesthetics (eg, benzocaine, phenol) are available to treat sore throat. However, such sprays are no more effective than sucking on hard candy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Lozenges",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of lozenges (cough drops) containing topical anesthetics are available to treat throat pain or relieve dryness Lozenges may persist longer in the throat than sprays or gargles and thus, may be more effective for symptom relief [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/15/36082/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Other treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other treatments that may help with throat pain include sipping warm beverages (eg, honey or lemon tea, chicken soup), cold beverages, or eating cold or frozen desserts (eg, ice cream, popsicles).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Alternative therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Health food stores, vitamin outlets, and Internet Web sites offer alternative treatments for relief of sore throat pain. We do not recommend these type of treatments due to the risks of contamination with",
"     <span class=\"nowrap\">",
"      pesticides/herbicides,",
"     </span>",
"     inaccurate labeling and dosing information, and a lack of studies showing that these treatments are safe and effective.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Strep throat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although strep throat typically resolves on its own within two to five days, treatment with antibiotics is recommended for adults whose rapid test or throat culture is positive for strep throat [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/15/36082/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Penicillin, or an antibiotic related to penicillin, is the treatment of choice for strep throat. It is usually given in pill or liquid form two to four times per day for 10 days. A one-time injection of penicillin is also available. People who are allergic to penicillin are given an alternate antibiotic. It is important to finish the entire course of treatment to completely eliminate the infection.",
"    </p>",
"    <p>",
"     If symptoms do not begin to improve or worsen by three days of antibiotic treatment, you should see your doctor or nurse again.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Return to work/school",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have been diagnosed with strep throat, stay home from work or school until you have completed 24 hours of antibiotics. Within 24 hours of beginning antibiotic treatment, you will feel better and will be less contagious [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/15/36082/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     If you have a sore throat (not diagnosed as strep), you may participate in your usual activities as soon as you feel well, though practical prevention measures such as good hand washing and cough etiquette should be observed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      SORE THROAT PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Hand washing is an essential and highly-effective way to prevent the spread of infection. Wet your hands with water and plain soap, and rub them together for 15 to 30 seconds. Pay special attention to the fingernails, between the fingers, and the wrists. Rinse your hands thoroughly, and dry them with a clean towel.",
"    </p>",
"    <p>",
"     Alcohol-based hand rubs are a good alternative for disinfecting hands if a sink is not available. Hand rubs should be spread over the entire surface of hands, fingers, and wrists until dry, and may be used several times. These rubs can be used repeatedly without skin irritation or loss of effectiveness. Hand rubs are available as a liquid or wipe in small, portable sizes that are easy to carry in a pocket or handbag. When a sink is available, visibly soiled hands should be washed with soap and water.",
"    </p>",
"    <p>",
"     Wash your hands after coughing, blowing the nose, or sneezing. While it is not always possible to avoid being near a person who is sick, avoiding touching your eyes, nose, or mouth to prevent the spread of infection.",
"    </p>",
"    <p>",
"     In addition, tissues should be used to cover the mouth when sneezing or coughing. These used tissues should be disposed of promptly.",
"     <span class=\"nowrap\">",
"      Sneezing/coughing",
"     </span>",
"     into your sleeve (at the inner elbow) is another way to contain sprays of saliva and secretions and will not contaminate your hands.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285037\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285044\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/57/914?source=see_link\">",
"      Patient information: Sore throat in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/29/26066?source=see_link\">",
"      Patient information: Laryngitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/10/19618?source=see_link\">",
"      Patient information: Cytomegalovirus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/24/20866?source=see_link\">",
"      Patient information: Erythema nodosum (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285067\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/22/3427?source=see_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44210?source=see_link\">",
"      Patient information: The common cold in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/0/7170?source=see_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/11/176?source=see_link\">",
"      Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/59/40881?source=see_link\">",
"      Patient information: Scarlet fever (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285082\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6758?source=see_link\">",
"      Antibiotic failure in the treatment of streptococcal tonsillopharyngitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27110?source=see_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=see_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39415?source=see_link\">",
"      Evaluation of sore throat in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/11/8377?source=see_link\">",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27224?source=see_link\">",
"      Symptomatic relief of sore throat in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=see_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infectious Diseases Society of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.idsociety.org\">",
"      www.idsociety.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (404) 639-3534",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 6, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/15/36082?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36082/abstract/1\">",
"      Humair JP, Revaz SA, Bovier P, Stalder H. Management of acute pharyngitis in adults: reliability of rapid streptococcal tests and clinical findings. Arch Intern Med 2006; 166:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36082/abstract/2\">",
"      Limb M, Connor A, Pickford M, et al. Scintigraphy can be used to compare delivery of sore throat formulations. Int J Clin Pract 2009; 63:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36082/abstract/3\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36082/abstract/4\">",
"      Snellman LW, Stang HJ, Stang JM, et al. Duration of positive throat cultures for group A streptococci after initiation of antibiotic therapy. Pediatrics 1993; 91:1166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_15_36082=[""].join("\n");
var outline_f35_15_36082=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SORE THROAT SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           SORE THROAT DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           TREATMENT OF SORE THROAT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           SORE THROAT PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/28/8641\" title=\"figure 1\">",
"           Strep throat PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36083="ECG torsades de pointes and ventricular flutter";
var content_f35_15_36083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of torsades de pointes and ventricular flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three ECG leads (I, II, III); bradycardia and prolongation of the QT interval are present. Several runs of polymorphic ventricular tachycardia, called torsades de pointes (TdP) when associated with QT prolongation are seen (panel A); after several minutes, a rapid sustained ventricular tachycardia, sometimes called ventricular flutter, occurs (panel B). This is closely related to ventricular fibrillation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Samuel Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36083=[""].join("\n");
var outline_f35_15_36083=null;
var title_f35_15_36084="Palifermin: Drug information";
var content_f35_15_36084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Palifermin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/17/25875?source=see_link\">",
"    see \"Palifermin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kepivance&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12785448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kepivance&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Keratinocyte Growth Factor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F205731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Oral mucositis associated with hematopoietic stem cell transplant (HSCT) conditioning regimens:",
"     </b>",
"     I.V.: 60 mcg/kg/day for 3 consecutive days before and 3 consecutive days after myelotoxic therapy; total of 6 doses (Spielberger, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Administer first 3 doses prior to myelotoxic therapy, with the 3rd dose given 24-48 hours before beginning the myelotoxic conditioning regimen. Administer the last 3 doses after completion of the conditioning regimen, with the first of these doses after but on the same day as HSCT infusion and at least 4 days after the most recent dose of palifermin.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6834090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14186920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kepivance&reg;: 6.25 mg [contains mannitol, sucrose 25 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F205718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by I.V. bolus. If heparin is used to maintain the patency of the I.V. line, flush line with saline prior to and after palifermin administration. Do not administer palifermin during or within 24 hours before or after chemotherapy. Allow solution to reach room temperature prior to administration; do not use if at room temperature &gt;1 hour. Do not filter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F205749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible:",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decrease the incidence and duration of severe oral mucositis associated with hematologic malignancies in patients receiving myelotoxic therapy requiring hematopoietic stem cell support (when the preparative regimen is expected to result in mucositis &ge;grade 3 in most patients)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use (safety and efficacy) is not established for nonhematologic malignancies; use is not recommended with conditioning regimens containing melphalan 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (39%); pain (16%); dysesthesia (oral hyperesthesia, hypoesthesia, and paresthesia 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (62%; grade 3: 3%), pruritus (35%), erythema (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Serum amylase increased (62%, grades 3/4: 38%), serum lipase increased (28%, grades 3/4: 11%), mouth/tongue discoloration or thickness (17%), taste alteration (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody formation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Cataracts, cough, flexural hyperpigmentation, palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome), perianal pain, rhinitis, vaginal edema, vaginal erythema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s U.S. product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to palifermin,",
"     <i>",
"      E. coli",
"     </i>",
"     -derived proteins, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mucocutaneous effects: Edema, erythema, pruritus, rash, oral/perioral dysesthesia, taste alteration, tongue discoloration, and tongue thickening may occur; instruct patients to report mucocutaneous effects. The median onset of cutaneous toxicities (following initial dose) is 6 days; median duration is 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nonhematologic malignancies: Safety and efficacy have not been established with nonhematologic malignancies; effect on the growth of keratinocyte growth factor (KGF) receptor expressing, nonhematopoietic human tumors is not known. Palifermin has been shown to enhance epithelial tumor cell lines",
"     <i>",
"      in vitro",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myelotoxic chemotherapy: Do not administer within 24 hours before, during, or after myelotoxic chemotherapy; may increase the severity and duration of oral mucositis (due to the increased sensitivity of rapidly-dividing epithelial cells).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: May increase the serum concentration of Palifermin. Management: Avoid coadministration of heparin with palifermin, and flush any heparin-maintained intravenous line with saline prior to administration of palifermin via that line.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin (Low Molecular Weight): May increase the serum concentration of Palifermin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palifermin has been shown to be embryotoxic in animal reproduction studies at doses also associated with maternal toxicity. Use in pregnancy only if the potential benefit outweighs the potential risk for the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F205734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14186878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer labeling, the decision to discontinue palifermin or discontinue breast-feeding during treatment should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Kepivance Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25 mg (1): $1914.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14186938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for oral mucositis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kepivance (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palifermin is a recombinant keratinocyte growth factor (KGF) produced in",
"     <i>",
"      E. coli",
"     </i>",
"     . Endogenous KGF is produced by mesenchymal cells in response to epithelial tissue injury. KGF binds to the KGF receptor resulting in proliferation, differentiation and migration of epithelial cells in multiple tissues, including (but not limited to) the tongue, buccal mucosa, esophagus, and salivary gland.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F205720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Epithelial cell proliferation (dose-dependent): 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 4.5 hours (range: 3.3-5.7 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gillespie B, Zia-Amirhosseini P, Salfi M, et al, &ldquo;Effect of Renal Function on the Pharmacokinetics of Palifermin,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2006, 46(12):1460-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/17101745/pubmed\" id=\"17101745\" target=\"_blank\">",
"        17101745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henke M, Alfonsi M, Foa P, et al, \"Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(20):2815-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/21670447/pubmed\" id=\"21670447\" target=\"_blank\">",
"        21670447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al, &ldquo;American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiotherapy Protectants,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(1): 127-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/19018081/pubmed\" id=\"19018081\" target=\"_blank\">",
"        19018081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keefe DM, Schubert MM, Elting LS, et al, &ldquo;Updated Clinical Practice Guidelines for the Prevention and Treatment of Mucositis,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2007, 109(5):820-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/17236223/pubmed\" id=\"17236223\" target=\"_blank\">",
"        17236223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le QT, Kim HE, Schneider CJ, et al, \"Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(20):2808-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/21670453/pubmed\" id=\"21670453\" target=\"_blank\">",
"        21670453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meropol NJ, Somer RA, Gutheil J, et al, &ldquo;Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(8):1452-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/12697866/pubmed\" id=\"12697866\" target=\"_blank\">",
"        12697866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sibelt LA, Aboosy M, van der Velden WJ, et al, &ldquo;Palifermin-Induced Flexural Hyperpigmentation: A Clinical and Histological Study of Five Cases,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 159(5):1200-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/18795935/pubmed\" id=\"18795935\" target=\"_blank\">",
"        18795935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spielberger R, Stiff P, Bensinger W, et al, &ldquo;Palifermin for Oral Mucositis After Intensive Therapy for Hematologic Cancers,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(25):2590-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/15602019/pubmed\" id=\"15602019\" target=\"_blank\">",
"        15602019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stiff PJ, Emmanouilides C, Bensinger WI, et al, \"Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(33):5186-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/16391299/pubmed\" id=\"16391299\" target=\"_blank\">",
"        16391299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vadhan-Raj S, Trent J, Patel S, et al, \"Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients With Cancer: A Randomized Trial,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2010, 153(6):358-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36084/abstract-text/20855800/pubmed\" id=\"20855800\" target=\"_blank\">",
"        20855800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10161 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36084=[""].join("\n");
var outline_f35_15_36084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205729\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12785448\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205743\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205731\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062245\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834090\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186920\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205716\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205705\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205718\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205749\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205717\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205741\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205721\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205707\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299811\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205711\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205713\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205723\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205734\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186878\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323592\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186938\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539910\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205706\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205720\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10161|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/17/25875?source=related_link\">",
"      Palifermin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36085="Terazosin: Drug information";
var content_f35_15_36085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Terazosin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/31/33268?source=see_link\">",
"    see \"Terazosin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/14/43236?source=see_link\">",
"    see \"Terazosin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Terazosin&reg;;",
"     </li>",
"     <li>",
"      Dom-Terazosin;",
"     </li>",
"     <li>",
"      Hytrin&reg;;",
"     </li>",
"     <li>",
"      Nu-Terazosin;",
"     </li>",
"     <li>",
"      PHL-Terazosin;",
"     </li>",
"     <li>",
"      PMS-Terazosin;",
"     </li>",
"     <li>",
"      ratio-Terazosin;",
"     </li>",
"     <li>",
"      Teva-Terazosin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       1",
"      </sub>",
"      Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If drug is discontinued for greater than several days, consider beginning with initial dose and retitrate as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 1 mg at bedtime; slowly increase dose to achieve desired blood pressure, up to 20 mg/day; usual dose range (JNC 7): 1-20 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage may be given on a twice daily regimen if response is diminished at 24 hours and hypotension is observed at 2-4 hours following a dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Benign prostatic hyperplasia:",
"     </b>",
"     Oral: Initial: 1 mg at bedtime; thereafter, titrate upwards, if needed, over several weeks, balancing therapeutic benefit with terazosin-induced postural hypotension; most patients require 10 mg day; if no response after 4-6 weeks of 10 mg/day, may increase to 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment with concurrent medication:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concurrent use with a diuretic or other antihypertensive agent (especially verapamil): Dosage reduction may be needed when adding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Concurrent use with PDE-5 inhibitors:",
"     </i>",
"     Initiate PDE-5 inhibitor therapy at the lowest dose due to additive orthostatic and blood pressure lowering effects",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4473153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/14/43236?source=see_link\">",
"      see \"Terazosin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hypertension (unlabeled use):",
"     </b>",
"     Oral: Initial: 1 mg once daily; gradually increase dose as necessary, up to maximum of 20 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F225504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg,  immediate release: 0.5 mg once daily) and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1 mg, 2 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9614178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild-to-moderate hypertension; alone or in combination with other agents such as diuretics or beta-blockers; benign prostate hyperplasia (BPH)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4589530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatric hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14187919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (9% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (1% to 6%), orthostatic hypotension (1% to 4%), palpitation (&le;4%), tachycardia (&le;2%), syncope (&le;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (4% to 5%), vertigo (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2% to 4%), weight gain (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (&le;2%), libido decreased (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Extremity pain (&le;4%), paresthesia (&le;3%), back pain (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (2% to 6%), dyspnea (2% to 3%), sinusitis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, abnormal vision, allergic reactions, anaphylaxis, anxiety, arrhythmia, arthralgia, arthritis, atrial fibrillation, bronchitis, chest pain, conjunctivitis, constipation, cough, diaphoresis, diarrhea, dyspepsia, epistaxis, facial edema, fever, flatulence, flu-like syndrome, gout, insomnia, intraoperative floppy iris syndrome (IFIS), joint disorder, myalgia, neck pain, pharyngitis, polyuria, priapism, pruritus, rash, rhinitis, shoulder pain, thrombocytopenia, tinnitus, urinary incontinence, urinary tract infection, vasodilation, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to terazosin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina: Discontinue if symptoms of angina occur or worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor is introduced. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Priapism has been associated with use (rarely).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: It is recommended to rule out prostatic carcinoma before beginning therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use as an antihypertensive due to high risk of orthostatic hypotension; alternative agents preferred due to a more favorable risk/benefit profile (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid saw palmetto. Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8119801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal studies. Decreased fetal weight and increased risk of fetal mortality were noted in some animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17916906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if terazosin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering terazosin to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F225486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Terazosin HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $160.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $160.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $160.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $160.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F225476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Standing and sitting/supine blood pressure, especially following the initial dose at 2-4 hours following the dose and thereafter at the trough point to ensure adequate control throughout the dosing interval; urinary symptoms",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F225487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adecur (CN, MX, PY);",
"     </li>",
"     <li>",
"      Adenex (PE);",
"     </li>",
"     <li>",
"      Benaprost (AR);",
"     </li>",
"     <li>",
"      Conmy (MY, PH, TW);",
"     </li>",
"     <li>",
"      Deflox (ES);",
"     </li>",
"     <li>",
"      Eglidon (AR);",
"     </li>",
"     <li>",
"      Flotrin (DE);",
"     </li>",
"     <li>",
"      Hitrin (CR, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Hykor (PH);",
"     </li>",
"     <li>",
"      Hyron (HU);",
"     </li>",
"     <li>",
"      Hytracin (JP);",
"     </li>",
"     <li>",
"      Hytrin (AU, BB, BE, BM, BR, BS, BZ, CL, CN, CO, CZ, EC, GB, GR, GY, HK, HU, IE, IL, IN, JM, LU, MX, MY, NL, NZ, PE, PH, PK, PL, PR, PT, RU, SR, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Hytrin BPH (CH);",
"     </li>",
"     <li>",
"      Hytrine (FR);",
"     </li>",
"     <li>",
"      Hytrinex (SE);",
"     </li>",
"     <li>",
"      Hytroz (ID);",
"     </li>",
"     <li>",
"      Hyzin (PH);",
"     </li>",
"     <li>",
"      Itrin (IT);",
"     </li>",
"     <li>",
"      Kinzosin (TW);",
"     </li>",
"     <li>",
"      Lontencin (PH);",
"     </li>",
"     <li>",
"      Magnurol (ES);",
"     </li>",
"     <li>",
"      Olyster (IN);",
"     </li>",
"     <li>",
"      Prostera (PH);",
"     </li>",
"     <li>",
"      Ralsin (MY);",
"     </li>",
"     <li>",
"      Setegis (HU);",
"     </li>",
"     <li>",
"      Sinalfa (DK, NO);",
"     </li>",
"     <li>",
"      Teralfa (IN);",
"     </li>",
"     <li>",
"      Terapam (KP);",
"     </li>",
"     <li>",
"      Terasin (MY);",
"     </li>",
"     <li>",
"      Terazoflo (DE);",
"     </li>",
"     <li>",
"      Tracin (KP);",
"     </li>",
"     <li>",
"      Tructum (CO);",
"     </li>",
"     <li>",
"      Vasomet (JP);",
"     </li>",
"     <li>",
"      Vicard (AT);",
"     </li>",
"     <li>",
"      Zayasel (CR, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Zytrin (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alpha",
"     <sub>",
"      1",
"     </sub>",
"     -specific blocking agent with minimal alpha",
"     <sub>",
"      2",
"     </sub>",
"     effects; this allows peripheral postsynaptic blockade, with the resultant decrease in arterial tone, while preserving the negative feedback loop which is mediated by the peripheral presynaptic alpha",
"     <sub>",
"      2",
"     </sub>",
"     -receptors; terazosin relaxes the smooth muscle of the bladder neck, thus reducing bladder outlet obstruction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; minimal first-pass",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~60%, ~20% as unchanged drug); urine (~40%, ~10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36085/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36085/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36085/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 283(15):1967-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36085/abstract-text/10789664/pubmed\" id=\"10789664\" target=\"_blank\">",
"        10789664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36085/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9975 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36085=[""].join("\n");
var outline_f35_15_36085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225538\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225503\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4473153\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225504\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225478\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225464\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9614178\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225480\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589530\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14187919\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225536\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225483\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225468\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300112\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225473\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225495\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225474\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119801\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225506\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17916906\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225486\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225485\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225476\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225487\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225467\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225482\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9975\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9975|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/31/33268?source=related_link\">",
"      Terazosin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/14/43236?source=related_link\">",
"      Terazosin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36086="Headache in children";
var content_f35_15_36086=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Headache in children (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36086/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36086/contributors\">",
"     Daniel J Bonthius, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36086/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36086/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36086/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36086/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36086/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36086/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/15/36086/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     HEADACHE OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches are common in children, occurring in up to 90 percent of school-age children. Headaches become more frequent as a child becomes older. There are many possible causes of headaches, from common and non-harmful to more serious but rare conditions.",
"   </p>",
"   <p>",
"    This topic reviews the causes, evaluation, and treatment of headaches in children. A separate topic discusses headaches in adults. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=see_link\">",
"     \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"     \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEADACHE CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous possible causes of headaches in children. The most common causes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Viral or upper respiratory infections (including ear infections, the common cold, allergies, sinus infections, strep throat)",
"     </li>",
"     <li>",
"      Stress-related or stress-worsened headaches (eg, family or school problems)",
"     </li>",
"     <li>",
"      Minor head injury",
"     </li>",
"     <li>",
"      Migraine or cluster headaches",
"     </li>",
"     <li>",
"      Tension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only a small minority of children with headaches have a serious cause, such as a brain tumor or life-threatening infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF HEADACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of a headache in a child depend upon the child's age and the type of headache. The most common types of headaches in childhood are illness or injury-related, tension-type, migraine, and cluster.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Illness or injury-related headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral or upper respiratory infections are a common cause of headaches in children. The headache may last for several days during the course of an illness.",
"   </p>",
"   <p>",
"    Bacterial meningitis, a serious and sometimes life-threatening infection, can also cause a headache, although other signs and symptoms are usually also present. These may include fever, sensitivity to light, neck stiffness, nausea, vomiting, confusion, lethargy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irritability. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=see_link\">",
"     \"Patient information: Meningitis in children (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Head injuries, which can occur at home, school, or while playing sports, are a common cause of headaches. Children who have a head injury and who also have nausea, vomiting, loss of consciousness, or other worrisome signs or symptoms should be evaluated by a healthcare provider. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'When to seek help'",
"    </a>",
"    below and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/44/14020?source=see_link\">",
"     \"Patient information: Head injury in children and adolescents (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tension-type headaches (TTH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headaches (TTH) cause a pressing tightness, usually located over the forehead, although it may feel like a tight band around the head. The pain is usually mild to moderate, does not throb, and it may last from 30 minutes to several days. Some children with TTH are sensitive to light or noise or feel lightheaded or tired. TTH does not usually cause nausea or vomiting and is not made worse by normal daily activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Migraine headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of migraine vary with age. Migraines in children may have different symptoms than in adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In toddlers, a caregiver may notice that the child is pale",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      less active than usual. An older child may vomit, cry, rock in place, or hide. Occasionally, toddlers with migraine become temporarily unsteady and off-balance, and act as though they are afraid to walk.",
"     </li>",
"     <li>",
"      In young children, the headache often begins in the late afternoon. The pain is usually pounding or throbbing, lasts between one and two hours, and may involve one or both sides of the head or the entire head. The headache is often accompanied by nausea and sensitivity to light and noise. A child may vomit one or more times.",
"     </li>",
"     <li>",
"      In adolescents, the headache pain usually begins gradually, intensifies over minutes to hours, and resolves gradually at the end of the attack. The headache is typically dull, deep, and steady at first, and may become throbbing or pounding if severe. Migraine headaches may be worsened by light, sneezing, straining, constant motion, physical exertion, or head movement. The pain usually lasts a few hours but can last up to 72 hours.",
"     </li>",
"     <li>",
"      Other symptoms can include passing out, abdominal pain, and motion sickness. Family members may have undiagnosed or misdiagnosed migraines (as an example, diagnosed with sinus headaches rather than migraines).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children with migraine headaches experience changes in their vision for several minutes before the headache. This is referred to as an aura. The aura may include flashing lights or bright spots, zigzag lines, or partial loss of vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cluster headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headaches are severe, debilitating headaches that occur repeatedly for weeks to months at a time, followed by headache-free periods. Fortunately, cluster headaches are rare in children younger than 10 years of age and only affect approximately 0.1 percent of children age 10 to 18 years. Cluster headaches are more common in boys.",
"   </p>",
"   <p>",
"    The headache is usually deep, excruciating, continuous, and explosive in quality. Cluster headaches commonly cause eye redness and tear production on the side where the pain occurs, a stuffy and runny nose, sweating, a pale appearance, and possibly drooping of the eyelid. The headache is usually short in duration (between 15 minutes and 3 hours). There are also shorter-duration cluster headaches that have a similar quality and associated features but that last only last seconds to minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic daily headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a headache is present for more than 15 days per month for at least three months, it is described as a chronic daily headache. Often, chronic daily headaches occur every day, and some people complain that they are present continuously for months. Chronic daily headache is not a type of headache but a category that includes frequent headaches of various kinds. Most children with chronic daily headache have migraine or tension-type headache as the underlying type of headache. Some children with frequent headache use headache medications too often, which may lead to the development of \"medication-overuse headache\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HEADACHE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches can often be treated at home. If a child is otherwise well and does not have worrisome signs or symptoms, it is reasonable to treat the child before seeking medical attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     When to seek help",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a child has one or more of the following,",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    should be evaluated by a healthcare provider before any treatment is given:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the headache occurs after a head injury",
"     </li>",
"     <li>",
"      If the pain is severe or there are associated symptoms, such as vomiting, changes in vision or double vision, neck pain or stiffness, confusion, loss of balance or unsteadiness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fever (temperature higher than",
"      <span class=\"nowrap\">",
"       100.4&ordm;F/38&ordm;C)",
"      </span>",
"     </li>",
"     <li>",
"      If the headache awakens the child or occurs upon waking",
"     </li>",
"     <li>",
"      If headaches occur more than once per month",
"     </li>",
"     <li>",
"      If the child is younger than three years of age",
"     </li>",
"     <li>",
"      If the child has certain underlying medical conditions such as sickle cell disease, immune deficiency, bleeding problems, neurofibromatosis, or tuberous sclerosis complex",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the cause of a child's headache can be determined with a complete medical history and physical examination.",
"   </p>",
"   <p>",
"    In some cases, the provider will ask the",
"    <span class=\"nowrap\">",
"     parent/child",
"    </span>",
"    to keep a headache diary for several months. A diary can provide detailed information about the time, date, and features of headaches (",
"    <a class=\"graphic graphic_table graphicRef78869 \" href=\"mobipreview.htm?39/35/40509\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for an imaging test depends upon the individual child's signs and symptoms, physical examination, and medical history. However, most children with a headache who have a normal physical examination will not require an imaging test such as a CT scan (computed tomography) or MRI (magnetic resonance imaging). If a child has an abnormal neurologic examination, has a new severe headache, or has other worrisome signs or symptoms, an imaging test will usually be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HEADACHE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of headaches depends upon the child's age, the type and frequency of headaches, and other characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Illness or injury-related headache treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child who has a headache caused by an underlying illness or minor head injury can be treated similarly to a child with a tension-type headache (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Infrequent TTH'",
"    </a>",
"    below). However, it is important to be aware of signs or symptoms that could indicate a more serious condition, which should be evaluated by a healthcare provider. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'When to seek help'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tension-type headache treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Infrequent TTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequent tension-type headache (TTH) is defined as occurring less than once per month. Children with infrequent tension-type headaches may be treated with an over-the-counter pain medication, such as children's",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (sample brand name: Tylenol) or",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (sample brand names: Advil, Motrin).",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"     Aspirin",
"    </a>",
"    is not recommended in children who are less than 18 years old due to the risk of a rare but serious condition called Reye syndrome. The dose of acetaminophen and ibuprofen should be based upon the child's weight, rather than age.",
"   </p>",
"   <p>",
"    Other suggestions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify and reduce or eliminate any factor that causes or worsens headaches, based upon information from the headache diary (eg, stress, lack of sleep, dietary factors).",
"     </li>",
"     <li>",
"      Notify the child's healthcare provider if any warning signs develop, including fever, stiff neck, loss of vision, or double vision.",
"     </li>",
"     <li>",
"      Rest &ndash; Ask the child to lie down and relax, and apply a cool wet cloth to the forehead. Talk to the child to determine if he or she is worried or anxious about activities at home or school.",
"     </li>",
"     <li>",
"      Stretch and massage &ndash; Stretch and massage the neck muscles if they are tight or tender.",
"     </li>",
"     <li>",
"      Food &ndash; If the child has not eaten recently, offer a snack. Skipping meals can sometimes worsen a headache.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Frequent or chronic TTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a child has frequent or chronic TTH, the first line of treatment is an over-the-counter (OTC) rescue pain medication, such as children's",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (sample brand name: Tylenol) or",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (sample brand names: Advil, Motrin).",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"     Aspirin",
"    </a>",
"    is not recommended in children who are less than 18 years due to the risk of a rare but serious condition called Reye syndrome.",
"   </p>",
"   <p>",
"    To avoid medication-overuse headache (also called \"rebound\" headaches), OTC pain medications should not be used more than two days in a given week without the express recommendation of a clinician. In addition, the daily dose should not exceed that recommended by the manufacturer.",
"   </p>",
"   <p>",
"    Programs that help to alleviate stress may also be helpful for children with chronic TTH. This may include psychological counseling, relaxation therapy, or biofeedback. Biofeedback teaches the child to voluntarily control certain body functions, like heart rate, blood pressure, and muscle tension.",
"   </p>",
"   <p>",
"    If the headaches do not improve with rescue medication, the healthcare provider may recommend that the child be evaluated by a specialist (eg, neurologist). The specialist may recommend a medication, such as a small daily dose of a tricyclic antidepressant (TCA), such as",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/17/32021?source=see_link\">",
"     amitriptyline",
"    </a>",
"    (Elavil). The dose of TCAs used for treating chronic pain is typically much lower than that used for treating depression. It is believed that TCAs reduce pain perception when used in low doses, although the exact mechanism of their benefit is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Migraine headache treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many triggers can bring on a headache attack or worsen a preexisting headache. The specific factors that trigger attacks can differ from one person to another. A partial list appears in the Table (",
"    <a class=\"graphic graphic_table graphicRef68062 \" href=\"mobipreview.htm?24/25/24988\">",
"     table 2",
"    </a>",
"    ). Children who have frequent or severe migraines should keep a record of their headaches in a headache diary (",
"    <a class=\"graphic graphic_table graphicRef78869 \" href=\"mobipreview.htm?39/35/40509\">",
"     table 1",
"    </a>",
"    ). This can help to determine if a specific trigger can be avoided to prevent future headaches.",
"   </p>",
"   <p>",
"    There are two types of migraine treatments: abortive and preventive. Abortive treatments are given to treat the current migraine symptoms (eg, pain, nausea, etc), while preventive treatments are given to prevent migraines from developing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Abortive treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first medication generally recommended to stop a migraine is an over-the-counter rescue pain medication, such as",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (sample brand name: Tylenol) or",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (sample brand names: Advil, Motrin). This should be given as soon as possible, at the first sign of the migraine.",
"   </p>",
"   <p>",
"    If the child develops nausea or vomiting, a prescription medication may be given to relieve these symptoms. One of the most commonly recommended antinausea medications for children older than two years is",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/47/2806?source=see_link\">",
"     promethazine",
"    </a>",
"    (sample brand name: Phenergan). Promethazine may be given by mouth or as a suppository in the rectum.",
"   </p>",
"   <p>",
"    If the headache does not improve or if the child begins vomiting before",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is given, a medication called a triptan may be recommended. In children who are five years and older, triptans are usually given by nasal spray. The best studied triptans in children are",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/37/15958?source=see_link\">",
"     sumatriptan",
"    </a>",
"    (sample brand name: Imitrex) and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/25/2454?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    (sample brand name: Zomig). Parents should discuss the potential risks and benefits of triptans with their child's healthcare provider.",
"   </p>",
"   <p>",
"    The most common side effect of",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/37/15958?source=see_link\">",
"     sumatriptan",
"    </a>",
"    nasal spray is an unpleasant taste in the mouth. This can be minimized by tilting the head forward",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sucking on a hard candy as the spray is given.",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/25/2454?source=see_link\">",
"     Zolmitriptan",
"    </a>",
"    nasal spray does not have an unpleasant taste.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Preventive treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of preventive treatments for migraine headaches in children have not been well studied. Some experts have found the following medications to be helpful, although the most effective treatment will depend upon the age and characteristics of the individual child.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/28/35268?source=see_link\">",
"       Cyproheptadine",
"      </a>",
"      (brand name: Periactin) is an antihistamine that is sometimes given to prevent migraines in adults. It may be recommended for migraine prevention in young children. Side effects can include sleepiness and increased appetite.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/4/43077?source=see_link\">",
"       Propranolol",
"      </a>",
"      (sample brand name: Inderal) is a blood pressure medication that is frequently given to prevent migraines in adults. It is sometimes recommended for prevention of migraines in children. The child's heart rate and blood pressure should be monitored during treatment, as both may be lowered by the medication. Propranolol should not be used by children with asthma or type 1 diabetes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/17/32021?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      (brand name: Elavil) is a tricyclic antidepressant that, when given at low doses, can help to reduce the frequency, severity, and duration of migraine headaches. The medication is usually given at bedtime because it can cause sleepiness. The dose may be increased slowly over time as needed.",
"     </li>",
"     <li>",
"      Although scientific studies have not shown herb or vitamin supplements to be effective in all cases, some patients have found riboflavin or coenzyme Q10 to be helpful as a preventive treatment for migraines. These agents are unlikely to be harmful. Nonetheless, parents should talk to their child's healthcare provider before using this type of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Menstrual migraine treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some adolescent girls have migraine headaches around the time that their menstrual period begins. If the migraines occur infrequently, they are usually treated with an abortive treatment, as described above. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Abortive treatments'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If menstrual migraines occur on a predictable schedule, a preventive treatment may be recommended. This is usually started a few days before and continues for a few days after the menstrual period starts. Preventive treatments may include a nonsteroidal antiinflammatory medication (eg,",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"     naproxen",
"    </a>",
"    ), a birth control pill, or a triptan. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"     \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cluster headache treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headaches are usually managed by a specialist (eg, neurologist). The treatment of cluster headaches in children is based upon treatments that have been successful in adults. Cluster headaches are poorly studied in children because they occur so rarely. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"     \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Chronic daily headache treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of chronic daily headaches usually centers on lifestyle changes. Since many children with chronic daily headache overuse headache medications, it is important to discontinue any overused pain medications (eg,",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [sample brand name: Tylenol]) as quickly as possible. Management of chronic daily headache requires a coordinated approach with the child's clinician and should be individualized according to the needs of the child; clear guidelines regarding the use of OTC medications should be discussed.",
"   </p>",
"   <p>",
"    Lifestyle changes include drinking an adequate amount of fluids, reducing or eliminating caffeine, getting regular exercise, eating and sleeping on a regular schedule, and stopping smoking.",
"   </p>",
"   <p>",
"    Some children with chronic daily headaches stop attending school or other normal daily activities. It is important to encourage the child to return to these activities as a part of treatment. If necessary, the child can be allowed to lie down in the school nurse's office for a brief period (eg, 15 minutes once daily) when headache pain is worst.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2413325840\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15026751\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/29/27090?source=see_link\">",
"     Patient information: Headaches in children (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"     Patient information: Headache (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/9/33938?source=see_link\">",
"     Patient information: Migraine headaches in children (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"     Patient information: Closed head injury (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15026766\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=see_link\">",
"     Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"     Patient information: Headache treatment in adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/44/14020?source=see_link\">",
"     Patient information: Head injury in children and adolescents (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=see_link\">",
"     Approach to the child with headache",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42327?source=see_link\">",
"     Classification of migraine in children",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/52/14153?source=see_link\">",
"     Emergent evaluation of headache in children",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18490?source=see_link\">",
"     Management of migraine headache in children",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8600?source=see_link\">",
"     Pathophysiology, clinical features, and diagnosis of migraine in children",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34744?source=see_link\">",
"     Tension-type headache in children",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Children's Hospital of Philadelphia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.chop.edu/healthinfo/headaches.html\">",
"     file://www.chop.edu/healthinfo/headaches.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Nemours Foundation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://kidshealth.org/parent/general/aches/headache.html\">",
"     kidshealth.org/parent/general/aches/headache.html",
"    </a>",
"    , available in Spanish)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Headache Society",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.achenet.org/resources/headaches_in_children/\">",
"     www.achenet.org/resources/headaches_in_children/",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36086/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36086/abstract/1\">",
"      Lewis DW, Ashwal S, Dahl G, et al. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002; 59:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36086/abstract/2\">",
"      Lewis DW, Dorbad D. The utility of neuroimaging in the evaluation of children with migraine or chronic daily headache who have normal neurological examinations. Headache 2000; 40:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36086/abstract/3\">",
"      Prensky A. Childhood Migraine Headache Syndromes. Curr Treat Options Neurol 2001; 3:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36086/abstract/4\">",
"      Dyb G, Holmen TL, Zwart JA. Analgesic overuse among adolescents with headache: the Head-HUNT-Youth Study. Neurology 2006; 66:198.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1179 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.15-0980553D96-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36086=[""].join("\n");
var outline_f35_15_36086=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      HEADACHE OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEADACHE CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF HEADACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Illness or injury-related headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tension-type headaches (TTH)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Migraine headaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Aura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cluster headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic daily headaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HEADACHE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      When to seek help",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HEADACHE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Illness or injury-related headache treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tension-type headache treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Infrequent TTH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Frequent or chronic TTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Migraine headache treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - General measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Abortive treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Preventive treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Menstrual migraine treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cluster headache treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Chronic daily headache treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2413325840\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15026751\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15026766\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/1179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/1179|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/35/40509\" title=\"table 1\">",
"      Pediatric headache diary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/25/24988\" title=\"table 2\">",
"      Headache triggers PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=related_link\">",
"      Approach to the child with headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/52/14153?source=related_link\">",
"      Emergent evaluation of headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18490?source=related_link\">",
"      Management of migraine headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8600?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/44/14020?source=related_link\">",
"      Patient information: Head injury in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/29/27090?source=related_link\">",
"      Patient information: Headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=related_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/9/33938?source=related_link\">",
"      Patient information: Migraine headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34744?source=related_link\">",
"      Tension-type headache in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36087="Butalbital compound: Drug information";
var content_f35_15_36087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Butalbital compound: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/6/33892?source=see_link\">",
"    see \"Butalbital compound: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fiorinal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fiorinal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Barbiturate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tension or muscle contraction headache: Oral: 1-2 tablets or capsules every 4 hours; not to exceed 6 tablets or capsules/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F143705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be reduced.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F143706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be reduced.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Butalbital 50 mg, aspirin 325 mg, and caffeine 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fiorinal&reg;: Butalbital 50 mg, aspirin 325 mg, and caffeine 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Butalbital 50 mg, aspirin 325 mg, and caffeine 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F143718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of the symptomatic complex of tension or muscle contraction headache",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fiorinal&reg; may be confused with Fioricet&reg;, Florical&reg;, Florinef&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, lightheadedness, drowsiness, &ldquo;hangover&rdquo; effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Heartburn, stomach pain, dyspepsia, epigastric discomfort, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion, mental depression, unusual excitement, nervousness, faint feeling, headache, insomnia, nightmares, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, vomiting, gastrointestinal ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Troubled breathing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic shock",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to butalbital or any component of the formulation; porphyria; pregnancy (prolonged use or high doses at term)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with platelet and bleeding disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with erosive gastritis or peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulant therapy: Use with caution in patients on anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye's syndrome; patients should be instructed to contact their healthcare provider if these occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Caffeine: May cause CNS and cardiovascular stimulation, as well as GI irritation in high doses. Use with caution in patients with a history of peptic ulcer or GERD; avoid in patients with symptomatic cardiac arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Barbiturates may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F143697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14286957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Withdrawal seizures were reported in an infant 2 days after birth following maternal use of a butalbital product during the last 2 months of pregnancy; butalbital was detected in the newborns serum. Also refer to individual monographs for information specific to aspirin or caffeine.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14286958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates, aspirin, and caffeine are excreted into breast milk. Also refer to individual monographs for information specific to aspirin or caffeine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Fiorinal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg (100): $261.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Butalbital-Aspirin-Caffeine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg (100): $70.25",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F143694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fiorinal (CA)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al,  &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36087/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36087/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/15/36087/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8823 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-7D04F74F15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36087=[""].join("\n");
var outline_f35_15_36087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143700\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143716\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143703\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143704\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143705\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143706\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143688\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143675\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143718\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143690\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143721\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143714\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143692\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143678\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143712\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143682\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143697\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143683\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286957\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143708\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286958\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143693\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143694\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/6/33892?source=related_link\">",
"      Butalbital compound: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36088="Wearable cardioverter-defibrillator";
var content_f35_15_36088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Wearable cardioverter-defibrillator",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36088/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36088/contributors\">",
"     Mina K Chung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36088/contributors\">",
"     Richard L Page, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36088/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/15/36088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6129224\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implantable cardioverter-defibrillator (ICD) has been shown to improve survival from sudden cardiac arrest and to improve overall survival in several populations at high risk for sudden cardiac death (SCD). However, there remain situations in which implantation of an ICD may be inappropriate or delayed. As an example, ICD implantation may be initially deferred and become unnecessary if the arrhythmic substrate is temporary, or if the risk for ICD implantation is high or without evidence for survival benefit. In cases where ICD implantation is deferred, a wearable cardioverter-defibrillator (WCD) may be an acceptable alternative approach for the prevention of sudden cardiac death. The WCD (LifeVest, ZOLL Lifecor Corporation, Pittsburgh, PA) is an external device capable of automatic detection and defibrillation of ventricular tachycardia and ventricular fibrillation (",
"    <a class=\"graphic graphic_picture graphicRef60103 \" href=\"mobipreview.htm?25/14/25826\">",
"     picture 1",
"    </a>",
"    ). While the WCD can be worn for years, typically the device is used for several months as temporary protection against SCD.",
"   </p>",
"   <p>",
"    The indications, efficacy, and limitations of the wearable cardioverter-defibrillator will be discussed here. Detailed discussions of the roles of the ICD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129231\">",
"    <span class=\"h1\">",
"     DESCRIPTION OF THE WCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wearable cardioverter-defibrillator (WCD) is an external device capable of automatic detection and defibrillation of ventricular tachycardia (VT) or ventricular fibrillation (VF). Currently the approved devices do not have pacing capabilities and therefore do not provide therapy for bradycardic or asystolic events or antitachycardic pacing.",
"   </p>",
"   <p>",
"    The WCD is composed of four dry, nonadhesive capacitive tantalum oxide monitoring electrodes, three defibrillation electrodes incorporated into a chest strap assembly, and a defibrillation unit carried on a waist belt (",
"    <a class=\"graphic graphic_picture graphicRef60103 \" href=\"mobipreview.htm?25/14/25826\">",
"     picture 1",
"    </a>",
"    ). The WCD can only be fitted on patients with a chest circumference less than 57 inches (144cm). The monitoring electrodes are positioned circumferentially around the chest, held in place by tension from an elastic belt, and provide two surface electrocardiogram leads. The defibrillation electrodes are positioned in a vest assembly for apex-posterior defibrillation. Proper fitting is required to achieve adequate skin contact to avoid noise and frequent alarms.",
"   </p>",
"   <p>",
"    Arrhythmia detection by the WCD is programmed using rate criteria. If an arrhythmia is detected, an escalating alarm sequence occurs, including a vibration against the skin and audible tones. Although shocks may be transmitted to bystanders in physical contact with the patient being shocked by a WCD, a voice cautions the patient and bystanders to the impending shock. Patients are trained to hold a pair of response buttons during these alarms to avoid receiving a shock while awake. A patient&rsquo;s response serves as a test of consciousness; if no response occurs, the device charges, extrudes gel from the defibrillation electrodes, and delivers up to five biphasic shocks at preprogrammed energy levels with a maximum output of 150 joules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129238\">",
"    <span class=\"h1\">",
"     RECORDING AND PROGRAMMING CAPACITY OF THE WCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to delivering therapeutic shocks for life-threatening ventricular arrhythmias, the wearable cardioverter-defibrillator (WCD) stores data regarding arrhythmias, patient compliance with the device, and noise or interference with its proper functioning. Arrhythmia recordings from the WCD are available for clinician review once stored data are transmitted via a modem to the manufacturer&rsquo;s network. Treatments, patient compliance, electrocardiogram (ECG) records, and system performance can be viewed using a secure website",
"    <span class=\"nowrap\">",
"     (https://wcdnet.lifecor.com/wcd/default.asp).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    WCD stores ECGs from both tachyarrhythmias and asystole:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The system is programmed to define ventricular arrhythmias when the ventricular heart rate exceeds a preprogrammed rate threshold with an ECG morphology that does not match a baseline electrocardiographic template. The monitoring software captures 30 seconds of ECG signal prior to the determination of ventricular tachycardia (VT) or ventricular fibrillation (VF) and continuously records until 15 seconds after the alarms stop.",
"     </li>",
"     <li>",
"      Asystole recordings are also triggered when ventricular heart rates drop below 20 beats per minute. The monitoring software also stores five minutes of ECG data prior to asystole determinations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tachycardia detection rate is programmable for VF between 120 and 250",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    and the VF shock delay can be programmed from 25 to 55 seconds. The VT detection rate is programmable between 120 bpm to the VF setting with a VT shock delay of 60 to 180 seconds. Additional shock delays (up to 30 seconds) may optionally be allowed during sleep. VT signals can allow synchronized shock delivery on the R wave, but if the R wave cannot be identified, unsynchronized shocks will be delivered. The shock energy is programmable from 75 to 150 joules, with up to five shocks delivered per event.",
"   </p>",
"   <p>",
"    The WCD also records information about patient compliance, ECG signal quality, alarm history, and noise occurrence.",
"    <span class=\"nowrap\">",
"     Time/date",
"    </span>",
"    stamps for device",
"    <span class=\"nowrap\">",
"     on/off",
"    </span>",
"    switching, monitor connection to the electrodes, and electrode-to-skin contact are recorded. ECG and defibrillation electrode contact is determined by micro-ampere AC signals similar to conventional monitoring systems. Compliance may be determined by assessing time that the user had the device turned on, the belt connected, and at least one monitoring electrode contacting the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129259\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR WCD USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wearable cardioverter-defibrillator (WCD) is indicated as temporary therapy for patients with a high risk for sudden cardiac death (SCD), such as those excluded from the original studies of implantable cardioverter-defibrillator (ICD) implantation for the primary prevention of SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Examples of persons who may benefit from the temporary use of a WCD include persons with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent myocardial infarction or coronary revascularization with severely reduced left ventricular ejection fraction (See",
"      <a class=\"local\" href=\"#H6129266\">",
"       'Early post-MI patients with severe LV dysfunction'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H6129289\">",
"       'Early after coronary revascularization with LVEF &le;35 percent'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Newly diagnosed nonischemic cardiomyopathy with severely reduced left ventricular ejection fraction (See",
"      <a class=\"local\" href=\"#H6129304\">",
"       'Newly diagnosed cardiomyopathy with LVEF &le;35 percent'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Severe cardiomyopathy as a bridge to heart transplantation (See",
"      <a class=\"local\" href=\"#H6129319\">",
"       'Bridge to heart transplant'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Need for interruption of implantable cardioverter-defibrillator (ICD) therapy, or the temporary inability to implant an ICD (eg, for infection) (See",
"      <a class=\"local\" href=\"#H6129340\">",
"       'Bridge to indicated or interrupted ICD therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Syncope and a high risk of ventricular tachyarrhythmias (See",
"      <a class=\"local\" href=\"#H6129326\">",
"       'Syncope of uncertain etiology but high risk for VT/VF'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are discussed in more detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129266\">",
"    <span class=\"h2\">",
"     Early post-MI patients with severe LV dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wearable cardioverter-defibrillator (WCD) can offer protection from sudden cardiac death (SCD) during the first few months after a myocardial infarction (MI) until arrhythmic risk may be reduced, as indicated by improvement in left ventricular ejection fraction (LVEF), or until implantable cardioverter-defibrillator (ICD) implantation is performed for those in whom the LVEF remains reduced.",
"   </p>",
"   <p>",
"    Despite advances in the treatment of acute coronary syndromes with early revascularization and effective medical therapies that have reduced mortality, the risk of SCD remains relatively high in the early period following an MI, especially in the setting of severely reduced LVEF (2.3",
"    <span class=\"nowrap\">",
"     percent/month",
"    </span>",
"    for patients with LVEF &le;30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. One analysis of the Sudden Cardiac Death in Heart Failure trial (SCD-HeFT) reported that among 712 patients with history of MI, there was no evidence of differential mortality benefit with ICDs as a function of time after implant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/6\">",
"     6",
"    </a>",
"    ]. The study concluded that the benefit of ICD therapy is not restricted only to remote MIs. However, the DINAMIT and IRIS trials reported that early ICD implantation 6 to 40 days after acute MI in patients with LVEF &le;35 percent does not improve early overall mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Despite a reduction in arrhythmic deaths in both trials in patients with an ICD, there was a higher risk of nonarrhythmic deaths during this early period, resulting in similar overall mortality rates. Thus, current guidelines do not recommend ICD implantation for primary prevention of SCD within 40 days of acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Wearable Defibrillator Investigative",
"    <span class=\"nowrap\">",
"     Trial/Bridge",
"    </span>",
"    to ICD in Patients at Risk of Arrhythmic Death",
"    <span class=\"nowrap\">",
"     (WEARIT/BIROAD)",
"    </span>",
"    study evaluated 289 patients with either symptomatic NYHA functional class III or IV heart failure with LVEF &lt;30 percent (WEARIT) or at high risk for SCD after MI or coronary artery bypass graft surgery not receiving an ICD for up to four months (BIROAD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/10\">",
"     10",
"    </a>",
"    ]. While wearing the WCD for a mean duration of three months, six successful defibrillations occurred in four patients (1.4 percent of total patients). Event rates and successful defibrillation via the WCD in the early post-MI period have subsequently been reported in 2.9 to 5 percent of users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the mortality rate from SCD in the first several months post-MI may exceed two percent per month, patients with severely reduced LVEF may be considered for WCD use in the early post-MI period. In patients with reduced LVEF post-MI, reevaluation of left ventricular function should occur one to three months after the MI. If LVEF remains &le;35 percent on follow-up assessment, despite appropriate medical therapy, ICD implantation is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129289\">",
"    <span class=\"h2\">",
"     Early after coronary revascularization with LVEF &le;35 percent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significant left ventricular (LV) dysfunction have higher 30-day mortality rates after coronary artery bypass graft (CABG) surgery than patients with normal LV function. While these persons have an increased risk of sudden cardiac death due to ventricular arrhythmias, they are also at risk for nonarrhythmic causes of death. The CABG Patch trial did not report a survival benefit from epicardial implantable cardioverter-defibrillator (ICD) implantation at the time of CABG in patients with LV ejection fraction (LVEF) &le;35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, several other ICD studies of primary prevention have excluded patients within one to three months after coronary revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As such, the benefit of ICD placement for primary prevention of SCD early after revascularization has not been well established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=see_link\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The wearable cardioverter-defibrillator (WCD) may provide protection from SCD in the first one to three months after CABG, allowing healing and potential recovery of LV function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/10\">",
"     10",
"    </a>",
"    ]. The potential utility for a WCD in this setting is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nonrandomized comparison of nearly 5000 patients with LVEF &le;35 percent from two separate cohorts who underwent revascularization with CABG or percutaneous coronary intervention (PCI) (809 patients discharged with a WCD from a national registry and 4149 patients discharged without WCD from Cleveland Clinic CABG and PCI registries), early mortality hazard was demonstrated in patients discharged without a WCD. Patients discharged with the WCD had less marked early hazard and significantly lower 90-day mortality rates (3 versus 7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/14\">",
"       14",
"      </a>",
"      ]. While patients using a WCD appear to have improved outcomes, only 1.3 percent of the WCD group received an appropriate therapy while wearing the device, thereby indicating that the majority of the mortality benefit was not attributable to life-saving therapies from the WCD.",
"     </li>",
"     <li>",
"      A German cohort of 354 patients prescribed a WCD included approximately 90 patients in the early post-CABG period, 7 percent of whom were shocked for a ventricular tachyarrhythmia during the three months of device use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 3569 patients in the United States using the WCD, 9 percent of WCD use was early post-CABG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Appropriate shocks for a ventricular tachyarrhythmia occurred in 0.8 percent of these patients over a mean follow-up of 47 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severely reduced LVEF (&le;35 percent) may be considered for WCD use in the first three months post-CABG. In patients with severe LV dysfunction prior to or after CABG, LVEF should be reassessed three months following revascularization. If a sustained ventricular tachyarrhythmia has occurred, or if the LVEF remains &le;35 percent three months after CABG, implantation of an ICD is usually indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129304\">",
"    <span class=\"h2\">",
"     Newly diagnosed cardiomyopathy with LVEF &le;35 percent",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in the risk of sudden cardiac death (SCD), and a potential benefit from implantable cardioverter-defibrillator (ICD) implantation, has long been recognized in patients with left ventricular dysfunction related to underlying ischemic heart disease. An increase in SCD risk and potential benefit from an ICD has also been demonstrated in patients with a nonischemic cardiomyopathy in two major studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCD-HeFT compared ICD implantation to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      treatment alone or placebo for primary prevention of SCD in patients with ischemic or nonischemic heart failure and LVEF &le;35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/3\">",
"       3",
"      </a>",
"      ]. SCD-HeFT demonstrated improved survival with an ICD; however, patients within three months of their initial heart failure diagnosis were excluded.",
"     </li>",
"     <li>",
"      The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial compared ICD implantation with standard medical therapy to standard medical therapy alone for primary prevention of SCD in patients with a nonischemic cardiomyopathy, nonsustained ventricular tachycardia, and LVEF &le;35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/15\">",
"       15",
"      </a>",
"      ]. DEFINITE showed a trend toward mortality benefit in patients who received an ICD, regardless of duration since diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following DEFINITE, another study reported similar occurrences of lethal arrhythmias irrespective of diagnosis duration in patients with a nonischemic cardiomyopathy and LVEF &le;35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Device implantation guidelines recommend implantation of an ICD for nonischemic cardiomyopathy with LVEF &le;35 percent, provided that a reversible cause of transient LV dysfunction has been excluded and that response to optimal medical therapy has been assessed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/9\">",
"     9",
"    </a>",
"    ]. The guidelines do not specify a waiting period prior to reassessing LVEF; in the United States, however, the Center for Medicare Services (CMS) requires a three-month period of optimal medical therapy prior to reimbursement for ICD placement (if repeat LVEF assessment continues to show LVEF &le;35 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link&amp;anchor=H16#H16\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Nonischemic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients felt to be at high risk of SCD while undergoing a trial of optimal medical therapy, the WCD provides protection against SCD while awaiting improvement in LV function. In the largest postmarketing study of the WCD, 0.7 percent of patients prescribed a WCD for recently diagnosed nonischemic cardiomyopathy required shocks for a ventricular tachyarrhythmia over a mean follow-up period of 57 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Although this event rate was relatively low, for selected patients with severe but potentially reversible cardiomyopathy, such as tachycardia- or myocarditis-associated cardiomyopathy, the WCD may be useful for the prevention of SCD due to ventricular arrhythmias while awaiting improvement in LV function, ICD implantation, or if needed, cardiac transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=see_link&amp;anchor=H27#H27\">",
"     \"Natural history and therapy of myocarditis in adults\", section on 'Arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129319\">",
"    <span class=\"h2\">",
"     Bridge to heart transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe heart failure awaiting heart transplantation represent a group at particularly high risk for sudden cardiac death (SCD). Implantable cardioverter-defibrillator (ICD) implantation is often recommended for such patients, particularly those discharged to home while awaiting transplantation. The WCD may be a reasonable noninvasive alternative approach, though data on its use in patients awaiting heart transplantation is limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 91 cardiac transplant candidates discharged to home (UNOS Status 1B patients receiving home inotrope infusion), 25 had an ICD and 13 used a WCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/17\">",
"       17",
"      </a>",
"      ]. Two patients died suddenly at home, one who was not wearing his WCD, and another who declined use of a WCD. In the 13 patients wearing the WCD, three asymptomatic events occurred with one shock delivered for rapid atrial fibrillation.",
"     </li>",
"     <li>",
"      In a German study of 354 WCD patients, 6 percent wore the WCD while awaiting heart transplantation, with an incidence of ventricular arrhythmias of 11 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the WEARIT study of WCD use in 177 patients with NYHA functional class III or IV heart failure (not listed for heart transplant but with similar functional status to patients who might be listed for heart transplant), one patient received two successful defibrillations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The International Society for Heart and Lung Transplantation Guidelines state as a Class I recommendation that an ICD or WCD should be provided for Status 1B patients who are discharged home given that the wait for transplantation remains significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/18\">",
"     18",
"    </a>",
"    ]. The WCD may also be appropriate in patients whose anticipated waiting time to transplant is short (ie, blood types A and B) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H479055\">",
"    <span class=\"h3\">",
"     WCD in patients with VADs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role for implantable cardioverter-defibrillator (ICD) and WCD therapy remains unclear in patients with ventricular assist devices (VADs). With VADs, circulatory support is often adequate even in the event of a ventricular tachyarrhythmia. However, one study reported the presence of an ICD was associated with improved survival in patients undergoing VAD support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/19\">",
"     19",
"    </a>",
"    ]. Whether the WCD could impart similar survival benefits in patients awaiting transplantation with VAD support has yet to be studied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129326\">",
"    <span class=\"h2\">",
"     Syncope of uncertain etiology but high risk for VT/VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have syncope without cardiac arrest, documented arrhythmias, or need for resuscitation may still have clinical features or potentially reversible causes that would make them at high risk for a life-threatening arrhythmia as the cause of syncope. Use of a WCD during a prolonged evaluation may provide protection against sudden cardiac death, particularly in patients in whom ICD implantation may not be immediately indicated or feasible.",
"   </p>",
"   <p>",
"    Ambulatory event monitoring, often performed for several weeks in an effort to determine an arrhythmic etiology for syncope, will not provide therapies in the event of a life-threatening arrhythmia. In a German study of 354 patients, 18 percent of the cohort wore the WCD for an average of 106 days during a prolonged diagnostic evaluation, including patients with syncope of unknown origin or survival of an episode of cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5\">",
"     5",
"    </a>",
"    ]. During this relatively short period, 13 percent of patients had a ventricular tachyarrhythmia requiring a shock. Thus, the WCD may be able to bridge this period of prolonged diagnostic evaluation until arrhythmic risk can be ascertained or improved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9034?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the adult patient with syncope in the emergency department\", section on 'Life-threatening conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5272?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis and etiology of syncope\", section on 'Cardiac arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129340\">",
"    <span class=\"h2\">",
"     Bridge to indicated or interrupted ICD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with an indication for implantable cardioverter-defibrillator (ICD) placement, implantation of the device may be delayed due to comorbid conditions, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Recovery from surgery",
"     </li>",
"     <li>",
"      Lack of vascular access",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with a preexisting ICD who develop device infection or endocarditis usually require system extraction to effectively treat the infection. Unless the patient is pacemaker dependent, reimplantation in many patients is deferred until the infection is completely cleared after an appropriate course of antibiotics. The WCD may provide protection against ventricular tachyarrhythmias during these periods until an ICD can be implanted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5,12\">",
"     5,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129355\">",
"    <span class=\"h1\">",
"     EFFICACY OF THE WCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the WCD has been tested for induced ventricular tachyarrhythmias as well as for spontaneous events during clinical trials and postmarket study. When worn properly, the WCD appears to be as effective as an implantable cardioverter-defibrillator (ICD) for the termination of ventricular tachycardia (VT) and ventricular fibrillation (VF), with successful shocks occurring in nearly 100 percent of cases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of induced",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      in the electrophysiology laboratory, the WCD successfully detected and terminated",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      with 100 percent first shock success [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the",
"      <span class=\"nowrap\">",
"       WEARIT/BIROAD",
"      </span>",
"      studies, six of eight defibrillations successfully terminated",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/10\">",
"       10",
"      </a>",
"      ]. The two unsuccessful defibrillations occurred in patients with incorrectly placed therapy electrodes (eg, defibrillating pads reversed and not directed to the skin) with one sudden death in a patient with reversed leads. No patients died from",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      while correctly wearing the WCD, but the study highlights the importance of proper patient instruction in the use of the WCD.",
"     </li>",
"     <li>",
"      In the German study of WCD use, 20 of the 21 episodes of sustained",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      were successfully defibrillated with one shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the U.S. postmarket study of 3569 patients, 80 sustained",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      events occurred [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/12\">",
"       12",
"      </a>",
"      ]. First shock success in terminating",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      was 100 percent among unconscious patients and 99 percent for all patients. The single failure to convert",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      on the first attempt occurred when a conscious patient with sustained VT allowed himself to be shocked 10 minutes after using the response buttons.",
"      <br/>",
"      <br/>",
"      Survival after successful conversion of unconscious",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      by the WCD was 86 percent. Of the patients who died, four died due to recurrent",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      after initial recovery and arrival of emergency personnel, one due to a bystander preventing therapy, two due to electrocardiogram signal disruption from a fall, and one due to inhibition of detection due to the pacing stimulus artifact from a unipolar pacemaker. This study also reported that long-term survival was similar in WCD patients compared to a cohort of ICD patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, shock efficacy with the WCD appears to be similar to that reported with ICDs. However, sudden cardiac death may still occur in those not wearing the device, those with improper positioning of the device, due to bystander interference, or inability of the WCD to detect the electrocardiogram signal. These results highlight the importance of patient education and promotion of compliance while using the WCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129392\">",
"    <span class=\"h2\">",
"     Inappropriate shocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the WCD and the implantable cardioverter-defibrillator (ICD) may inappropriately deliver shocks due to electronic noise, device malfunction, or detection of supraventricular tachycardia (SVT) above the preprogrammed rate criteria. Compared to inappropriate shock rates reported for ICDs, reported inappropriate shock rates appear to be comparable for the WCD. Studies of ICDs have reported an incidence of inappropriate shock of 0.2 to 2.3 percent of patients per month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/15,21-27\">",
"     15,21-27",
"    </a>",
"    ]. In contrast, reported rates of inappropriate shocks from the WCD range from 0.7 to 1.4 percent per month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5,10,12\">",
"     5,10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inappropriate shocks with a WCD can be potentially reduced due to the ability to abort shocks while awake by pressing response buttons. When electronic noise occurs, the WCD emits a noise alarm. This electronic noise can often be minimized or eliminated by changing body position or tightening of the electrode belt, and shocks can be avoided by pushing the response buttons. While a dual-chamber ICD with an atrial lead would seemingly have greater ability to discriminate between SVT and ventricular tachycardia, the incidence of inappropriate shocks due to atrial fibrillation, sinus tachycardia, or other supraventricular arrhythmias in clinical studies of WCDs has been low. The WCD uses a two-channel proprietary vectorcardiogram morphology matching algorithm to prevent shocks during SVT if the QRS is unchanged, and inappropriate shocks can also be averted when the patient presses the response buttons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129406\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF THE WCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of its overall efficacy for terminating life-threatening ventricular arrhythmias, the WCD does have some limitations. Its external nature does not allow for pacemaker functionality and introduces a component of patient interaction and compliance. The device must be removed for bathing, but no protection is afforded while the device is off. Therefore, it is advisable that caregivers or other persons be nearby during these periods when the WCD is not worn. Comfort may also be an issue for some patients due to the size and weight of the device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442706\">",
"    <span class=\"h2\">",
"     Lack of pacemaker functionality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its external nature, the WCD is not able to function as a pacemaker, which limits the possible therapies it can deliver in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The WCD cannot deliver pacing therapies to treat bradycardia or asystole. In the German study, two patients developed asystole while wearing the WCD, and both patients died [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5\">",
"       5",
"      </a>",
"      ]. In the U.S. postmarketing registry study, 23 of 3569 patients (0.6 percent) experienced asystole, with an associated mortality of 74 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The WCD cannot provide antitachycardia pacing for ventricular tachycardia (VT), which can reduce patient shocks, when effective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When considering these limitations, an implantable cardioverter-defibrillator (ICD) would be preferred, if indicated, in a patient who is pacemaker-dependent or in whom antitachycardia pacing is desired as the initial therapy for VT. The ICD would allow for treatment of asystolic events and may deliver fewer shocks if antitachycardia pacing effectively terminates VT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Antitachycardia pacing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442795\">",
"    <span class=\"h2\">",
"     Patient compliance and complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy of the WCD in the prevention of sudden cardiac death is highly dependent on patient compliance and appropriate use of the device.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the",
"      <span class=\"nowrap\">",
"       WEARIT/BIROAD",
"      </span>",
"      study, 23 percent of the 289 subjects withdrew before reaching a study endpoint, with size and weight of the monitor being the most frequent reason for withdrawal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/10\">",
"       10",
"      </a>",
"      ]. Skin rash",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      itching were also reported by 6 percent of patients.",
"     </li>",
"     <li>",
"      In the German study, mean daily use of the WCD was 21.3 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5\">",
"       5",
"      </a>",
"      ]. Excellent compliance (defined as 22 to 24",
"      <span class=\"nowrap\">",
"       hrs/day)",
"      </span>",
"      was achieved in 72 percent and good compliance (20 to 22",
"      <span class=\"nowrap\">",
"       hrs/day)",
"      </span>",
"      in 13 percent. The primary complaints associated with the WCD were the weight of the device and problems sleeping, particularly when noise alarms occurred more frequently.",
"     </li>",
"     <li>",
"      In the U.S. postmarket study, median and mean daily use were 21.7 hours and 19.9 hours, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/12\">",
"       12",
"      </a>",
"      ]. Daily use was &gt;90 percent (&gt;21.6 hours) in 52 percent of patients and &gt;80 percent (&gt;19.2 hours) in 71 percent of patients. Longer duration of monitoring correlated with higher compliance rates. Patients using the WCD for more than 60 days averaged 20.8 hours of daily use, while patients using it for less than 15 days averaged only 17.2 hours. WCD use was stopped prematurely in 14 percent, primarily because of comfort issues related to the size and weight of the WCD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rates of WCD discontinuation appear similar to reported rates of compliance with other prescribed therapies. One study reported that 15 percent of patients stop using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , ACE inhibitors and beta-blockers within 30 days of a myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/28\">",
"     28",
"    </a>",
"    ]. Improved compliance and acceptance of the WCD may be seen with newer devices, which are 40 percent smaller in size and weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129421\">",
"    <span class=\"h1\">",
"     USE OF THE WCD IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with the WCD is limited in children. One series reported on WCD use in four children aged 9 to 17 years with anthracycline-induced cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36088/abstract/29\">",
"     29",
"    </a>",
"    ]. No inappropriate shocks were delivered. Compliance was problematic with a 14 year old, who had cardiac arrest due to ventricular fibrillation with the vest unfastened. Because the WCD was not being used correctly, it did not detect the arrhythmia; however, the patient was resuscitated by emergency personnel. Two children, aged 15 and 17 years, required adjustment of the WCD with downsizing or refitting of the vest to achieve better electrode contact and reduction in noise.",
"   </p>",
"   <p>",
"    More data are required to assess the efficacy of WCD in children prior to widespread use. In addition, children require special attention to assure compliance and correct fitting for optimal use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6129217\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The wearable cardioverter-defibrillator (WCD, also known as the LifeVest) is an external device capable of automatic detection and defibrillation of ventricular tachycardia (VT) or ventricular fibrillation (VF) (",
"      <a class=\"graphic graphic_picture graphicRef60103 \" href=\"mobipreview.htm?25/14/25826\">",
"       picture 1",
"      </a>",
"      ). In cases where the need for an implantable cardioverter-defibrillator (ICD) is felt to be temporary or implantation of the ICD must be deferred, a WCD may be an acceptable alternative approach for the prevention of sudden cardiac death. (See",
"      <a class=\"local\" href=\"#H6129231\">",
"       'Description of the WCD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to delivering therapeutic shocks for life-threatening ventricular arrhythmias, the WCD stores data regarding arrhythmias, patient compliance with the device, and noise or interference with its proper functioning. Arrhythmia recordings from the WCD are available for clinician review once stored data are transmitted via a modem to the manufacturer&rsquo;s network. (See",
"      <a class=\"local\" href=\"#H6129238\">",
"       'Recording and programming capacity of the WCD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The WCD is indicated as temporary therapy for patients with a high risk for sudden cardiac death (SCD):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with left ventricular ejection fraction (LVEF) &le;35 percent less than 40 days postmyocardial infarction (MI), we suggest the use of a wearable cardioverter-defibrillator for primary prevention against sudden cardiac death (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Reevaluation of LVEF should occur one to three months after the MI. If LVEF remains &le;35 percent on follow-up assessment, despite appropriate medical therapy, ICD implantation is indicated and should be considered. (See",
"      <a class=\"local\" href=\"#H6129266\">",
"       'Early post-MI patients with severe LV dysfunction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with LVEF &le;35 percent who have undergone coronary revascularization with coronary artery bypass graft (CABG) surgery in the past three months, we suggest the use of a wearable cardioverter-defibrillator for primary prevention against sudden cardiac death (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). LVEF should be reassessed three months following CABG. If a sustained ventricular tachyarrhythmia has occurred, or if the LVEF remains &le;35 percent three months after CABG, implantation of an ICD is usually indicated. (See",
"      <a class=\"local\" href=\"#H6129289\">",
"       'Early after coronary revascularization with LVEF &le;35 percent'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In selected patients with severe but potentially reversible cardiomyopathy, such as tachycardia- or myocarditis-associated cardiomyopathy, the WCD may be useful for the prevention of SCD due to ventricular arrhythmias while awaiting improvement in LV function, ICD implantation, or if needed, cardiac transplantation. (See",
"      <a class=\"local\" href=\"#H6129304\">",
"       'Newly diagnosed cardiomyopathy with LVEF &le;35 percent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe heart failure awaiting heart transplantation represent a group at particularly high risk for SCD in whom ICD implantation is often recommended. The WCD may be a reasonable noninvasive alternative approach, particularly for patients whose anticipated waiting time to transplant is short. (See",
"      <a class=\"local\" href=\"#H6129319\">",
"       'Bridge to heart transplant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with an indication for an ICD may require a delay in ICD implantation due to comorbid conditions (ie, infection, recovery from surgery, lack of vascular access). In such patients, the WCD may provide protection against ventricular tachyarrhythmias until an ICD can be implanted. (See",
"      <a class=\"local\" href=\"#H6129340\">",
"       'Bridge to indicated or interrupted ICD therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When worn properly, the WCD appears to be as effective as an ICD for the termination of VT and VF, with successful shocks occurring in nearly 100 percent of cases. In addition, inappropriate shock rates from the WCD appear to be comparable to and in some studies lower than those reported for ICDs. (See",
"      <a class=\"local\" href=\"#H6129355\">",
"       'Efficacy of the WCD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6129392\">",
"       'Inappropriate shocks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limitations of the WCD (compared to a traditional ICD) include the lack of pacemaker functionality, the requirement for patient interaction and compliance, and potential discomfort due to the size and weight of the device. (See",
"      <a class=\"local\" href=\"#H6129406\">",
"       'Limitations of the WCD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/1\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/2\">",
"      Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/3\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/4\">",
"      Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/5\">",
"      Klein HU, Meltendorf U, Reek S, et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). Pacing Clin Electrophysiol 2010; 33:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/6\">",
"      Piccini JP, Al-Khatib SM, Hellkamp AS, et al. Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Heart Rhythm 2011; 8:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/7\">",
"      Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/8\">",
"      Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/9\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/10\">",
"      Feldman AM, Klein H, Tchou P, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol 2004; 27:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/11\">",
"      Verdino RJ. The wearable cardioverter-defibrillator: lifesaving attire or \"fashion faux pas?\". J Am Coll Cardiol 2010; 56:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/12\">",
"      Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol 2010; 56:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/13\">",
"      Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/14\">",
"      Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2013; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/15\">",
"      Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/16\">",
"      Makati KJ, Fish AE, England HH, et al. Equivalent arrhythmic risk in patients recently diagnosed with dilated cardiomyopathy compared with patients diagnosed for 9 months or more. Heart Rhythm 2006; 3:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/17\">",
"      Lang CC, Hankins S, Hauff H, et al. Morbidity and mortality of UNOS status 1B cardiac transplant candidates at home. J Heart Lung Transplant 2003; 22:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/18\">",
"      Gronda E, Bourge RC, Costanzo MR, et al. Heart rhythm considerations in heart transplant candidates and considerations for ventricular assist devices: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant 2006; 25:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/19\">",
"      Cantillon DJ, Tarakji KG, Kumbhani DJ, et al. Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm 2010; 7:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/20\">",
"      Reek S, Geller JC, Meltendorf U, et al. Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. Pacing Clin Electrophysiol 2003; 26:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/21\">",
"      Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005; 111:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/22\">",
"      Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/23\">",
"      Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/24\">",
"      Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 2003; 14:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/25\">",
"      Wilkoff BL, Ousdigian KT, Sterns LD, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006; 48:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/26\">",
"      Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008; 52:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/27\">",
"      Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 2004; 15:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/28\">",
"      Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36088/abstract/29\">",
"      Everitt MD, Saarel EV. Use of the wearable external cardiac defibrillator in children. Pacing Clin Electrophysiol 2010; 33:742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15824 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36088=[""].join("\n");
var outline_f35_15_36088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6129217\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6129224\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6129231\">",
"      DESCRIPTION OF THE WCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6129238\">",
"      RECORDING AND PROGRAMMING CAPACITY OF THE WCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6129259\">",
"      INDICATIONS FOR WCD USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6129266\">",
"      Early post-MI patients with severe LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6129289\">",
"      Early after coronary revascularization with LVEF &le;35 percent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6129304\">",
"      Newly diagnosed cardiomyopathy with LVEF &le;35 percent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6129319\">",
"      Bridge to heart transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H479055\">",
"      - WCD in patients with VADs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6129326\">",
"      Syncope of uncertain etiology but high risk for VT/VF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6129340\">",
"      Bridge to indicated or interrupted ICD therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6129355\">",
"      EFFICACY OF THE WCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6129392\">",
"      Inappropriate shocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6129406\">",
"      LIMITATIONS OF THE WCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442706\">",
"      Lack of pacemaker functionality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442795\">",
"      Patient compliance and complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6129421\">",
"      USE OF THE WCD IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6129217\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/15824\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/15824|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/14/25826\" title=\"picture 1\">",
"      Wearable defibrillator",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9034?source=related_link\">",
"      Approach to the adult patient with syncope in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36089="Occupational asthma: Clinical features and diagnosis";
var content_f35_15_36089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Occupational asthma: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Jean-Luc Malo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Catherine Lemi&egrave;re, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Andr&eacute; Cartier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Moira Chan-Yeung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36089/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/15/36089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational asthma (OA) is a form of work-related asthma characterized by variable airflow obstruction, airway hyperresponsiveness, and airway inflammation attributable to exposures in the workplace and not due to stimuli encountered outside the workplace [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/1\">",
"     1",
"    </a>",
"    ]. Work-exacerbated asthma (also known as work-aggravated asthma) is defined as preexisting or concurrent asthma that subjectively worsens in the workplace.",
"   </p>",
"   <p>",
"    OA is triggered by exposure to immunologic or nonimmunologic stimuli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/2\">",
"     2",
"    </a>",
"    ]. Immunologic OA has a latency period during which the immunologic sensitization develops. Nonimmunologic OA has no latency period and is caused by exposure to high levels of irritants; it is also known as irritant-induced asthma or reactive airways dysfunction syndrome (RADS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OA accounts for approximately 10 to 25 percent of adult onset asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. This implies that investigation of the causal relationship between workplace exposure and asthma is indicated in approximately one of every 5 to 10 subjects with adult-onset asthma.",
"   </p>",
"   <p>",
"    The evaluation and diagnosis of suspected OA will be reviewed here. The pathophysiology definition, epidemiology, causes, risk factors, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link\">",
"     \"Occupational asthma: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14489?source=see_link\">",
"     \"Occupational asthma: Management, prognosis, and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/13/14553?source=see_link\">",
"     \"Overview of occupational and environmental health\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OCCUPATIONAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history in patients with possible occupational asthma (OA) should include detailed information about the job description and potential exposures to causal agents, in addition to the routine evaluation of adult-onset asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/7\">",
"     7",
"    </a>",
"    ]. The clinical history, while important, does not confirm or exclude the diagnosis of OA, although the negative predictive value is better than the positive predictive value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;All adults with asthma should be questioned not only about their current occupation and exposures, but also about their previous occupations and exposures. Once the patient&rsquo;s occupation is ascertained, the potential associated exposures can be evaluated in greater detail. Asking about exposure to vapors, gas, fumes, or dust may help the patient&rsquo;s recall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples, the job description of \"engineer\" or \"clerk\" does not yield a full account of the actual exposures in the workplace, and either may be exposed indirectly to a sensitizing agent depending upon the particular work environment (eg, auto body shop, office building, epoxy paint factory).",
"   </p>",
"   <p>",
"    Certain industries or professions are associated with greater contact with agents that have a high potential for provoking OA. As examples, nurses may be exposed to latex,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    , pharmaceutical products, enzymes, glutaraldehyde, or formaldehyde, while spray painters may be exposed to isocyanates, acrylates, and various amines (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"     table 1",
"    </a>",
"    ). A description of the more common causative agents and their associated occupations is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link&amp;anchor=H1191269#H1191269\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Causative agents'",
"    </a>",
"    .) Additional information on agents that cause OA is available at",
"    <a class=\"external\" href=\"file://www.asthme.csst.qc.ca/document/Info_Med/IdCauses/Bernstein/AgentsAnglais.pdf\">",
"     file://www.asthme.csst.qc.ca/document/Info_Med/IdCauses/Bernstein/AgentsAnglais.pdf",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    When OA is suspected, but the exact cause is unclear, it is important to obtain a list of all potentially causative agents. If the names of the chemicals in the workplace are not known, the worker can be asked to obtain the Material Safety Data Sheet (MSDS) from the employer. In the United States, the US Occupational Safety and Health Administration (OSHA) requires that suppliers include a MSDS with each shipment of an industrial material or chemical, and workers are entitled to receive copies of these sheets. However, one should not depend entirely upon the information present in safety data sheets, because regulations stipulate that materials present in concentrations less than 1 percent need not be reported and high molecular weight compounds from animal and plant sources are typically omitted.",
"   </p>",
"   <p>",
"    Asking about exposure to nonspecific irritants (eg, environmental tobacco smoke, strong fumes, extremes of temperature and humidity) is important as all types of asthma can be worsened by exposure to nonspecific irritants at work, a condition that is labeled work-exacerbated asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/12\">",
"     12",
"    </a>",
"    ]. This sensitivity to nonspecific irritants is particularly likely among patients with high degrees of nonspecific bronchial hyperresponsiveness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those who are undertreated with medication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link&amp;anchor=H2#H2\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies have investigated non-allergic irritant-induced asthma in which multiple irritant exposures at low concentrations appear to induce asthma in the absence of preexisting asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/13\">",
"     13",
"    </a>",
"    ]. Since there is no specific testing that can prove that asthma has been caused by repetitive exposure to an irritant agent, it is often difficult to establish the diagnosis of irritant-induced asthma with certainty. However, epidemiologic studies suggest that some jobs, like cleaners and pulp mill workers, associated with exposure to high concentration of irritants are associated with an increasing risk for the occurrence of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/14\">",
"     14",
"    </a>",
"    ]. Irritant-induced asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866399778\">",
"    <span class=\"h2\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of occupational asthma (OA) is characterized by the following progression (",
"    <a class=\"graphic graphic_algorithm graphicRef80111 \" href=\"mobipreview.htm?2/63/3071\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of exposure",
"     </li>",
"     <li>",
"      Sensitization",
"     </li>",
"     <li>",
"      Onset of upper and lower airway inflammation",
"     </li>",
"     <li>",
"      Clinical disease",
"     </li>",
"     <li>",
"      Cessation or persistence of exposure",
"     </li>",
"     <li>",
"      Cure, improvement, or persistence of asthma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latency period between the onset of exposure and the onset of symptoms is highly variable in OA. In general, the latency period is shorter with exposure to low molecular weight (LMW) agents, such as isocyanates and plicatic acid (Western red cedar), than with high molecular weight (HMW) agents (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/15\">",
"     15",
"    </a>",
"    ]. As an example, approximately 50 percent of subjects who develop OA due to isocyanates experience symptoms within the first two years after the onset of exposure, whereas the median latency period after exposure to HMW agents is approximately five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/15\">",
"     15",
"    </a>",
"    ]. The latency period also varies between high molecular weight agents; sensitization to laboratory animals occurs more commonly and rapidly than sensitization to flour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866399597\">",
"    <span class=\"h2\">",
"     Atopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should take a history of preexisting asthma and atopy in all patients with asthma. However, these characteristics have a poor positive predictive value for the presence of OA. As an example, one study found that only approximately one-third of atopic subjects developed rhinoconjunctivitis or asthma symptoms in the five years following onset of exposure to laboratory animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/17\">",
"     17",
"    </a>",
"    ]. Atopy is associated, though often weakly, with OA due to HMW agents, but because atopy is present in almost 50 percent of young adults, it cannot satisfactorily predict the development of OA. Preexisting asthma is not a predisposing factor for immunologic OA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5063656\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical symptoms of occupational asthma are the same as nonoccupational asthma and include cough, dyspnea, wheeze, and chest tightness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of asthma in adolescents and adults\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5064106\">",
"    <span class=\"h2\">",
"     Pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pattern of increased symptoms while at work or within several hours of the completion of a shift, and a definite improvement on weekends or during vacations, is common in OA, but documenting this feature is not necessarily helpful. The value of this pattern of improvement of symptoms at weekends or in holidays as a discriminator for the diagnosis of OA, was examined in a study of 162 patients referred for possible OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/8\">",
"     8",
"    </a>",
"    ]. Eighty-eight percent with confirmed OA stated that their symptoms improved during holidays, while 76 percent of patients without OA reported a similar improvement. In addition, the absence of this pattern does not exclude the possibility of OA.",
"   </p>",
"   <p>",
"    Workers with more advanced OA and those who are only away from work for brief intervals are less likely to report this classic pattern, possibly due to a combination of early and late phase reactions that lead to persistent symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4937?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of asthma\", section on 'Early and late phase reactions'",
"    </a>",
"    .) Furthermore, workers may not be exposed to the etiologic agent every day, and intermittent exposures make it difficult to relate symptoms to work.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5064099\">",
"    <span class=\"h2\">",
"     Extrapulmonary symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of work-related rhinoconjunctivitis (itchy eyes, tearing, sneezing, nasal congestion, rhinorrhea) often precede symptoms of OA caused by high molecular weight (HMW) proteinaceous agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], or may accompany symptoms of OA caused by other high molecular weight agents and the low molecular weight agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/21\">",
"     21",
"    </a>",
"    ]. The report of work-related wheezing, nasal symptoms, and ocular itching increases the likelihood of OA, especially among workers exposed to high molecular weight agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/21\">",
"     21",
"    </a>",
"    ]. However, these symptoms are not predictive in subjects exposed to low molecular weight agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link&amp;anchor=H1191269#H1191269\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Causative agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several agents that cause OA (eg, isocyanates, epoxies, latex, or cleaning agents) have been associated with allergic contact dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/22-29\">",
"     22-29",
"    </a>",
"    ]. However, the occurrence of contact dermatitis is generally not predictive of OA. An exception comes from a study of adolescent car painting apprentices (exposed to isocyanates) in which occupational dermatitis was predictive of work-related asthma like symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/22\">",
"     22",
"    </a>",
"    ]. Cobalt exposure has also been associated with the combination of OA and contact dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11943?source=see_link\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Work-related urticaria on exposed body parts is sometimes seen with exposure to high molecular weight agents such as latex or crab and may suggest an IgE-mediated process, but there are no studies looking at its predictive value for the development of OA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86045157\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in OA is generally nonspecific and may be normal during office visits away from the occupational exposure. Widespread, high-pitched wheezes are characteristic of asthma, heard most commonly on expiration, but sometimes also during inspiration. However, the presence or absence of wheezing on physical examination is a poor predictor of the presence or severity of OA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of asthma in adolescents and adults\", section on 'Physical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with OA may also have pale, swollen nasal mucosa on examination of the nasal passages, suggesting concomitant occupational rhinitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, an erythematous, scaling rash consistent with allergic contact dermatitis may be present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11943?source=see_link\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\"",
"    </a>",
"    .) Also rarely, patients may present with a skin rash suggestive of urticaria on exposed body parts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344157802\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of disease processes have symptoms that mimic OA, such as asthma due to nonoccupational causes, chronic obstructive pulmonary disease (COPD), nonasthmatic eosinophilic bronchitis, work-related irritable larynx syndrome, upper respiratory tract irritation, hyperventilation syndrome, occupational rhinitis, hypersensitivity pneumonitis, and bronchiolitis obliterans. Certain distinguishing features can help to differentiate OA from the other diagnoses. The differential diagnosis of asthma and the diagnosis of occupational rhinitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link&amp;anchor=H20489068#H20489068\">",
"     \"Diagnosis of asthma in adolescents and adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Workers can develop COPD due to personal or workplace exposure to tobacco smoke or other pollutants. A careful history can elicit the intensity and duration of tobacco smoke exposure. Spirometry will typically show a substantial component of irreversible airflow obstruction in patients with COPD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link&amp;anchor=H8#H8\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Pulmonary function tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonasthmatic eosinophilic bronchitis (NAEB) due to occupational exposure differs from occupational asthma in the absence of bronchial hyperresponsiveness. In NAEB, spirometry is normal and non-specific bronchoprovocation challenge is negative, but induced sputum shows airway eosinophilia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=see_link&amp;anchor=H13#H13\">",
"       \"Evaluation of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Work-related irritable larynx syndrome refers to hyperkinetic laryngeal symptoms triggered by sensory stimuli in the workplace, such as odors and irritants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/30\">",
"       30",
"      </a>",
"      ]. This syndrome includes paradoxical vocal cord motion (PVCM, also known as vocal cord dysfunction), dysphonia due to laryngeal muscle tension (also known as muscle tension dysphonia), globus (ie, sensation of tension in the throat or neck), and chronic cough. In a case series, dysphonia was present in 86 percent and chronic cough in 76 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/30\">",
"       30",
"      </a>",
"      ]. PVCM can mimic asthma and OA, and can also coexist with these diagnoses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/31\">",
"       31",
"      </a>",
"      ]. Typically, the diagnosis of PVCM is suspected when the patient has stridorous sounds, loudest above the throat and less audible through the chest wall, dysphonia, and an abnormal inspiratory flow volume curve, and does not respond as expected to treatment with an inhaled bronchodilator. Ascertaining the diagnosis requires the visualization of paradoxical motion of the vocal cords during symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=see_link\">",
"       \"Paradoxical vocal cord motion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25878?source=see_link&amp;anchor=H4#H4\">",
"       \"Flow-volume loops\", section on 'Variable extrathoracic obstruction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperventilation syndrome is frequently misdiagnosed as asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/8,32\">",
"       8,32",
"      </a>",
"      ]. It is characterized by a variety of somatic symptoms induced by physiologically inappropriate hyperventilation and usually reproduced in whole or in part by voluntary hyperventilation.",
"     </li>",
"     <li>",
"      A number of the same antigens that cause OA can also cause hypersensitivity pneumonitis. Unlike OA, hypersensitivity pneumonitis is typically associated with a restrictive ventilatory defect and interstitial opacities on radiographic imaging. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34087?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\", section on 'Etiologic agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchiolitis obliterans presents with dyspnea and cough and has been reported in popcorn workers and nylon flock workers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28629?source=see_link\">",
"       \"Nylon flock worker's lung\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344158038\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of occupational asthma (OA) is based upon a combination of exposure history, time course of symptom onset, pulmonary function test, evidence of reversible airflow limitation, and specific testing to establish an occupational contribution to asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Confirmation of asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in evaluating a patient with suspected occupational asthma is to confirm that the patient indeed has asthma. The diagnosis of asthma based on history alone may not be accurate, and therefore additional testing is warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Baseline spirometry is obtained to determine the presence and severity of any airflow limitation. The results of spirometry determine the most appropriate next test.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a subject with airflow obstruction (ie, a ratio of forced expiratory volume in one second",
"      <span class=\"nowrap\">",
"       (FEV1)/forced",
"      </span>",
"      vital capacity (FVC) below the lower limit of normal), the next step is to assess reversibility with inhaled bronchodilator. The presence of a significant increase in FEV1 (12 percent and &gt;200 mL) after inhaling a bronchodilator supports the diagnosis of asthma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22487?source=see_link&amp;anchor=H6#H6\">",
"       \"Use of pulmonary function testing in the diagnosis of asthma\", section on 'Bronchodilator responses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of airflow obstruction, the next step is to assess bronchial hyperresponsiveness to a pharmacologic agent, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      or histamine. If the FEV1 falls by 20 percent with a methacholine dose of 4",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      or less, the test confirms bronchial hyperresponsiveness, supporting a diagnosis of asthma. If the dose of methacholine that causes a 20 percent fall in FEV1 is between 4 and 16",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      the patient is considered to have borderline bronchial hyperresponsiveness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/33\">",
"       33",
"      </a>",
"      ]. Absence of bronchial hyperresponsiveness could be due to lack of recent exposure to the sensitizing agent in a worker who has been away from work, but virtually rules out occupational asthma in a worker who has continued to work and is symptomatic. For patients who have been away from the workplace and have negative initial bronchoprovocation testing, repeat bronchoprovocation testing after an exposure to the causative agent (in the laboratory or at work) may then reveal bronchial hyperresponsiveness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=see_link&amp;anchor=H4#H4\">",
"       \"Bronchoprovocation testing\", section on 'Diagnosis of asthma'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Specific bronchoprovocation challenge'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Restrictive physiology in the absence of airflow limitation suggests that the patient&rsquo;s symptoms may have an alternate etiology. Further evaluation usually includes full pulmonary function testing and radiographic imaging. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of pulmonary function testing in adults\", section on 'Restrictive lung disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5738461\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographic imaging is typically performed to exclude other possible causes of the patient&rsquo;s symptoms and is appropriate in adults who present with new onset dyspnea. The chest radiograph in OA may be normal or may show hyperinflation. A chest computed tomographic scan is usually not needed for the evaluation of a patient with suspected OA, unless an unexplained abnormality is noted on the plain chest radiograph.",
"   </p>",
"   <p>",
"    A possible exception is when a worker has known exposure to agents that cause both OA and hypersensitivity pneumonitis (eg, acid anhydrides), a chest CT scan, combined with pulmonary function testing, may help in differentiating between these possibilities. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Confirmation of asthma'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1225?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\", section on 'High resolution CT scan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Establishing occupational relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients who have a clear diagnosis of asthma, the next step is to establish that an occupational agent is causing the worker&rsquo;s asthma and, when possible, to identify the causative agent. Several tests are available to determine whether a given patient's symptoms are caused by OA and whether a particular occupational exposure is the inciting agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/34\">",
"     34",
"    </a>",
"    ]. The most commonly used procedures involve monitoring peak expiratory flow rates, spirometry, or nonspecific bronchial reactivity during and away from the workplace. Specific skin and immunoassay tests for occupational agents, assessment of airways inflammation, and specific bronchoprovocation are less widely available. Only these latter tests can confirm the identity of the causative agent.",
"   </p>",
"   <p>",
"    Stepwise schemes have been proposed for the diagnosis and management of OA using these various methods (",
"    <a class=\"graphic graphic_algorithm graphicRef53605 \" href=\"mobipreview.htm?23/14/23790\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/35\">",
"     35",
"    </a>",
"    ]. The exact order of testing depends on the available expertise and the degree of suspicion for a particular sensitizing agent. If a potential sensitizing agent has not been identified, supervised monitoring of peak expiratory flow rate or spirometry during and away from workplace exposures may be more appropriate as initial tests. If a likely causative agent has been identified and skin or immunologic testing is available, that testing may be performed first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344157636\">",
"    <span class=\"h3\">",
"     Peak expiratory flow rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial measurement of peak expiratory flow rates (PEFR) is useful in the investigation and assessment of occupational asthma (OA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The subject is instructed on the proper use of the peak flow meter and asked to record his or her PEFR a minimum of four times per day for a period of at least two weeks at work and during a similar period away from work [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/39\">",
"     39",
"    </a>",
"    ]. The period of testing at work should be shortened if the patient develops pronounced airway obstruction or has severe symptoms.",
"   </p>",
"   <p>",
"    A number of potential problems are inherent to serial PEFR monitoring, including the reproducibility of readings, compliance and honesty of subjects, interpretation of results, and sensitivity and specificity compared with specific inhalation challenges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/34\">",
"     34",
"    </a>",
"    ]. Newer portable peak flow meters store values electronically, enabling identification of falsified patient logs. Interpretation of graphs of serial PEFR measurements can be carried out by using a computer program called OASYS, although this is more typically used in workplace investigations than in the care of an individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, all patients suspected of having OA should have baseline spirometry. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Confirmation of asthma'",
"    </a>",
"    above.) Spirometry can also be used to measure serial changes in airflow limitation in and away from the workplace, similar to the procedure for serial PEFR monitoring. Spirometry provides more detailed information about airflow and more reliable results than peak flow monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/42\">",
"     42",
"    </a>",
"    ]. On the other hand, a spirometer is more expensive than a peak expiratory flow meter and the technician training more complex. The spirometric parameter that is most reliable is the forced expiratory volume in one second (FEV1); changes in the forced vital capacity and forced expiratory flow at 25 to 75 percent of vital capacity are less reliable due to their dependence on the duration of expiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5607?source=see_link&amp;anchor=H7#H7\">",
"     \"Office spirometry\", section on 'Interpretation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comparisons between data from exposure and non-exposure days can support (or refute) work-related exacerbations of asthma. A single measurement of FEV1 when the subject is at work and repeating once away from work (eg, pre and post shift) does not have sufficient sensitivity to detect a relationship between work and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periodic spirometry measurements can be used for workplace surveillance when occupational exposures place workers at risk for OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/42\">",
"     42",
"    </a>",
"    ]. Typically, measurements are repeated at one to two year intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nonspecific bronchoprovocation testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among subjects with OA, nonspecific bronchial responsiveness is increased after exposure to the causative agent. This effect may last for years in patients with established OA, but in milder OA will last for at least a day or two. Thus, nonspecific bronchial hyperresponsiveness can be measured after two or more weeks away from work and again after workplace exposure to obtain more objective evidence of an occupational cause of symptoms and airflow limitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/34\">",
"     34",
"    </a>",
"    ]. This testing is particularly helpful when the baseline spirometry and initial testing of nonspecific bronchial hyperresponsiveness are normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=see_link&amp;anchor=H9#H9\">",
"     \"Bronchoprovocation testing\", section on 'Pharmacologic challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When assessing changes in bronchoprovocation before and after workplace or antigen exposure, a decrease of two doublings (eg, 16",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    to 4",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    in the concentration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    or histamine that causes a 20 percent fall in forced expiratory volume in one second (FEV1) is considered clinically significant.",
"   </p>",
"   <p>",
"    When a symptomatic subject is tested within 24 hours of exposure to the suspected work sensitizer, the absence of bronchial hyperresponsiveness virtually excludes OA. On the other hand, absence from work for several days or longer has been associated with a falsely negative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    inhalation challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. If bronchoprovocation testing is negative, but OA is still strongly suspected clinically, skin or immunoassay testing may provide evidence of sensitization. For confirmation of OA in this setting, specific bronchoprovocation with the relevant antigen is needed. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Specific bronchoprovocation challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When baseline spirometry is normal and nonspecific bronchoprovocation challenge testing negative, induced sputum may be assessed to look for occupational nonasthmatic eosinophilic bronchitis as a cause of the patient&rsquo;s symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H866400052\">",
"     'Airway inflammation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In asymptomatic workers who are undergoing surveillance because of known exposure to an occupational sensitizer, an increase in nonspecific bronchial responsiveness and sputum eosinophil numbers after antigen exposure may precede the onset of asthmatic reactions and provide an early and sensitive marker of an abnormal airway response to inhalation of occupational agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H866400052\">",
"     'Airway inflammation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866400045\">",
"    <span class=\"h3\">",
"     Skin and immunologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin test reagents for documenting hypersensitivity are only available for a few occupational agents. Extracts of high molecular weight (HMW) antigens, such as plant or animal proteins, and some low molecular weight (LMW) agents, such as platinum salts can be developed for skin testing, but these are usually not standardized (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"     table 1",
"    </a>",
"    ). The presence of immediate skin test reactivity reflects IgE-specific sensitization; however, a positive result may be found in some patients without symptoms of asthma or rhinoconjunctivitis. Therefore, it is important to document objective evidence of physiological changes (eg, airflow obstruction, airway hyperresponsiveness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased sputum eosinophils) related to exposure, in addition to skin test reactivity.",
"   </p>",
"   <p>",
"    Negative skin prick tests (eg, cereals, mites, and enzymes in a baker) virtually exclude the possibility that OA is caused by that specific antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin testing with a panel of common aeroallergens is often performed to identify nonoccupational allergens (eg, pets, pollen) that may be contributing to the patient&rsquo;s asthma.",
"   </p>",
"   <p>",
"    In vitro immunoassay for IgE antibodies to occupational sensitizers is available for a limited number of high molecular weight agents (eg, animal danders, latex) and low molecular weight chemical-protein conjugates (eg, diisocyanates), but these are not standardized or commercially available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/2\">",
"     2",
"    </a>",
"    ]. When positive, they support the diagnosis of OA to that agent, although the sensitivity of this testing is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866400052\">",
"    <span class=\"h3\">",
"     Airway inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying increased airway inflammation with noninvasive tests, such as sputum eosinophil counts and exhaled nitric oxide, at the end of a period at work provides supportive evidence of airway inflammation and, thus, indirect evidence of OA, although supportive data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sputum cell counts",
"      </strong>",
"      &ndash; Asthmatic airway inflammation is characterized by the presence of eosinophils in induced sputum samples; neutrophils may also be involved, especially in more severe asthma. In OA, either eosinophilic or neutrophilic inflammation is seen, the latter being more common in OA induced by low molecular weight agents (",
"      <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. Sputum is usually induced using inhalation of hypertonic saline; inhalation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      prior to sputum induction will inhibit airway constriction due to the hypertonic saline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/55\">",
"       55",
"      </a>",
"      ]. The sputum sample is processed and stained with Wright&rsquo;s or Hansel&rsquo;s stain. The nonsquamous cell differential counts are expressed as a percentage of the total nonsquamous cell counts. This test is only available at specialized centers.",
"      <br/>",
"      <br/>",
"      The use of sputum eosinophil counts in the diagnosis of OA was compared with peak expiratory flow rate (PEFR) monitoring in a case series of 49 patients with suspected OA who were evaluated during two weeks at work and two weeks away [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/52\">",
"       52",
"      </a>",
"      ]. The combination of work-related decreases in PEFR and the presence of a greater than 1 percent increase in sputum eosinophils after two weeks at work increased both the sensitivity and specificity of OA diagnosis, compared to PEFR monitoring alone.",
"     </li>",
"     <li>",
"      <strong>",
"       Exhaled nitric oxide",
"      </strong>",
"      &ndash; The fractional concentration of exhaled nitric oxide (eNO) generally correlates with bronchial reactivity and induced sputum eosinophilia and has been assessed as a potential noninvasive marker for OA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/56-58\">",
"       56-58",
"      </a>",
"      ]. Among 26 subjects with a positive specific inhalation challenge (SIC), significant increases over baseline were noted in sputum eosinophils at 7 and 24 hours and exhaled nitric oxide (eNO) at 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/57\">",
"       57",
"      </a>",
"      ]. However, sputum eosinophil counts achieved a higher sensitivity and positive predictive value than eNO. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7416?source=see_link\">",
"       \"Exhaled nitric oxide analysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of eosinophils in induced sputum (&ge;2 percent) or increased exhaled nitric oxide (eNO) suggests that either asthma or nonasthmatic eosinophilic bronchitis (NAEB) is present. NAEB can be occupationally induced and cause cough and sputum production in the absence of bronchial hyperresponsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/49,59,60\">",
"     49,59,60",
"    </a>",
"    ]. The best test for NAEB is assessment of induced sputum eosinophil counts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/16/27913?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Specific bronchoprovocation challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoprovocation tests with specific occupational agents are performed in specialized centers. These tests consist of exposing subjects to occupational agents in a hospital laboratory or, occasionally, at work [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/61\">",
"     61",
"    </a>",
"    ]. When these tests are carried out in a hospital laboratory, low doses of the occupational agent are used to avoid a nonspecific irritant effect. Dose response curves are constructed in which the dose (concentration multiplied by duration) is progressively increased and compared with lung function changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=see_link&amp;anchor=H26846610#H26846610\">",
"     \"Bronchoprovocation testing\", section on 'Antigen challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, specific bronchoprovocation challenges are performed in patients with documented bronchial hyperresponsiveness when skin or immunoassay testing is not available and results of serial peak expiratory flow rate or spirometry measurements are unclear about whether asthma is occupationally induced.",
"   </p>",
"   <p>",
"    In the presence of normal airway caliber and responsiveness, as well as normal cell content in induced sputum, in a symptomatic patient with current workplace exposure to a known OA sensitizer, the diagnosis of OA can be excluded and further specific testing is not needed.",
"   </p>",
"   <p>",
"    In the case of high molecular weight agents, specific bronchoprovocation testing can be carried out in a single day, because an immediate reaction that is maximal during the first hour following exposure is expected. Low molecular weight agents often cause nonimmediate or late reactions and therefore require daily challenges of escalating doses of the agent on sequential days.",
"   </p>",
"   <p>",
"    If airflow obstruction is not induced by inhalation of the specific agent, assessment of nonspecific bronchial hyperresponsiveness is carried out toward the end of the challenge day or at 24 hours after inhalation. An increase in nonspecific bronchial responsiveness, sputum eosinophils, or exhaled nitric oxide after specific antigen challenge supports the likelihood that the patient has OA or nonasthmatic eosinophilic bronchitis due to that antigen. A negative specific bronchoprovocation challenge in the laboratory may not exclude entirely the diagnosis of OA as the worker may have become &ldquo;desensitized&rdquo; or the wrong agent may have been used. If possible, the worker can return to work and be reassessed if symptoms develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36089/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A list of centers in the United States and Canada that perform specific bronchoprovocation testing for occupational asthma is available at:",
"    <a class=\"external\" href=\"file://www.thoracic.org/clinical/environmental-and-occupational/clinical-tests.php\">",
"     file://www.thoracic.org/clinical/environmental-and-occupational/clinical-tests.php",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational asthma (OA) is a disease characterized by variable airflow obstruction, airway hyperresponsiveness, and airway inflammation attributable to a particular occupational exposure and not due to stimuli encountered outside the workplace. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical history typically includes current and previous job titles, job descriptions, known exposures, and also any exposures to unknown vapors, gas, fumes, or dust. However, clinical history, while important, is inadequate to confirm or exclude the diagnosis of OA. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Occupational history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the case of high molecular weight agents, questions related to the presence of work-related wheezing and nasal symptoms are the best predictors of OA. For low molecular weight agents, no specific question accurately predicts the presence of OA. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Occupational history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the latency period from onset of exposure to onset of symptoms is shorter with low molecular weight (LMW) agents, such as isocyanates and plicatic acid (Western red cedar), than with high molecular weight (HMW) agents (",
"      <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5063656\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of disease processes can mimic OA, such as asthma due to non-occupational causes, chronic obstructive pulmonary disease (COPD), hyperventilation syndrome, upper respiratory tract irritation, occupational rhinitis, hypersensitivity pneumonitis, and bronchiolitis obliterans. (See",
"      <a class=\"local\" href=\"#H344157802\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of asthma should be confirmed through pulmonary function testing that identifies reversible airflow obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      airway hyperresponsiveness. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Confirmation of asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A stepwise scheme for the diagnosis of OA may be useful (",
"      <a class=\"graphic graphic_algorithm graphicRef53605 \" href=\"mobipreview.htm?23/14/23790\">",
"       algorithm 2",
"      </a>",
"      ). Several types of tests are used to determine whether asthma is related to an occupational exposure. The most frequently used tests are monitoring of peak expiratory flow rates or spirometry during and away from workplace exposures and measuring nonspecific bronchoprovocation testing before and after work exposure. When available, skin test reactivity or immunoassay for specific IgE to known occupational sensitizers is performed. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Establishing occupational relationship'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link&amp;anchor=H344156515#H344156515\">",
"       \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Low-molecular-weight'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When a patient is symptomatic and has ongoing exposure to an agent known to cause OA (eg, Western red cedar, isocyanates), the combined presence of normal airway caliber (ie, normal spirometry) and absence of bronchial hyperresponsiveness (ie, negative nonspecific bronchoprovocation challenge) virtually excludes the possibility of OA. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonspecific bronchoprovocation testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occupational nonasthmatic eosinophilic bronchitis is an infrequent cause of occupational respiratory symptoms without bronchial hyperresponsiveness and can be evaluated by assessing induced sputum for eosinophilia or exhaled nitric oxide levels for evidence of airway inflammation. (See",
"      <a class=\"local\" href=\"#H866400052\">",
"       'Airway inflammation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=see_link&amp;anchor=H13#H13\">",
"       \"Evaluation of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7416?source=see_link&amp;anchor=H13#H13\">",
"       \"Exhaled nitric oxide analysis\", section on 'Nonasthmatic eosinophilic bronchitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When a patient has adult-onset asthma (ie, reversible airflow obstruction or bronchial hyperresponsiveness) and the diagnosis of OA is suspected but uncertain, specific bronchoprovocation testing may be helpful. Bronchoprovocation testing with specific occupational agents is only available in specialized centers. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Specific bronchoprovocation challenge'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=see_link&amp;anchor=H26846610#H26846610\">",
"       \"Bronchoprovocation testing\", section on 'Antigen challenge'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of OA is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14489?source=see_link&amp;anchor=H293008677#H293008677\">",
"       \"Occupational asthma: Management, prognosis, and prevention\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI. Definition and Classification of Asthma in the Workplace. In: Asthma in the workplace, 3rd, Bernstein IL, Chan-Yeung M, Malo IL, Bernstein DI (Eds), Taylor and Francis, New York 2006. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/2\">",
"      Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2009; 123:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/3\">",
"      Brooks SM, Weiss MA, Bernstein IL. Reactive airways dysfunction syndrome (RADS). Persistent asthma syndrome after high level irritant exposures. Chest 1985; 88:376.",
"     </a>",
"    </li>",
"    <li>",
"     Gautrin, D, Bernstein, et al. Reactive Airways Dysfunction Syndrome and Irritant-Induced Asthma. In: Asthma in the workplace, 3rd ed, Bernstein, IL, Chan-Yeung, M, Malo, IL, Bernstein, DI (Eds), Taylor and Francis, New York 2006. p.579.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/5\">",
"      Blanc PD, Toren K. How much adult asthma can be attributed to occupational factors? Am J Med 1999; 107:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/6\">",
"      Maestrelli P, Boschetto P, Fabbri LM, Mapp CE. Mechanisms of occupational asthma. J Allergy Clin Immunol 2009; 123:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/7\">",
"      Le Moual N, Bakke P, Orlowski E, et al. Performance of population specific job exposure matrices (JEMs): European collaborative analyses on occupational risk factors for chronic obstructive pulmonary disease with job exposure matrices (ECOJEM). Occup Environ Med 2000; 57:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/8\">",
"      Malo JL, Ghezzo H, L'Archev&ecirc;que J, et al. Is the clinical history a satisfactory means of diagnosing occupational asthma? Am Rev Respir Dis 1991; 143:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/9\">",
"      Baur X, Huber H, Degens PO, et al. Relation between occupational asthma case history, bronchial methacholine challenge, and specific challenge test in patients with suspected occupational asthma. Am J Ind Med 1998; 33:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/10\">",
"      Vandenplas O, Binard-Van Cangh F, Brumagne A, et al. Occupational asthma in symptomatic workers exposed to natural rubber latex: evaluation of diagnostic procedures. J Allergy Clin Immunol 2001; 107:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/11\">",
"      Quinlan PJ, Earnest G, Eisner MD, et al. Performance of self-reported occupational exposure compared to a job-exposure matrix approach in asthma and chronic rhinitis. Occup Environ Med 2009; 66:154.",
"     </a>",
"    </li>",
"    <li>",
"     Wagner, GR, Henneberger, PK. Asthma exacerbated at work. In: Asthma in the workplace, 3rd ed, Bernstein, IL, Chan-Yeung, M, Malo, IL, Bernstein, DI (Eds), Taylor and Francis, New York 2006. p.631.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/13\">",
"      Malo JL. Future advances in work-related asthma and the impact on occupational health. Occup Med (Lond) 2005; 55:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/14\">",
"      Zock JP, Kogevinas M, Sunyer J, et al. Asthma characteristics in cleaning workers, workers in other risk jobs and office workers. Eur Respir J 2002; 20:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/15\">",
"      Malo JL, Ghezzo H, D'Aquino C, et al. Natural history of occupational asthma: relevance of type of agent and other factors in the rate of development of symptoms in affected subjects. J Allergy Clin Immunol 1992; 90:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/16\">",
"      Gautrin D, Ghezzo H, Infante-Rivard C, Malo JL. Natural history of sensitization, symptoms and occupational diseases in apprentices exposed to laboratory animals. Eur Respir J 2001; 17:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/17\">",
"      Slovak AJ, Hill RN. Does atopy have any predictive value for laboratory animal allergy? A comparison of different concepts of atopy. Br J Ind Med 1987; 44:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/18\">",
"      Malo JL, Lemi&egrave;re C, Desjardins A, Cartier A. Prevalence and intensity of rhinoconjunctivitis in subjects with occupational asthma. Eur Respir J 1997; 10:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/19\">",
"      Siracusa A, Desrosiers M, Marabini A. Epidemiology of occupational rhinitis: prevalence, aetiology and determinants. Clin Exp Allergy 2000; 30:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/20\">",
"      Castano R, Gautrin D, Th&eacute;riault G, et al. Occupational rhinitis in workers investigated for occupational asthma. Thorax 2009; 64:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/21\">",
"      Vandenplas O, Ghezzo H, Munoz X, et al. What are the questionnaire items most useful in identifying subjects with occupational asthma? Eur Respir J 2005; 26:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/22\">",
"      Eifan AO, Derman O, Kanbur N, et al. Occupational asthma in apprentice adolescent car painters. Pediatr Allergy Immunol 2005; 16:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/23\">",
"      Sastre J, Carnes J, Garc&iacute;a del Potro M, et al. Occupational asthma caused by triglycidyl isocyanurate. Int Arch Occup Environ Health 2011; 84:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/24\">",
"      Redlich CA. Skin exposure and asthma: is there a connection? Proc Am Thorac Soc 2010; 7:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/25\">",
"      Bello D, Herrick CA, Smith TJ, et al. Skin exposure to isocyanates: reasons for concern. Environ Health Perspect 2007; 115:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/26\">",
"      Redlich CA, Herrick CA. Lung/skin connections in occupational lung disease. Curr Opin Allergy Clin Immunol 2008; 8:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/27\">",
"      Kusaka Y. [Asthma due to hard alloy dusts--a case of allergic bronchial asthma and contact dermatitis due to metallic cobalt]. Nihon Kyobu Shikkan Gakkai Zasshi 1983; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/28\">",
"      Lynde CB, Obadia M, Liss GM, et al. Cutaneous and respiratory symptoms among professional cleaners. Occup Med (Lond) 2009; 59:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/29\">",
"      Bousquet J, Flahault A, Vandenplas O, et al. Natural rubber latex allergy among health care workers: a systematic review of the evidence. J Allergy Clin Immunol 2006; 118:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/30\">",
"      Hoy RF, Ribeiro M, Anderson J, Tarlo SM. Work-associated irritable larynx syndrome. Occup Med (Lond) 2010; 60:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/31\">",
"      Tonini S, Dellabianca A, Costa C, et al. Irritant vocal cord dysfunction and occupational bronchial asthma: differential diagnosis in a health care worker. Int J Occup Med Environ Health 2009; 22:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/32\">",
"      Thomas M, McKinley RK, Freeman E, Foy C. Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. BMJ 2001; 322:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/33\">",
"      Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/34\">",
"      Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/35\">",
"      Chan-Yeung M, Malo JL. Occupational asthma. N Engl J Med 1995; 333:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/36\">",
"      Burge PS, O'Brien IM, Harries MG. Peak flow rate records in the diagnosis of occupational asthma due to isocyanates. Thorax 1979; 34:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/37\">",
"      Moscato G, Godnic-Cvar J, Maestrelli P. Statement on self-monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol 1995; 96:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/38\">",
"      Park D, Moore VC, Burge CB, et al. Serial PEF measurement is superior to cross-shift change in diagnosing occupational asthma. Eur Respir J 2009; 34:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/39\">",
"      Moore VC, Jaakkola MS, Burge CB, et al. Do long periods off work in peak expiratory flow monitoring improve the sensitivity of occupational asthma diagnosis? Occup Environ Med 2010; 67:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/40\">",
"      Gannon PF, Newton DT, Belcher J, et al. Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma. Thorax 1996; 51:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/41\">",
"      Fishwick D, Barraclough R, Pickering T, et al. Comparison of various airflow measurements in symptomatic textile workers. Occup Med (Lond) 2010; 60:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/42\">",
"      Townsend MC. ACOEM position statement. Spirometry in the occupational setting. American College of Occupational and Environmental Medicine. J Occup Environ Med 2000; 42:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/43\">",
"      Burge PS. Occupational asthma due to soft soldering fluxes containing colophony (rosin, pine resin). Eur J Respir Dis Suppl 1982; 123:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/44\">",
"      Bardy JD, Malo JL, S&eacute;guin P, et al. Occupational asthma and IgE sensitization in a pharmaceutical company processing psyllium. Am Rev Respir Dis 1987; 135:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/45\">",
"      Nicholson PJ, Cullinan P, Taylor AJ, et al. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 2005; 62:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/46\">",
"      Malo JL. Utilization of pulmonary function measurements in the assessment of occupational asthma. Curr Opin Allergy Clin Immunol 2002; 2:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/47\">",
"      Mapp CE, Dal Vecchio L, Boschetto P, et al. Toluene diisocyanate-induced asthma without airway hyperresponsiveness. Eur J Respir Dis 1986; 68:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/48\">",
"      Sastre J, Fern&aacute;ndez-Nieto M, Novalbos A, et al. Need for monitoring nonspecific bronchial hyperresponsiveness before and after isocyanate inhalation challenge. Chest 2003; 123:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/49\">",
"      Quirce S. Eosinophilic bronchitis in the workplace. Curr Opin Allergy Clin Immunol 2004; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/50\">",
"      Vandenplas O, Delwiche JP, Jamart J, Van de Weyer R. Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges. Thorax 1996; 51:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/51\">",
"      Lemi&egrave;re C, Chaboillez S, Malo JL, Cartier A. Changes in sputum cell counts after exposure to occupational agents: what do they mean? J Allergy Clin Immunol 2001; 107:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/52\">",
"      Girard F, Chaboillez S, Cartier A, et al. An effective strategy for diagnosing occupational asthma: use of induced sputum. Am J Respir Crit Care Med 2004; 170:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/53\">",
"      Anees W, Huggins V, Pavord ID, et al. Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants. Thorax 2002; 57:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/54\">",
"      Lemi&egrave;re C, Romeo P, Chaboillez S, et al. Airway inflammation and functional changes after exposure to different concentrations of isocyanates. J Allergy Clin Immunol 2002; 110:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/55\">",
"      Chan-Yeung M, Obata H, Dittrick M, et al. Airway inflammation, exhaled nitric oxide, and severity of asthma in patients with western red cedar asthma. Am J Respir Crit Care Med 1999; 159:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/56\">",
"      Obata H, Dittrick M, Chan H, Chan-Yeung M. Sputum eosinophils and exhaled nitric oxide during late asthmatic reaction in patients with western red cedar asthma. Eur Respir J 1999; 13:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/57\">",
"      Lemi&egrave;re C, D'Alpaos V, Chaboillez S, et al. Investigation of occupational asthma: sputum cell counts or exhaled nitric oxide? Chest 2010; 137:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/58\">",
"      Tossa P, Paris C, Zmirou-Navier D, et al. Increase in exhaled nitric oxide is associated with bronchial hyperresponsiveness among apprentices. Am J Respir Crit Care Med 2010; 182:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/59\">",
"      Lemi&egrave;re C, Efthimiadis A, Hargreave FE. Occupational eosinophilic bronchitis without asthma: an unknown occupational airway disease. J Allergy Clin Immunol 1997; 100:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/60\">",
"      Quirce S, Fern&aacute;ndez-Nieto M, de Miguel J, Sastre J. Chronic cough due to latex-induced eosinophilic bronchitis. J Allergy Clin Immunol 2001; 108:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/61\">",
"      Rioux JP, Malo JL, L'Archev&ecirc;que J, et al. Workplace-specific challenges as a contribution to the diagnosis of occupational asthma. Eur Respir J 2008; 32:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36089/abstract/62\">",
"      Vandenplas O, Malo JL. Inhalation challenges with agents causing occupational asthma. Eur Respir J 1997; 10:2612.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 550 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36089=[""].join("\n");
var outline_f35_15_36089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OCCUPATIONAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H866399778\">",
"      Time course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H866399597\">",
"      Atopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5063656\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5064106\">",
"      Pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5064099\">",
"      Extrapulmonary symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86045157\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344157802\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344158038\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Confirmation of asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5738461\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Establishing occupational relationship",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344157636\">",
"      - Peak expiratory flow rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nonspecific bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H866400045\">",
"      - Skin and immunologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H866400052\">",
"      - Airway inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Specific bronchoprovocation challenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/550|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?2/63/3071\" title=\"algorithm 1\">",
"      Natural hx occupational asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?23/14/23790\" title=\"algorithm 2\">",
"      Algorithm for Diagnosis of OA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/550|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/53/28508\" title=\"table 1\">",
"      Causes of occupational asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11943?source=related_link\">",
"      Clinical features and diagnosis of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34087?source=related_link\">",
"      Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7416?source=related_link\">",
"      Exhaled nitric oxide analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28629?source=related_link\">",
"      Nylon flock worker's lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14489?source=related_link\">",
"      Occupational asthma: Management, prognosis, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=related_link\">",
"      Occupational asthma: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/13/14553?source=related_link\">",
"      Overview of occupational and environmental health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=related_link\">",
"      Reactive airways dysfunction syndrome and irritant-induced asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/16/27913?source=related_link\">",
"      Treatment of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36090="Overview of nail disorders";
var content_f35_15_36090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of nail disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36090/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36090/contributors\">",
"     Phoebe Rich, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36090/contributors\">",
"     Julie A Jefferson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36090/contributors\">",
"     Erik Stratman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/15/36090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/15/36090/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/15/36090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H176463636\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human nail shields the distal digit from harm, assists in the picking-up of small objects, improves fine touch, and enhances the aesthetic appearance of the hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/1\">",
"     1",
"    </a>",
"    ]. Aesthetically displeasing nails and nail-associated symptoms such as pain or throbbing are common factors that contribute to a patient&rsquo;s decision to seek medical attention.",
"   </p>",
"   <p>",
"    This topic will discuss the clinical features, diagnosis, and treatment of common acquired nail disorders. Nail patella syndrome, pachyonychia congenita, nail surgery, and nail biopsy techniques are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1973?source=see_link\">",
"       \"Nail-patella syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H3247114#H3247114\">",
"       \"The genodermatoses\", section on 'Pachyonychia congenita'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12758?source=see_link\">",
"       \"Nail surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/51/38713?source=see_link\">",
"       \"Principles and overview of nail surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/0/36869?source=see_link\">",
"       \"Nail biopsy: Indications and techniques\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463643\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY OF THE NAIL UNIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nail unit is composed of the nail matrix, the nail bed, the proximal and lateral nail folds, and the hyponychium (",
"    <a class=\"graphic graphic_picture graphicRef85578 \" href=\"mobipreview.htm?35/18/36132\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef85616 \" href=\"mobipreview.htm?42/11/43187\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nail matrix is the germinative epithelium from which nail matrix keratinocytes differentiate to ultimately form the nail plate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Most of the nail matrix is hidden beneath the proximal nail fold, but the distal third is sometimes visible through the proximal portion of the nail plate as a half-moon shaped structure called the lunula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Maturation and differentiation of the nail matrix occurs along a diagonal axis oriented distally (",
"    <a class=\"graphic graphic_figure graphicRef85617 \" href=\"mobipreview.htm?39/48/40706\">",
"     figure 2",
"    </a>",
"    ). Thus, the keratinization of the distal matrix cells forms the ventral portion of the nail plate whereas the keratinization of the proximal matrix cells forms the dorsal portion of the nail plate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Nail plate abnormalities typically result from pathological processes involving the nail matrix or space-occupying lesions involving the overlying nail fold.",
"   </p>",
"   <p>",
"    On average, fingernail regrowth takes approximately 6 months and toenail regrowth about 12 months and up to 18 months for the great toenail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/6\">",
"     6",
"    </a>",
"    ]. Nail growth slows with advancing age and vascular disease and can be partially or completely interrupted by systemic illness, trauma, or medications (eg, antimitotic drugs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nail bed dermis lies directly beneath the nail plate and is believed to contribute some epithelial cells to the ventral surface of the nail, allowing the nail to grow continuously while adhering to the nail bed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2\">",
"     2",
"    </a>",
"    ]. For this reason, nail bed surgery may be complicated by mild onycholysis and rarely by permanent nail dystrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H429649\">",
"     'Onycholysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The dermoepithelial interface of the nail bed is composed of longitudinal rete ridges and papillary body ridges. Each papillary body ridge contains three to five longitudinally-oriented capillaries, explaining the longitudinal orientation of splinter hemorrhages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H429742\">",
"     'Splinter hemorrhages'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The proximal and lateral nail folds are collectively known as the paronychium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The nail folds serve to protect the nail plate and direct nail plate growth in the correct orientation. The hyponychium, located at the distal free edge of the nail plate just proximal to the distal groove, is contiguous with the volar skin. The hyponychium functions to seal and protect the distal nail unit from the environment. Disruption of the hyponychium may result in onycholysis and allow the penetration of pathogens that are unable to digest keratin. The paronychium plus the hyponychium and nail bed is called the perionychium.",
"   </p>",
"   <p>",
"    The surgical anatomy and blood and nerve supply of the nail apparatus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/51/38713?source=see_link&amp;anchor=H120459084#H120459084\">",
"     \"Principles and overview of nail surgery\", section on 'Surgical anatomy of the nail unit'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39940124\">",
"    <span class=\"h1\">",
"     NAIL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39940132\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history in a patient with a complaint of nail problems include the time of onset of the disease, occupation, hobbies, topical substance exposure, medical history, medication history, and family history of nail disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Some clinicians ask their patients to complete a detailed nail questionnaire before the visit (",
"    <a class=\"graphic graphic_table graphicRef85548 \" href=\"mobipreview.htm?1/10/1197\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H176463799\">",
"     'Skin diseases with nail involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients should be asked to bring all nail care products, including cosmetics and instruments, to the appointment. Nail polish, lacquer, or other topical substances should be removed before the appointment to allow the examination of all nails.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39940139\">",
"    <span class=\"h2\">",
"     Nail examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;All nails should be examined under adequate lighting without glare and with magnification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Natural sunlight is preferred over artificial light. Transillumination of the distal phalanx by using a penlight may help in localizing an abnormality such as a myxoid cyst. To detect subtle changes of the nail plate surface, alcohol or acetone can be used to cleanse the surface, remove any adherent substances, and reduce glare.",
"   </p>",
"   <p>",
"    Digits should be relaxed and not pressed against a surface during the examination since any alteration in the hemodynamics of the nail bed can change the nail appearance. Each component of the nail apparatus, including the nail plate, nail bed, proximal and lateral nail folds, and hyponychium, should be evaluated for any abnormalities.",
"   </p>",
"   <p>",
"    The nail plate is assessed for discoloration, onycholysis, and changes in thickness and surface texture, including pitting, ridging, longitudinal and transverse grooving. (See",
"    <a class=\"local\" href=\"#H565492\">",
"     'Signs of nail disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The nail bed, nail folds, and hyponychium should be assessed for discoloration, erythema, growths, scale, cuticle attachment, and vascular abnormalities. If a subtle change in pigmentation is found, squeezing the tip of the digit may be helpful in identifying vascular lesions, which become less visible with the application of pressure.",
"   </p>",
"   <p>",
"    The pattern of nail involvement must be identified. In cases where only one or a few nails are affected, infection, trauma, tumor, or circulation disturbances are possible etiologic factors. However, dermatoses such as lichen planus or psoriasis may affect only one nail.",
"   </p>",
"   <p>",
"    The skin should also be examined for any concurrent findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Appropriate referral is indicated for patients with nail signs associated with systemic diseases. (See",
"    <a class=\"local\" href=\"#H176463829\">",
"     'Nail signs of systemic diseases'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565492\">",
"    <span class=\"h1\">",
"     SIGNS OF NAIL DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3161596\">",
"    <span class=\"h2\">",
"     Transverse grooves (Beau lines and onychomadesis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beau lines result from a temporary arrest of proximal nail matrix proliferation and appear as transverse grooves that move distally with nail growth (",
"    <a class=\"graphic graphic_picture graphicRef85706 graphicRef78502 \" href=\"mobipreview.htm?23/49/24343\">",
"     picture 2A-B",
"    </a>",
"    ). The detachment of the nail plate from the proximal nail fold by a whole-thickness sulcus is called onychomadesis and results from a more severe or prolonged insult to the nail matrix (",
"    <a class=\"graphic graphic_picture graphicRef62607 graphicRef85705 \" href=\"mobipreview.htm?26/54/27495\">",
"     picture 3A-B",
"    </a>",
"    ). The time of the insult leading to transverse grooving can be dated by measuring the distance of the groove from the proximal nail fold (approximately one month for every mm from the proximal nailfold).",
"   </p>",
"   <p>",
"    Causes of transverse grooving and onychomadesis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Local trauma (eg, manicure, onychotillomania [habit tic deformity], ill fitting footwear)",
"     </li>",
"     <li>",
"      Local cutaneous disease (eg, dermatitis, paronychia)",
"     </li>",
"     <li>",
"      Drugs (eg, retinoids, chemotherapy agents)",
"     </li>",
"     <li>",
"      Viral infections (eg, hand, foot, and mouth disease) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Hand, foot, and mouth syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pemphigus",
"     </li>",
"     <li>",
"      Kawasaki disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link&amp;anchor=H7#H7\">",
"       \"Kawasaki disease: Clinical features and diagnosis\", section on 'Extremity changes'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare idiopathic or familial cases of onychomadesis have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565532\">",
"    <span class=\"h2\">",
"     Longitudinal grooves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal compression of the nail matrix from tumors located in the proximal nail fold or nail bed may produce a longitudinal groove (",
"    <a class=\"graphic graphic_picture graphicRef51899 \" href=\"mobipreview.htm?43/34/44578\">",
"     picture 29D",
"    </a>",
"    ). Median nail dystrophy, also called median canaliform dystrophy of Heller, is a distinctive form of longitudinal groove characterized by a paramedian canal or split in the nail plate of one or more nails (",
"    <a class=\"graphic graphic_picture graphicRef85707 \" href=\"mobipreview.htm?42/58/43940\">",
"     picture 2C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/15\">",
"     15",
"    </a>",
"    ]. Small cracks or fissures that extend laterally from the central canal or split toward the nail edge give the appearance of an inverted fir tree. The condition is usually symmetric and most often affects the thumbs. The condition results from a temporary defect of matrix function of unknown etiology. Trauma, including habitual nail picking, has been implicated as a causative factor in some cases.",
"   </p>",
"   <p>",
"    Longitudinal grooves must be distinguished from physiological furrows and ridges, which are accentuated in lichen planus, rheumatoid arthritis, peripheral vascular disease, older age, and Darier disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23576022\">",
"    <span class=\"h2\">",
"     Onychorrhexis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onychorrhexis occurs when superficial grooves in the nail plate lead to a distal split (",
"    <a class=\"graphic graphic_picture graphicRef85708 \" href=\"mobipreview.htm?39/8/40067\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3161608\">",
"    <span class=\"h2\">",
"     Pitting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail pitting results from focal areas of abnormal keratinization of the nail matrix that produce foci of parakeratotic cells in the dorsal nail plate as it grows beyond the cuticle (",
"    <a class=\"graphic graphic_picture graphicRef70962 graphicRef73527 \" href=\"mobipreview.htm?28/14/28902\">",
"     picture 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3161650\">",
"    <span class=\"h2\">",
"     Trachyonychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trachyonychia is a nail plate abnormality characterized by roughness, excessive longitudinal ridging, pitting, thickening of the cuticle, and distal brittleness (",
"    <a class=\"graphic graphic_picture graphicRef64919 \" href=\"mobipreview.htm?39/48/40704\">",
"     picture 5C",
"    </a>",
"    ). Trachyonychia results from multiple foci of defective keratinization of the proximal nail matrix.",
"   </p>",
"   <p>",
"    Trachyonychia involving most or all nails is also called &ldquo;twenty nail dystrophy&rdquo; (",
"    <a class=\"graphic graphic_picture graphicRef85528 \" href=\"mobipreview.htm?17/17/17685\">",
"     picture 6",
"    </a>",
"    ). It occurs predominantly in children, may be idiopathic or associated with other skin diseases, most commonly psoriasis, lichen planus, alopecia areata, or atopic eczema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/16\">",
"     16",
"    </a>",
"    ]. Histology shows a",
"    <span class=\"nowrap\">",
"     psoriasiform/lichenoid",
"    </span>",
"    infiltrate or a spongiotic infiltrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/17\">",
"     17",
"    </a>",
"    ]. In approximately 50 percent of children, the disease resolves spontaneously over several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549321\">",
"    <span class=\"h2\">",
"     Leukonychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukonychia results from defective keratinization of the distal matrix with persistence of parakeratotic cells in the ventral nail plate. The nail has opaque white patches or striae, which often disappear before reaching the distal edge of the nail (",
"    <a class=\"graphic graphic_picture graphicRef85709 \" href=\"mobipreview.htm?19/16/19715\">",
"     picture 7",
"    </a>",
"    ). Punctate leukonychia is due to microtrauma and is typically seen in the fingernails of children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549604\">",
"    <span class=\"h2\">",
"     Longitudinal melanonychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal melanonychia is a banded brown to black pigmentation of the nail due to the presence of melanin in the nail plate. Longitudinal melanonychia may appear as a single band involving one nail or as multiple bands affecting several nails. The latter form is most commonly seen in dark-skinned individuals (",
"    <a class=\"graphic graphic_picture graphicRef85701 \" href=\"mobipreview.htm?23/6/23653\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hutchinson sign is the periungual spread of pigment into the proximal or lateral nail folds (",
"    <a class=\"graphic graphic_picture graphicRef85612 \" href=\"mobipreview.htm?14/52/15170\">",
"     picture 9",
"    </a>",
"    ). It may increase the suspicion of ungual melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H176463792\">",
"     'Melanoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hutchinson sign also may be seen in about one third of cases of nail lentigines or nevi (",
"    <a class=\"graphic graphic_picture graphicRef85613 \" href=\"mobipreview.htm?15/55/16240\">",
"     picture 10",
"    </a>",
"    ) and in other benign conditions such as Laugier-Hunziker syndrome (mucosal pigmentation), ethnic pigmentation, or the use of certain medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In these circumstances, it is referred to as pseudo-Hutchinson sign (",
"    <a class=\"graphic graphic_table graphicRef85614 \" href=\"mobipreview.htm?17/46/18155\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef85613 \" href=\"mobipreview.htm?15/55/16240\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On histologic examination, longitudinal melanonychia may result from activation or hyperplasia of nail matrix melanocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/19,23,25\">",
"     19,23,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2728225\">",
"    <span class=\"h3\">",
"     Melanocytic activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanocytic activation (also termed melanocytic stimulation) causes an increased melanic pigmentation of the nail matrix epithelium without a concurrent increase in the number of melanocytes (",
"    <a class=\"graphic graphic_picture graphicRef64603 graphicRef54197 graphicRef85702 \" href=\"mobipreview.htm?32/17/33049\">",
"     picture 11A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 70 percent of cases of longitudinal melanonychia in adults result from melanocytic activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. Physiologic (ethnic or pregnancy related), traumatic, dermatologic, systemic, or iatrogenic factors may be the underlying cause (",
"    <a class=\"graphic graphic_table graphicRef85700 graphicRef85615 \" href=\"mobipreview.htm?2/52/2894\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. Melanonychia caused by melanocyte activation often involves several nails and occurs more frequently in patients with darker skin phototypes (ethnic melanonychia) (",
"    <a class=\"graphic graphic_picture graphicRef64603 \" href=\"mobipreview.htm?27/6/27745\">",
"     picture 11A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    On dermoscopy, melanonychia due to melanocytic activation appears as a gray background with thin gray regular parallel lines. In melanocyte activation caused by chronic trauma, tiny dark red to brown spots corresponding to extravasation of blood may also be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2728232\">",
"    <span class=\"h3\">",
"     Melanocytic hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal melanonychia caused by a proliferation of melanocytes within the nail matrix or nail bed epithelium is a diagnostic challenge for the clinician and the pathologist. Differentiating a benign pigmented lesion of the nail (lentigo or nevus) from early nail melanoma may be extremely difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lentigines and nevi appear as tan to brown bands &lt;3 to 5 mm in width (",
"    <a class=\"graphic graphic_picture graphicRef85703 graphicRef85704 \" href=\"mobipreview.htm?12/63/13304\">",
"     picture 12A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/23,28\">",
"     23,28",
"    </a>",
"    ]. In about one third of cases, there is associated periungual pigmentation (pseudo-Hutchinson sign) (",
"    <a class=\"graphic graphic_picture graphicRef85613 \" href=\"mobipreview.htm?15/55/16240\">",
"     picture 10",
"    </a>",
"    ). Other conditions associated with a pseudo-Hutchinson sign include ethnic melanonychia, Laugier-Hunziker syndrome (mucosal hyperpigmentation), or congenital nevus (",
"    <a class=\"graphic graphic_table graphicRef85614 \" href=\"mobipreview.htm?17/46/18155\">",
"     table 2",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Nail lentigines are seen more often than nevi in adults, whereas nevi are the most common cause of melanonychia in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/29\">",
"     29",
"    </a>",
"    ]. Nail nevi may be congenital or acquired and most are junctional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/19,23,26,29,30\">",
"     19,23,26,29,30",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    They usually occur on the fingernails, with the thumbnail being most commonly affected.",
"   </p>",
"   <p>",
"    On dermoscopy, lentigines generally appear as homogeneous, longitudinal thin gray lines on a gray background. In contrast, nail matrix nevi appear as a band of regular lines of light brown to black color on a brown background [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On histology, lentigines consist of a slight to moderate increase in the number of single matrical melanocytes without evidence of confluence (nests) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast, nests of melanocytes sometimes large and hyperchromatic are always present in nail matrix nevi.",
"   </p>",
"   <p>",
"    Malignant melanocytic hyperplasia is characterized by an increased number of atypical matrix melanocytes with large, hyperchromatic, pleomorphic nuclei, prominent nucleoli, increased mitoses, and long branching dendrites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/19\">",
"     19",
"    </a>",
"    ]. Malignant melanocytic hyperplasia manifests clinically as in situ or invasive nail melanoma (",
"    <a class=\"graphic graphic_picture graphicRef85611 \" href=\"mobipreview.htm?20/39/21106\">",
"     picture 13",
"    </a>",
"    ). The clinical and dermoscopic features of nail melanoma are discussed below. (See",
"    <a class=\"local\" href=\"#H176463792\">",
"     'Melanoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39940661\">",
"    <span class=\"h3\">",
"     When to biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical differentiation of a benign longitudinal melanonychia from early nail melanoma may be extremely difficult. Thus, a diagnostic biopsy is often necessary to rule out melanoma. The clinical features of longitudinal melanonychia that may suggest early nail melanoma and warrant a biopsy of the nail matrix are discussed below. (See",
"    <a class=\"local\" href=\"#H176463792\">",
"     'Melanoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2728344\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the frequency and modalities of follow-up for pigmented nail bands. A &lsquo;&lsquo;wait and see&rsquo;&rsquo; approach may be appropriate in adults and children when clinical and dermoscopic features indicate a low risk of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/33\">",
"     33",
"    </a>",
"    ]. Some experts recommend clinical and dermoscopic examination every six months for lesions that have subtle irregular features that do not require immediate biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/25,32\">",
"     25,32",
"    </a>",
"    ]. However, melanonychia should be totally excised when worrisome features (eg, wide band, presence of the Hutchinson sign, or irregular dermoscopic features) are noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H429302\">",
"    <span class=\"h2\">",
"     Longitudinal erythronychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal erythronychia is a pink to red longitudinal streak in the nail plate that corresponds to a band of thinned, more transparent nail plate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Longitudinal erythronychia is caused by a focal reduction of function in the distal matrix. The nail bed underlying the band is less compressed than the adjacent portions so that blood pools and the engorged tissue swells and fills the ventral groove of the nail plate.",
"   </p>",
"   <p>",
"    Splinter hemorrhages are commonly found in longitudinal erythronychia. The thinned portion of nail plate extends to the distal free margin and is easily traumatized during the daily activities resulting in splitting and v-shaped chipping. Reactive hyperkeratosis of the underlying hyponychium may also occur.",
"   </p>",
"   <p>",
"    Localized (monodactylous) longitudinal erythronychia involves one nail and may be associated with benign or malignant nail tumors, including (",
"    <a class=\"graphic graphic_picture graphicRef85710 graphicRef85607 \" href=\"mobipreview.htm?41/48/42757\">",
"     picture 14A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onychopapilloma",
"     </li>",
"     <li>",
"      Warty dyskeratoma",
"     </li>",
"     <li>",
"      Glomus tumor (see",
"      <a class=\"local\" href=\"#H176463763\">",
"       'Glomus tumor'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Squamous cell carcinoma (SCC), including SCC in situ (Bowen disease) (see",
"      <a class=\"local\" href=\"#H176463785\">",
"       'Squamous cell carcinoma'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Amelanotic melanoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longitudinal erythronychia involving multiple nails (polydactylous longitudinal erythronychia) is most often associated with lichen planus or Darier disease, but systemic amyloidosis, hemiplegia, graft versus host disease, acantholytic epidermolysis bullosa, and idiopathic cases have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/38-42\">",
"     38-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The necessity of biopsy depends upon the number of involved digits and associated conditions or symptoms. Biopsy is necessary for the diagnosis of monodactylus longitudinal erythronychia. For patients with polydactylous longitudinal erythronychia and a known associated condition, biopsy is not generally required for diagnosis. Patients with polydactylous longitudinal erythronychia without associated cutaneous or systemic symptoms are generally observed over time for development of cutaneous or systemic symptoms of associated conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy indications and techniques for longitudinal erythronychia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/51/38713?source=see_link&amp;anchor=H120459137#H120459137\">",
"     \"Principles and overview of nail surgery\", section on 'Longitudinal erythronychia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H429742\">",
"    <span class=\"h2\">",
"     Splinter hemorrhages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splinter hemorrhages appear as red to black small thin longitudinal lines under the nail plate. In general, they are more commonly located in the distal nail plate and represent rupture of the longitudinally oriented nail bed capillaries (",
"    <a class=\"graphic graphic_picture graphicRef86420 graphicRef85510 \" href=\"mobipreview.htm?14/21/14680\">",
"     picture 15A-B",
"    </a>",
"    ). Splinter hemorrhages that are due to systemic illness (eg, infective endocarditis) are often proximal in the nail, whereas those due to trauma usually are distal. However, all splinter hemorrhages grow out distally (",
"    <a class=\"graphic graphic_picture graphicRef72076 \" href=\"mobipreview.htm?15/63/16369\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H429649\">",
"    <span class=\"h2\">",
"     Onycholysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onycholysis is defined as distal or distolateral separation of the nail plate from the underlying nail bed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lateral supporting structures such as the hyponychium and lateral nail folds (",
"    <a class=\"graphic graphic_picture graphicRef85510 \" href=\"mobipreview.htm?34/39/35442\">",
"     picture 15B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The onycholytic portion of the nail plate appears white due to air beneath the nail plate.",
"   </p>",
"   <p>",
"    Onycholysis may be associated with many conditions, including trauma, wet work, psoriasis, lichen planus, medications, onychomycosis, allergic or irritant contact dermatitis, or yellow nail syndrome. For cases of chronic unexplained onycholysis subungual squamous cell carcinoma should be included in the differential diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/44\">",
"     44",
"    </a>",
"    ]. (See appropriate topics.)",
"   </p>",
"   <p>",
"    Onycholysis is a predisposing condition for secondary subungual infections from yeasts, such as",
"    <em>",
"     Candida albicans",
"    </em>",
"    , or bacteria, including",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    or",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    . If infection is suspected, cultures should be obtained and appropriate antifungal or antibacterial treatment started.",
"   </p>",
"   <p>",
"    The management of onycholysis involves the identification and treatment of the underlying condition. General nail care measures for onycholysis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Keeping nails trimmed short",
"     </li>",
"     <li>",
"      Avoiding trauma",
"     </li>",
"     <li>",
"      Avoiding contact irritants",
"     </li>",
"     <li>",
"      Keeping nails dry (avoiding wet work)",
"     </li>",
"     <li>",
"      Avoiding all nail cosmetics",
"     </li>",
"     <li>",
"      Protecting hands from cold or windy weather",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H429734\">",
"    <span class=\"h2\">",
"     Subungual hyperkeratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subungual hyperkeratosis is due to an abnormal keratinization of the distal nail bed and hyponychium with accumulation of scales under the distal nail plate (",
"    <a class=\"graphic graphic_picture graphicRef53509 \" href=\"mobipreview.htm?28/29/29138\">",
"     picture 15D",
"    </a>",
"    ). The most common causes include psoriasis, onychomycosis, trauma, and eczema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463680\">",
"    <span class=\"h1\">",
"     INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463698\">",
"    <span class=\"h2\">",
"     Fungal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onychomycosis, a fungal infection of the nail unit, is characterized by nail discoloration, thickening, and deformity (",
"    <a class=\"graphic graphic_picture graphicRef85579 graphicRef72013 graphicRef81063 graphicRef74473 graphicRef61687 \" href=\"mobipreview.htm?39/20/40266\">",
"     picture 17A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/45\">",
"     45",
"    </a>",
"    ]. The clinical presentation, diagnosis, and treatment of onychomycosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=see_link\">",
"     \"Onychomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463705\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57682911\">",
"    <span class=\"h3\">",
"     Acute paronychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute paronychia is the most common infection of the hand and typically results from local injuries to the nail fold (",
"    <a class=\"graphic graphic_picture graphicRef70107 graphicRef55415 \" href=\"mobipreview.htm?30/26/31143\">",
"     picture 18A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/46\">",
"     46",
"    </a>",
"    ]. It may also occur as a complication of chronic paronychia. Most acute nail unit infections are caused by",
"    <em>",
"     S. aureus",
"    </em>",
"    . Other bacteria, including",
"    <em>",
"     Streptococcus",
"    </em>",
"    or",
"    <em>",
"     P.",
"    </em>",
"    <em>",
"     aeruginosa",
"    </em>",
"    , may cause acute paronychia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37846?source=see_link\">",
"     \"Paronychia and ingrown toenails\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57682918\">",
"    <span class=\"h3\">",
"     Blistering distal dactylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blistering distal dactylitis is a localized infection involving the volar pad of the distal phalanx of the digits. It occurs in children and adults. Tense, nontender oval bullae filled with thin, seropurulent fluid usually lie over the anterior fat pad and may extend dorsally to involve the proximal or lateral nail fold (",
"    <a class=\"graphic graphic_picture graphicRef85580 graphicRef85581 graphicRef85582 \" href=\"mobipreview.htm?34/62/35817\">",
"     picture 19A-C",
"    </a>",
"    ). Cultures from the blister fluid most commonly grow group A beta-hemolytic",
"    <em>",
"     Streptococcus",
"    </em>",
"    and less often",
"    <em>",
"     S. aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57682925\">",
"    <span class=\"h3\">",
"     Felon (pulp space infection)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Felon is an acute infection of the fingertip pulp space usually involving the thumb and index finger (",
"    <a class=\"graphic graphic_picture graphicRef55298 \" href=\"mobipreview.htm?9/22/9581\">",
"     picture 20",
"    </a>",
"    ). Abscess forms in the small compartments of the fingertip pulp separated by vertical fibrous septa (",
"    <a class=\"graphic graphic_figure graphicRef69094 \" href=\"mobipreview.htm?25/36/26191\">",
"     figure 3",
"    </a>",
"    ). Penetrating trauma is the most common cause of felon but it can also be a complication of untreated paronychia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27993?source=see_link&amp;anchor=H27991150#H27991150\">",
"     \"Overview of hand infections\", section on 'Pulp space infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57682932\">",
"    <span class=\"h3\">",
"     Green nail syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    , a water-borne bacterium, may secondarily infect injured or onycholytic nails [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/49\">",
"     49",
"    </a>",
"    ]. The infection is characterized by a blue-greenish color of the nail plate due to the deposition of pyocyanin, a blue-green pigment produced by this bacterium (",
"    <a class=\"graphic graphic_picture graphicRef85584 \" href=\"mobipreview.htm?12/50/13091\">",
"     picture 21",
"    </a>",
"    ). The pyocyanin pigmentation can persist for months despite adequate treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43142?source=see_link&amp;anchor=H15#H15\">",
"     \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\", section on 'Green nail syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10917221\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10917231\">",
"    <span class=\"h3\">",
"     Warts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papilloma virus infection is the most common viral infection of the nail. Warts usually occur in the nail fold and, less frequently, in the nail bed (",
"    <a class=\"graphic graphic_picture graphicRef72268 \" href=\"mobipreview.htm?26/51/27454\">",
"     picture 22",
"    </a>",
"    ). Warts involving the proximal nail fold result in longitudinal ridging and nail plate dystrophy. Nail bed warts may cause onycholysis. Periungual and subungual warts are especially resistant to treatment, and overzealous treatment in the area of the nail matrix can cause permanent nail dystrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26249?source=see_link\">",
"     \"Cutaneous warts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10917254\">",
"    <span class=\"h3\">",
"     Herpetic whitlow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpetic whitlow is a herpes simplex virus (HSV) infection of the hand that involves the skin or the periungual area of a finger (",
"    <a class=\"graphic graphic_picture graphicRef75510 \" href=\"mobipreview.htm?30/31/31231\">",
"     picture 23",
"    </a>",
"    ). The infection is acquired by direct inoculation of the virus following a minor local trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/46,50\">",
"     46,50",
"    </a>",
"    ]. Herpetic whitlow typically occurs in children who suck their finger during a primary herpetic gingivostomatitis, but is also an occupational hazard for medical and dental personnel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27993?source=see_link&amp;anchor=H27991206#H27991206\">",
"     \"Overview of hand infections\", section on 'Herpetic whitlow'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463719\">",
"    <span class=\"h1\">",
"     BENIGN TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463727\">",
"    <span class=\"h2\">",
"     Fibroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail fibromas are benign tumors of the connective tissue that most commonly originate in the nail matrix. However, they can also arise in the nail bed or in the proximal nail fold and extend to the nail plate surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. There are several types of nail fibromas, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acquired periungual fibrokeratoma",
"      </strong>",
"      &ndash; Acquired periungual fibrokeratoma is an acquired tumor presenting as a small, asymptomatic fleshy growth with a keratotic distal tip (",
"      <a class=\"graphic graphic_picture graphicRef85594 \" href=\"mobipreview.htm?4/5/4180\">",
"       picture 24C",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/54\">",
"       54",
"      </a>",
"      ]. It usually arises following local trauma.",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatofibroma",
"      </strong>",
"      &ndash; A dermatofibroma is a flesh-colored, pea-shaped growth that usually develops spontaneously (",
"      <a class=\"graphic graphic_picture graphicRef85597 graphicRef85598 \" href=\"mobipreview.htm?21/52/22344\">",
"       picture 24A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Koenen tumor (periungual fibroma)",
"      </strong>",
"      &ndash; Koenen tumors are periungual or subungual fibromas that develop in approximately 50 percent of patients with tuberous sclerosis during childhood or adolescence. Koenen tumors occur more commonly on the toenails than on the fingernails. They present as erythematous, polypoid, digitated growths, are often multiple, and may produce a longitudinal groove in the nail plate due to matrix compression (",
"      <a class=\"graphic graphic_picture graphicRef85599 \" href=\"mobipreview.htm?21/19/21813\">",
"       picture 24D",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H11#H11\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Dermatologic features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463734\">",
"    <span class=\"h2\">",
"     Onychomatricoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onychomatricoma is a rare benign fibroepithelial tumor that originates from the nail matrix. Clinical manifestations of onychomatricoma include (",
"    <a class=\"graphic graphic_picture graphicRef85600 \" href=\"mobipreview.htm?20/62/21473\">",
"     picture 25",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Yellow longitudinal bands of variable width",
"     </li>",
"     <li>",
"      Splinter hemorrhages of the proximal portion of the nail plate",
"     </li>",
"     <li>",
"      Prominent longitudinal ridging associated with woodworm-like cavities",
"     </li>",
"     <li>",
"      Increased transverse curvature of the nail plate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less frequent presentations of onychomatricoma include pincer nail deformity (",
"    <a class=\"graphic graphic_picture graphicRef85601 \" href=\"mobipreview.htm?21/29/21972\">",
"     picture 26",
"    </a>",
"    ), cutaneous horn, melanonychia, nail bleeding, or pterygium (the extension and adherence of the proximal nail fold to the nail bed secondary to scarring of the nail matrix) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/57-64\">",
"     57-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Onychomatricoma may mimic subungual fibroma, fibrokeratoma, or squamous cell carcinoma (including squamous cell carcinoma in situ [Bowen disease]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=see_link&amp;anchor=H574597#H574597\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\", section on 'SCC in situ (Bowen's disease)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nail plate avulsion in onychomatricoma reveals finger-like projections originating from a villous tumor of the nail matrix.",
"   </p>",
"   <p>",
"    The surgical removal of onychomatricoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/51/38713?source=see_link&amp;anchor=H120459144#H120459144\">",
"     \"Principles and overview of nail surgery\", section on 'Onychomatricoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463741\">",
"    <span class=\"h2\">",
"     Digital myxoid cyst or myxoid pseudocyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;A digital myxoid cyst (DMC) or myxoid pseudocyst typically presents as a translucent nodule on the dorsum of the digit between the distal interphalangeal joint and the proximal nail fold (",
"    <a class=\"graphic graphic_picture graphicRef85602 \" href=\"mobipreview.htm?13/31/13812\">",
"     picture 27A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/65\">",
"     65",
"    </a>",
"    ]. DMCs are more frequently located on the radial fingers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DMCs result from mucoid degeneration of the connective tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joint fluid leaking from an osteoarthritic distal interphalangeal joint by way of a communicating canal. Although DMC is commonly referred to as a cyst, on histologic examination the collection of mucinous fluid is not surrounded by an epithelial lining. Thus, a more appropriate term is myxoid pseudocyst.",
"   </p>",
"   <p>",
"    A DMC located distally in the proximal nail fold may exert pressure on the underlying nail matrix, resulting in a longitudinally-oriented, depressed groove in the nail plate (",
"    <a class=\"graphic graphic_picture graphicRef85603 \" href=\"mobipreview.htm?20/24/20867\">",
"     picture 27B",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H565532\">",
"     'Longitudinal grooves'",
"    </a>",
"    above). Occasionally, a DMC may discharge its mucinous content and reduce the pressure on the nail matrix, resulting in an irregular longitudinal depression in the nail plate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/65\">",
"     65",
"    </a>",
"    ]. Subungual DMC variants may present as subungual tumors associated with a red lunula, transverse nail plate overcurvature, and ingrowing nail plate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/51,66\">",
"     51,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-resolution ultrasonography or magnetic resonance imaging (MRI) may confirm the diagnosis in cases that are clinically ambiguous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/51\">",
"     51",
"    </a>",
"    ]. The communicating canal between the DMC and the distal interphalangeal joint are visible on MRI in over 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A wide range of therapies are used to treat DMCs, including digital compression, cryotherapy, sclerosant injection, or surgical excision. Spontaneous discharge of a DMC is a risk factor for septic osteoarthritis of the distal interphalangeal joint and is an indication for DMC removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/51\">",
"     51",
"    </a>",
"    ]. The surgical treatment of digital myxoid cysts is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/51/38713?source=see_link&amp;anchor=H120459151#H120459151\">",
"     \"Principles and overview of nail surgery\", section on 'Digital myxoid cyst'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463748\">",
"    <span class=\"h2\">",
"     Pyogenic granuloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pyogenic granuloma is a benign vascular tumor presenting as a rapidly-evolving sessile or polypoid nodule composed of red, friable granulation tissue that bleeds easily (",
"    <a class=\"graphic graphic_picture graphicRef85604 \" href=\"mobipreview.htm?21/42/22177\">",
"     picture 28",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/68\">",
"     68",
"    </a>",
"    ]. Pyogenic granuloma may involve the nail fold or be subungual and penetrate the nail plate. Subungual pyogenic granulomas arise from the nail matrix and produce a localized deformity of the nail plate. Local trauma or medications have been associated with the development of periungual or subungual pyogenic granuloma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29785?source=see_link\">",
"     \"Pyogenic granuloma (Lobular capillary hemangioma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463763\">",
"    <span class=\"h2\">",
"     Glomus tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomus tumor is a rare benign tumor composed of cells resembling the smooth cells of the normal glomus body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/69\">",
"     69",
"    </a>",
"    ]. It presents as a red to purple or blue lesion under the nail plate (",
"    <a class=\"graphic graphic_picture graphicRef77094 graphicRef72924 graphicRef61115 graphicRef51899 \" href=\"mobipreview.htm?34/21/35162\">",
"     picture 29A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Symptoms include paroxysmal pain, cold sensitivity, and tenderness. The diagnosis is suspected based upon clinical appearance and history of paroxysmal pain and cold sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=see_link&amp;anchor=H14616899#H14616899\">",
"     \"Overview of benign lesions of the skin\", section on 'Glomus tumor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging studies with MRI or high-variable frequency ultrasonography may be helpful for confirming the clinical suspicion and assessing the size and location of the tumor preoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. The treatment of glomus tumors is surgical. Histologic examination of the excised tumor is necessary to confirm the diagnosis. &nbsp;",
"   </p>",
"   <p>",
"    The surgical treatment of glomus tumor is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/51/38713?source=see_link&amp;anchor=H120459165#H120459165\">",
"     \"Principles and overview of nail surgery\", section on 'Glomus tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463770\">",
"    <span class=\"h2\">",
"     Subungual exostosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subungual exostosis is a benign osteocartilaginous tumor that most commonly occurs on the dorsomedial aspect of the tip of the great toe in adolescents or young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/76\">",
"     76",
"    </a>",
"    ]. In its early stage, the tumor typically presents as a firm, porcelain-white, telangiectatic nodule with an overlying collarette of scale that extends from beneath the distal nail causing reddish onycholysis. With time, the tumor becomes hyperkeratotic (",
"    <a class=\"graphic graphic_picture graphicRef85605 \" href=\"mobipreview.htm?35/8/35969\">",
"     picture 30",
"    </a>",
"    ). Pain is variable and can be absent in some patients. Plain radiographs may confirm the clinical diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/76\">",
"     76",
"    </a>",
"    ]. Treatment is surgical excision.",
"   </p>",
"   <p>",
"    The surgical treatment of subungual exostosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/51/38713?source=see_link&amp;anchor=H120459172#H120459172\">",
"     \"Principles and overview of nail surgery\", section on 'Subungual exostosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463777\">",
"    <span class=\"h1\">",
"     MALIGNANT TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463785\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma (SCC), including squamous cell carcinoma in situ (Bowen disease), is the most common malignant tumor of the nail, occurring most often within the nail bed or lateral nail grooves. Trauma, radiation exposure, and infection with human papilloma virus types 16 and 18 are predisposing factors for SCC development. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of periungual or subungual SCC are generally nonspecific, often causing prolonged delay in the diagnosis. SCC of the nail bed or lateral groove may present as hyperkeratosis, persistent onycholysis, longitudinal erythronychia, verruca, paronychia, nail plate dystrophy, or a subungual mass (",
"    <a class=\"graphic graphic_picture graphicRef85607 graphicRef85606 graphicRef85608 graphicRef85609 \" href=\"mobipreview.htm?39/19/40250\">",
"     picture 14B-E",
"    </a>",
"    ). SCC should be suspected when a verrucous or keratotic lesion of the lateral nail groove or fold is persistent or recurs after cryotherapy or other treatment for common warts.",
"   </p>",
"   <p>",
"    Keratoacanthoma, a rare clinical variant of SCC, typically presents with painful onycholysis, digital erythema and swelling, or painful paronychia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/68\">",
"     68",
"    </a>",
"    ]. Keratoacanthomas usually grow rapidly, and osteolysis of the bone is commonly observed on radiography. Patients with incontinentia pigmenti may develop multiple subungual keratoacanthomas at a young age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lesion suspicious for SCC or keratoacanthoma should be biopsied using the punch, excisional, or tangential (shave) excision techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/0/36869?source=see_link\">",
"     \"Nail biopsy: Indications and techniques\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Mohs micrographic surgery is the preferred treatment for SCC without bone involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Alternative treatments include wide surgical excision or digit amputation if the bone is involved. The recurrence rate is low after wide excision or amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463792\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma of the nail apparatus is a form of acral melanoma that arises from the nail matrix. Nail melanoma is rare. It accounts for 1 to 3 percent of melanomas occurring in white populations and 15 to 30 percent of melanomas occurring in dark-skinned populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two-thirds of cases, nail melanoma presents as a brown to black longitudinal stripe in the nail plate, known as longitudinal melanonychia (",
"    <a class=\"graphic graphic_picture graphicRef51165 graphicRef64134 \" href=\"mobipreview.htm?10/22/10597\">",
"     picture 31A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/19\">",
"     19",
"    </a>",
"    ]. In one third of cases, nail melanoma is amelanotic and presents as a nail bed mass or nail plate abnormality (",
"    <a class=\"graphic graphic_picture graphicRef85672 \" href=\"mobipreview.htm?0/63/1011\">",
"     picture 32",
"    </a>",
"    ). &nbsp;(See",
"    <a class=\"local\" href=\"#H549604\">",
"     'Longitudinal melanonychia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many patients with nail melanoma are initially misdiagnosed as having a benign condition and the diagnosis of melanoma may be delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/23\">",
"     23",
"    </a>",
"    ]. Because of the diagnostic delay, subungual melanoma has a poor prognosis with reported 5- and 10-year survival rates of 30 and 13 percent, respectively.",
"   </p>",
"   <p>",
"    Early nail melanoma may first appear as narrow longitudinal melanonychia with subtle variegation of color [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/32\">",
"     32",
"    </a>",
"    ]. Additional clinical features that may suggest early nail melanoma and warrant a biopsy of the nail matrix in patients with longitudinal melanonychia include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/25,30,83\">",
"     25,30,83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melanonychia that develops during adulthood, involves a single digit (in particular, the thumb, index finger, or great toe), and enlarges rapidly.",
"     </li>",
"     <li>",
"      Longitudinal melanonychia &gt;4 mm in width (",
"      <a class=\"graphic graphic_picture graphicRef85612 \" href=\"mobipreview.htm?14/52/15170\">",
"       picture 9",
"      </a>",
"      ) with variegated pigmentation or proximal widening (triangular shape) (",
"      <a class=\"graphic graphic_picture graphicRef51165 \" href=\"mobipreview.htm?38/19/39231\">",
"       picture 31A",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Preexisting longitudinal melanonychia that becomes darker or wider or demonstrates blurred lateral borders &nbsp;",
"     </li>",
"     <li>",
"      Longitudinal melanonychia associated with nail plate fissuring, splitting, or dystrophy (",
"      <a class=\"graphic graphic_picture graphicRef85611 \" href=\"mobipreview.htm?20/39/21106\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Melanonychia extending to the nail folds (Hutchinson sign) (",
"      <a class=\"graphic graphic_picture graphicRef64134 \" href=\"mobipreview.htm?42/33/43536\">",
"       picture 31B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H549604\">",
"       'Longitudinal melanonychia'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ABCDEF mnemonic may also be helpful in recalling clinical features that raise the suspicion of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/84\">",
"     84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       A",
"      </strong>",
"      ge of patient (range 20 to 90 years, peak fifth to seventh",
"      <sup>",
"      </sup>",
"      decade)",
"     </li>",
"     <li>",
"      <strong>",
"       B",
"      </strong>",
"      and of",
"      <strong>",
"       <span class=\"nowrap\">",
"        B",
"       </span>",
"      </strong>",
"      rown/",
"      <strong>",
"       B",
"      </strong>",
"      lack",
"      color;",
"      <strong>",
"       B",
"      </strong>",
"      readth greater than 3 mm;",
"      <strong>",
"       B",
"      </strong>",
"      order",
"      <span class=\"nowrap\">",
"       (irregular/blurred)",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       C",
"      </strong>",
"      hange in the band (rapid increase in size or growth rate)",
"     </li>",
"     <li>",
"      <strong>",
"       D",
"      </strong>",
"      igit involved (thumb &gt; hallux &gt; index finger &gt; single digit &gt; multiple digits)",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      xtension of pigment to the proximal or lateral nail fold (Hutchison&rsquo;s sign) or free edge of nail plate",
"     </li>",
"     <li>",
"      <strong>",
"       F",
"      </strong>",
"      amily history of melanoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nail plate dermoscopy may be helpful in the early diagnosis of nail melanoma. Dermoscopic features associated with nail melanoma include (",
"    <a class=\"graphic graphic_picture graphicRef85618 \" href=\"mobipreview.htm?13/60/14273\">",
"     picture 33",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/31,32,85\">",
"     31,32,85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brown background hue",
"     </li>",
"     <li>",
"      Presence of irregular longitudinal lines (in their color, spacing, thickness, and parallelism)",
"     </li>",
"     <li>",
"      Micro-Hutchinson sign (pigmentation of the cuticle seen on dermoscopy but not with the naked eye)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, histopathology is the gold standard for the diagnosis of nail apparatus melanoma. On histology, early nail melanoma is characterized by an increased number of atypical melanocytes at the dermoepidermal junction, with a predominance of single cells over nests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/30\">",
"     30",
"    </a>",
"    ]. Suprabasal scatter involving the superficial aspect of the matrix may be seen. Atypical melanocytes have large, hyperchromatic, pleomorphic nuclei, prominent nucleoli, increased mitoses, and long branching dendrites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/19\">",
"     19",
"    </a>",
"    ]. Invasive nail unit melanoma displays many of the features that are observed elsewhere on the acral skin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathologic characteristics of melanoma\", section on 'Acral lentiginous melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The techniques for performing nail matrix biopsy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/0/36869?source=see_link&amp;anchor=H190722931#H190722931\">",
"     \"Nail biopsy: Indications and techniques\", section on 'Nail matrix biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical treatment of subungual melanoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Subungual'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463799\">",
"    <span class=\"h1\">",
"     SKIN DISEASES WITH NAIL INVOLVEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463808\">",
"    <span class=\"h2\">",
"     Psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis is the most common dermatosis involving the nails [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Nail psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features that suggest nail psoriasis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nail plate pitting",
"      </strong>",
"      &ndash; Nail pitting is the most common sign of nail psoriasis. It results from focal areas of abnormal keratinization of the nail matrix that produce foci of parakeratotic cells in the dorsal nail plate as it grows beyond the cuticle. Psoriatic pits are typically irregular, deep, and randomly distributed within the nail plate (",
"      <a class=\"graphic graphic_picture graphicRef70962 \" href=\"mobipreview.htm?15/7/15474\">",
"       picture 5A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Nail bed salmon patches",
"      </strong>",
"      &ndash; Nail bed salmon patches (also termed &ldquo;oil drops&rdquo;) are irregular areas of yellow or pink discoloration in the nail bed visible through the nail plate, resulting from psoriatic inflammation of the nail bed (",
"      <a class=\"graphic graphic_picture graphicRef66374 \" href=\"mobipreview.htm?32/51/33585\">",
"       picture 15C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Onycholysis",
"      </strong>",
"      &ndash; Onycholysis results from the distal separation of the nail plate from the inflamed underlying nail bed. An erythematous border and splinter hemorrhages are often associated with onycholysis (",
"      <a class=\"graphic graphic_picture graphicRef85510 \" href=\"mobipreview.htm?34/39/35442\">",
"       picture 15B",
"      </a>",
"      ). Onycholysis and subungual hyperkeratosis may be the only manifestations of psoriasis of the toenails (",
"      <a class=\"graphic graphic_picture graphicRef53509 \" href=\"mobipreview.htm?28/29/29138\">",
"       picture 15D",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other signs of nail psoriasis include paronychia, leukonychia (white nails), erythema of the lunula, and trachyonychia (rough, lusterless nails) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H549321\">",
"     'Leukonychia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3161650\">",
"     'Trachyonychia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Psoriasis of the nail folds resembles chronic paronychia and is often precipitated by treatment with systemic retinoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mycology testing is indicated to differentiate psoriatic nail disease from onychomycosis, particularly if the disease is limited to the toenails. However, onychomycosis and nail psoriasis may coexist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H9#H9\">",
"     \"Dermatologic procedures\", section on 'Fungal culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of nail psoriasis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of psoriasis\", section on 'Nail psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75739458\">",
"    <span class=\"h2\">",
"     Parakeratosis pustulosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parakeratosis pustulosa is a nail disorder that occurs almost exclusively in children (",
"    <a class=\"graphic graphic_picture graphicRef85511 \" href=\"mobipreview.htm?41/63/42996\">",
"     picture 34",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/90\">",
"     90",
"    </a>",
"    ]. In most cases the disease is limited to one nail, usually the thumb or the index finger, and presents with distal onycholysis, fingertip desquamation, and mild subungual hyperkeratosis. Parakeratosis pustulosa begins with an acute eczematous inflammation of the periungual skin causing hyperkeratosis and thickening of the free edges of the nail. Scaling is more marked than pustulation. The course is often protracted, and recurrences are the rule. Spontaneous regression may occur after puberty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463815\">",
"    <span class=\"h2\">",
"     Lichen planus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen planus is an inflammatory condition of unknown etiology that affects the skin, mucous membranes, hair follicles, and nails.",
"   </p>",
"   <p>",
"    Approximately 10 to 25 percent of patients with lichen planus have nail involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/86,87,91,92\">",
"     86,87,91,92",
"    </a>",
"    ]. Lichen planus of the nails occurs more commonly in the adult population and typically affects several or most nails.",
"   </p>",
"   <p>",
"    The clinical features of lichen planus vary by site of involvement within the nail apparatus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Lichen planus of the nail matrix results in longitudinal ridging, nail plate thinning, longitudinal fissuring (",
"    <a class=\"graphic graphic_picture graphicRef85621 \" href=\"mobipreview.htm?4/22/4452\">",
"     picture 35A",
"    </a>",
"    ), trachyonychia (",
"    <a class=\"graphic graphic_picture graphicRef85620 \" href=\"mobipreview.htm?30/12/30915\">",
"     picture 35B",
"    </a>",
"    ), and erythema of the lunula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/86\">",
"     86",
"    </a>",
"    ]. Postinflammatory hyperpigmentation of the proximal nail fold and longitudinal melanonychia can also occur with nail matrix involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/93\">",
"     93",
"    </a>",
"    ]. Nail bed lichen planus usually occurs in conjunction with nail matrix involvement and is characterized by onycholysis with or without subungual hyperkeratosis.",
"   </p>",
"   <p>",
"    Lichen planus of the nails can be rapidly progressive. Permanent nail dystrophy in the forms of anonychia and dorsal pterygium (the extension and adherence of the proximal nail fold to the nail bed secondary to scarring of the nail matrix) (",
"    <a class=\"graphic graphic_picture graphicRef85619 \" href=\"mobipreview.htm?26/58/27560\">",
"     picture 35C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86822 \" href=\"mobipreview.htm?38/24/39297\">",
"     picture 36",
"    </a>",
"    ) may occur.",
"   </p>",
"   <p>",
"    Lichen planus is usually diagnosed by clinical examination alone, but if the diagnosis is questionable, a 3 mm punch biopsy of the nail matrix",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nail bed is usually conclusive. Histology reveals a band-like infiltrate of the nail matrix and nail bed dermis, with hyperkeratosis, hypergranulosis, and acanthosis of the nail matrix epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lichen planus of the nails is generally treated with systemic or intralesional corticosteroids. Systemic corticosteroids are preferred in cases that are rapidly progressive or involve more than three nails. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 60 mg per day) is given for four to six weeks and then tapered over the next four to six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/95\">",
"     95",
"    </a>",
"    ]. As an alternative, monthly intramuscular injections of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    may be given for three to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/86,87,96\">",
"     86,87,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intralesional corticosteroid therapy is an option when less than three nails are involved.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    acetonide diluted to 2.5 to 5.0",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    can be injected into the proximal and lateral nail folds at monthly intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/96\">",
"     96",
"    </a>",
"    ]. These injections are placed intradermally in the nail folds, from which the solution can diffuse to the underlying matrix. Injection directly into the nail matrix is uncomfortable and unnecessary. Treatment is generally continued at monthly intervals until the proximal one-half of the nail appears normal, at which time injections can be tapered.",
"   </p>",
"   <p>",
"    In patients who do not respond to treatment, systemic or topical corticosteroids should be stopped after five to six months.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    at a dose of 0.35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day may be a treatment option in recalcitrant cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of nail lichen planus with topical or systemic corticosteroids has not been evaluated in randomized trials. Their use is based upon clinical experience and limited evidence from small case series.",
"   </p>",
"   <p>",
"    In a study of 27 patients with nail lichen planus treated with intramuscular or intralesional corticosteroids who were followed for more than five years (mean follow-up 10 years), nine patients did not respond to treatment, 18 were cured, and 11 relapsed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/96\">",
"     96",
"    </a>",
"    ]. In another study, 67 patients with histologically confirmed lichen planus of the nails were treated with systemic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intralesional corticosteroids for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/94\">",
"     94",
"    </a>",
"    ]. Complete or substantial improvement was reported in 42 patients (63 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463822\">",
"    <span class=\"h2\">",
"     Alopecia areata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail involvement occurs in approximately 50 percent of children and 20 percent of adults with alopecia areata [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/97\">",
"     97",
"    </a>",
"    ]. Nail changes may not occur at the same time as hair loss and are more common in males and severe cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/86,87,97-99\">",
"     86,87,97-99",
"    </a>",
"    ]. Abnormalities may involve one or more nails and include mottled erythema of the lunula (&ldquo;spotted lunula&rdquo;), longitudinal ridging or trachyonychia (",
"    <a class=\"graphic graphic_picture graphicRef64919 \" href=\"mobipreview.htm?39/48/40704\">",
"     picture 5C",
"    </a>",
"    ), and geometric pitting (multiple, small, superficial pits regularly distributed along longitudinal and transverse lines on the nail plate) (",
"    <a class=\"graphic graphic_picture graphicRef73527 \" href=\"mobipreview.htm?16/37/16976\">",
"     picture 5B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/46/1768?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is usually made clinically but a nail matrix biopsy may be performed in questionable cases. Pathology reveals a lymphocytic infiltrate with spongiosis in the proximal nail fold, matrix, nail bed, and hyponychium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nail abnormalities are typically stable and improve spontaneously over a period of years. Topical corticosteroids or monthly intralesional injections of 2.5 to 3",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide into the proximal nail fold can be administered if spontaneous clearing of the nails does not occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343070\">",
"    <span class=\"h2\">",
"     Darier disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Darier disease, also termed keratosis follicularis, is an autosomal dominant condition characterized by greasy hyperkeratotic papules in seborrheic regions. Approximately 90 percent of patients with Darier disease have nail involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24776?source=see_link\">",
"     \"Darier disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fingernails are affected more often than toenails. Nail matrix involvement results in onychorrhexis (nail fragility), splitting, fragility, and red and white longitudinal streaks in the nail plate (",
"    <a class=\"graphic graphic_picture graphicRef81865 \" href=\"mobipreview.htm?25/36/26178\">",
"     picture 37",
"    </a>",
"    ). Nail bed involvement is characterized by subungual hyperkeratosis and V-shaped notches in the distal nail plate at the free edge. Keratotic papules may be present over the proximal nail fold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343077\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail involvement is rare in patients with sarcoidosis. Nails appear yellow and dystrophic, often with splinter hemorrhages, nail plate pitting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    crumbling, subungual hyperkeratosis, and painful paronychia (",
"    <a class=\"graphic graphic_picture graphicRef64864 \" href=\"mobipreview.htm?18/12/18626\">",
"     picture 38",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/20/19786?source=see_link&amp;anchor=H18191913#H18191913\">",
"     \"Cutaneous manifestations of sarcoidosis\", section on 'Nail sarcoidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463829\">",
"    <span class=\"h1\">",
"     NAIL SIGNS OF SYSTEMIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail abnormalities associated with systemic diseases usually involve most or all nails. Signs of temporary disturbance in nail growth such as Beau lines and onychomadesis may occur in association with high fever, viral diseases (eg, hand, foot, and mouth disease), or Kawasaki syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/9,10,102\">",
"     9,10,102",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3161596\">",
"     'Transverse grooves (Beau lines and onychomadesis)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Permanent or prolonged abnormalities of nail shape, thickness, and color associated with systemic diseases include yellow nail syndrome, digital clubbing, and half-and-half nails (apparent leukonychia) and koilonychia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463994\">",
"    <span class=\"h2\">",
"     Yellow nail syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yellow nail syndrome is an uncommon disorder characterized by the triad of pulmonary disease, lymphedema, and slow-growing, yellow nails without a cuticle or lunula (",
"    <a class=\"graphic graphic_picture graphicRef85762 \" href=\"mobipreview.htm?23/6/23649\">",
"     picture 39",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. Nails progressively thicken, become opaque and curved with loss of the lunula and cuticle. Swelling of the periungual tissue and onycholysis can occur. In most cases yellow nail syndrome is sporadic, but it may be inherited in autosomal dominant or recessive fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/106\">",
"     106",
"    </a>",
"    ]. A number of pulmonary diseases are associated with this syndrome including pleural effusion, bronchiectasis, and chronic sinusitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463837\">",
"    <span class=\"h2\">",
"     Clubbing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digital clubbing is characterized by increased distal finger tip mass and increased longitudinal and transverse nail plate curvature (",
"    <a class=\"graphic graphic_picture graphicRef85718 graphicRef80452 graphicRef61526 \" href=\"mobipreview.htm?22/10/22697\">",
"     picture 40A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/100,103,108\">",
"     100,103,108",
"    </a>",
"    ]. The Lovibond angle, the angle between the nail plate and the proximal nail fold when viewed from the side, is &gt;180 in clubbed nails and &lt;160 in normal nails (",
"    <a class=\"graphic graphic_figure graphicRef52839 \" href=\"mobipreview.htm?42/58/43951\">",
"     figure 4",
"    </a>",
"    ). Digital clubbing can be acquired or hereditary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired bilateral clubbing is the most common form. It usually begins in the thumb and index fingers and is most often associated with pulmonary or cardiovascular diseases, including bronchiectasis, emphysema, pneumonia, pulmonary lymphoma, congestive heart failure, and congenital heart disease. Less frequently, digital clubbing may occur in patients with extrathoracic disease, including inflammatory bowel disease, liver cirrhosis, and gastrointestinal neoplasms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/108\">",
"       108",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link&amp;anchor=H16#H16\">",
"       \"Approach to the adult with interstitial lung disease: Clinical evaluation\", section on 'Clubbing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link&amp;anchor=H1351752#H1351752\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Extraintestinal manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acquired unilateral or single-digit clubbing is commonly related to nearby vascular lesions such as a peripheral shunt, arteriovenous fistula, or aneurysm, but Pancoast tumors, lymphadenitis, or erythromelalgia can also cause unilateral clubbing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/100,103\">",
"       100,103",
"      </a>",
"      ]. Single nail involvement is typically traumatic but may be congenital. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/58/14250?source=see_link\">",
"       \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hereditary clubbing is considered an incomplete form of primary hypertrophic osteoarthropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/108\">",
"       108",
"      </a>",
"      ]. Primary hypertrophic osteoarthropathy is an autosomal dominant disorder that presents in otherwise healthy children with clubbing, periostosis, and skin manifestations including thickening of the skin of the face and scalp, coarsening of facial features, hyperhidrosis, and seborrhea. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"       \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176463844\">",
"    <span class=\"h2\">",
"     Half-and-half nails",
"    </span>",
"    &nbsp;&mdash;&nbsp;Half-and-half nails (also termed apparent leukonychia or Lindsay nails) are a manifestation of chronic renal insufficiency and uremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. A half-and-half nail typically exhibits a red, pink, or brown horizontal distal band that occupies 20 to 60 percent of the total length of the nail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/100,103,111\">",
"     100,103,111",
"    </a>",
"    ]. The proximal portion of a half-and-half nail usually has a dull, white ground-glass appearance due to underlying nail bed changes (",
"    <a class=\"graphic graphic_picture graphicRef85717 \" href=\"mobipreview.htm?40/18/41251\">",
"     picture 41",
"    </a>",
"    ). The nails may revert to normal following renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/112\">",
"     112",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369081736\">",
"    <span class=\"h2\">",
"     Koilonychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Koilonychia, also called spoon nail, is the upward curving of the distal nail plate that results in a spoon-shaped nail that could hold a drop of water on the surface (",
"    <a class=\"graphic graphic_picture graphicRef86418 graphicRef86419 \" href=\"mobipreview.htm?26/15/26871\">",
"     picture 42A-B",
"    </a>",
"    ). Koilonychia has been associated with iron deficiency and other systemic conditions in rare case reports; however, it is more commonly seen as an occupational change in nails and may be idiopathic. Ruling out iron deficiency anemia in someone with koilonychias is the only work-up necessary in this condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399961\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nail unit is composed of the nail matrix, nail bed, proximal and lateral nail folds, and hyponychium (",
"      <a class=\"graphic graphic_picture graphicRef85578 \" href=\"mobipreview.htm?35/18/36132\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef85616 \" href=\"mobipreview.htm?42/11/43187\">",
"       figure 1",
"      </a>",
"      ). Acquired nail disorders may involve all the components of the nail unit. They include infections, tumors, disorders associated with skin or systemic diseases, and abnormal pigmentation. (See",
"      <a class=\"local\" href=\"#H176463643\">",
"       'Anatomy and physiology of the nail unit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common signs of nail disease include transverse and longitudinal grooves (",
"      <a class=\"graphic graphic_picture graphicRef62607 graphicRef85706 graphicRef78502 graphicRef85705 graphicRef51899 graphicRef85707 \" href=\"mobipreview.htm?42/6/43114\">",
"       picture 2A-C, 3A-B, 29D",
"      </a>",
"      ), onychorrhexis (",
"      <a class=\"graphic graphic_picture graphicRef85708 \" href=\"mobipreview.htm?39/8/40067\">",
"       picture 4",
"      </a>",
"      ), pitting (",
"      <a class=\"graphic graphic_picture graphicRef70962 graphicRef73527 \" href=\"mobipreview.htm?28/14/28902\">",
"       picture 5A-B",
"      </a>",
"      ), trachyonychia (",
"      <a class=\"graphic graphic_picture graphicRef64919 \" href=\"mobipreview.htm?39/48/40704\">",
"       picture 5C",
"      </a>",
"      ), leukonychia (",
"      <a class=\"graphic graphic_picture graphicRef85709 \" href=\"mobipreview.htm?19/16/19715\">",
"       picture 7",
"      </a>",
"      ), longitudinal melanonychia (",
"      <a class=\"graphic graphic_picture graphicRef85701 \" href=\"mobipreview.htm?23/6/23653\">",
"       picture 8",
"      </a>",
"      ), longitudinal erythronychia (",
"      <a class=\"graphic graphic_picture graphicRef85710 graphicRef85607 \" href=\"mobipreview.htm?41/48/42757\">",
"       picture 14A-B",
"      </a>",
"      ), splinter hemorrhages, onycholysis (",
"      <a class=\"graphic graphic_picture graphicRef85510 \" href=\"mobipreview.htm?34/39/35442\">",
"       picture 15B",
"      </a>",
"      ), and subungual hyperkeratosis (",
"      <a class=\"graphic graphic_picture graphicRef53509 \" href=\"mobipreview.htm?28/29/29138\">",
"       picture 15D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H565492\">",
"       'Signs of nail disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Longitudinal melanonychia is a longitudinal pigmented band in the nail caused by the presence of melanin in the nail plate. Most cases of longitudinal melanonychia, including ethnic melanonychia and melanonychia associated with skin or systemic disease or drugs result from activation of nail matrix melanocytes (",
"      <a class=\"graphic graphic_picture graphicRef64603 graphicRef54197 \" href=\"mobipreview.htm?1/62/2024\">",
"       picture 11A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef85700 graphicRef85615 \" href=\"mobipreview.htm?2/52/2894\">",
"       table 3A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longitudinal melanonychia may also be the manifestation of melanocytic proliferation within the epithelium of the nail matrix. Differentiating a benign pigmented lesion of the nail lesion (lentigo or nevus) (",
"    <a class=\"graphic graphic_picture graphicRef85703 graphicRef85704 \" href=\"mobipreview.htm?12/63/13304\">",
"     picture 12A-B",
"    </a>",
"    )from early nail melanoma (",
"    <a class=\"graphic graphic_picture graphicRef85611 \" href=\"mobipreview.htm?20/39/21106\">",
"     picture 13",
"    </a>",
"    ) may be extremely difficult. Thus, a diagnostic biopsy is often necessary to rule out melanoma. (See",
"    <a class=\"local\" href=\"#H549604\">",
"     'Longitudinal melanonychia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H176463792\">",
"     'Melanoma'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H39940661\">",
"     'When to biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common nail infections include onychomycosis (",
"      <a class=\"graphic graphic_picture graphicRef85579 graphicRef72013 graphicRef81063 graphicRef74473 graphicRef61687 \" href=\"mobipreview.htm?39/20/40266\">",
"       picture 17A-E",
"      </a>",
"      ); bacterial infections, including acute paronychia (",
"      <a class=\"graphic graphic_picture graphicRef70107 graphicRef55415 \" href=\"mobipreview.htm?30/26/31143\">",
"       picture 18A-B",
"      </a>",
"      ), blistering distal dactylitis (",
"      <a class=\"graphic graphic_picture graphicRef85580 graphicRef85581 graphicRef85582 \" href=\"mobipreview.htm?34/62/35817\">",
"       picture 19A-C",
"      </a>",
"      ), pulp space infection (felon) (",
"      <a class=\"graphic graphic_picture graphicRef55298 \" href=\"mobipreview.htm?9/22/9581\">",
"       picture 20",
"      </a>",
"      ), and green nail syndrome (",
"      <a class=\"graphic graphic_picture graphicRef85584 \" href=\"mobipreview.htm?12/50/13091\">",
"       picture 21",
"      </a>",
"      ); and viral infections such as warts (",
"      <a class=\"graphic graphic_picture graphicRef72268 \" href=\"mobipreview.htm?26/51/27454\">",
"       picture 22",
"      </a>",
"      ), and herpetic whitlow (",
"      <a class=\"graphic graphic_picture graphicRef75510 \" href=\"mobipreview.htm?30/31/31231\">",
"       picture 23",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H176463680\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign nail tumors include fibromas (",
"      <a class=\"graphic graphic_picture graphicRef85594 graphicRef85597 graphicRef85598 graphicRef85599 \" href=\"mobipreview.htm?38/45/39642\">",
"       picture 24A-D",
"      </a>",
"      ), onychomatricoma (",
"      <a class=\"graphic graphic_picture graphicRef85600 \" href=\"mobipreview.htm?20/62/21473\">",
"       picture 25",
"      </a>",
"      ), digital myxoid cyst (",
"      <a class=\"graphic graphic_picture graphicRef85602 graphicRef85603 \" href=\"mobipreview.htm?35/50/36648\">",
"       picture 27A-B",
"      </a>",
"      ), pyogenic granuloma (",
"      <a class=\"graphic graphic_picture graphicRef85604 \" href=\"mobipreview.htm?21/42/22177\">",
"       picture 28",
"      </a>",
"      ), glomus tumor (",
"      <a class=\"graphic graphic_picture graphicRef77094 graphicRef72924 graphicRef61115 graphicRef51899 \" href=\"mobipreview.htm?34/21/35162\">",
"       picture 29A-D",
"      </a>",
"      ), and subungual exostosis (",
"      <a class=\"graphic graphic_picture graphicRef85605 \" href=\"mobipreview.htm?35/8/35969\">",
"       picture 30",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H176463719\">",
"       'Benign tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Squamous cell carcinoma (SCC), including squamous cell carcinoma in situ, is the most common malignant tumor of the nail. It presents with nonspecific symptoms, such as hyperkeratosis, persistent onycholysis, longitudinal erythronychia, verruca, paronychia, nail plate dystrophy, or a subungual mass (",
"      <a class=\"graphic graphic_picture graphicRef85607 graphicRef85606 graphicRef85608 graphicRef85609 \" href=\"mobipreview.htm?39/19/40250\">",
"       picture 14B-E",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H176463785\">",
"       'Squamous cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nail melanoma is a rare form of acral melanoma. In two thirds of cases, nail melanoma presents as a brown to black longitudinal stripe in the nail plate, known as longitudinal melanonychia (",
"      <a class=\"graphic graphic_picture graphicRef51165 graphicRef64134 \" href=\"mobipreview.htm?10/22/10597\">",
"       picture 31A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/15/36090/abstract/19\">",
"       19",
"      </a>",
"      ]. In one-third of cases, nail melanoma is amelanotic and presents as a nail bed mass or nail plate abnormality (",
"      <a class=\"graphic graphic_picture graphicRef85672 \" href=\"mobipreview.htm?0/63/1011\">",
"       picture 32",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H176463792\">",
"       'Melanoma'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Clinical features that may suggest early nail melanoma and warrant a biopsy of the nail matrix include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Melanonychia that develops during adulthood, involves a single digit (in particular, the thumb, index finger, or great toe), and enlarges rapidly.",
"     </li>",
"     <li>",
"      Longitudinal melanonychia &gt;6 mm in width (",
"      <a class=\"graphic graphic_picture graphicRef85612 \" href=\"mobipreview.htm?14/52/15170\">",
"       picture 9",
"      </a>",
"      ) with variegated pigmentation or proximal widening (triangular shape) (",
"      <a class=\"graphic graphic_picture graphicRef51165 \" href=\"mobipreview.htm?38/19/39231\">",
"       picture 31A",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Preexisting longitudinal melanonychia that becomes darker or wider or demonstrates blurred lateral borders",
"     </li>",
"     <li>",
"      Longitudinal melanonychia associated with nail plate fissuring, splitting, or dystrophy (",
"      <a class=\"graphic graphic_picture graphicRef85611 \" href=\"mobipreview.htm?20/39/21106\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Melanonychia extending to the nail folds (Hutchinson sign) (",
"      <a class=\"graphic graphic_picture graphicRef64134 \" href=\"mobipreview.htm?42/33/43536\">",
"       picture 31B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nails may be involved in numerous skin diseases, including psoriasis (",
"      <a class=\"graphic graphic_picture graphicRef70962 graphicRef66374 graphicRef85510 graphicRef53509 \" href=\"mobipreview.htm?29/30/30186\">",
"       picture 5A, 15B-D",
"      </a>",
"      ), parakeratosis pustulosa (",
"      <a class=\"graphic graphic_picture graphicRef85511 \" href=\"mobipreview.htm?41/63/42996\">",
"       picture 34",
"      </a>",
"      ), lichen planus (",
"      <a class=\"graphic graphic_picture graphicRef85621 graphicRef85620 graphicRef85619 \" href=\"mobipreview.htm?37/20/38218\">",
"       picture 35A-C",
"      </a>",
"      ), alopecia areata (",
"      <a class=\"graphic graphic_picture graphicRef73527 graphicRef64919 \" href=\"mobipreview.htm?32/19/33077\">",
"       picture 5B-C",
"      </a>",
"      ), Darier disease (",
"      <a class=\"graphic graphic_picture graphicRef81865 \" href=\"mobipreview.htm?25/36/26178\">",
"       picture 37",
"      </a>",
"      ), and sarcoidosis (",
"      <a class=\"graphic graphic_picture graphicRef64864 \" href=\"mobipreview.htm?18/12/18626\">",
"       picture 38",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nail abnormalities associated with systemic diseases usually involve most or all nails. Signs of temporary disturbance in nail growth such as Beau lines and onychomadesis may occur in association with high fever, viral diseases (eg, hand, foot, and mouth disease), or Kawasaki syndrome. Permanent or prolonged abnormalities of nail shape, thickness, and color associated with systemic diseases include yellow nail syndrome (",
"      <a class=\"graphic graphic_picture graphicRef85762 \" href=\"mobipreview.htm?23/6/23649\">",
"       picture 39",
"      </a>",
"      ), clubbing (",
"      <a class=\"graphic graphic_picture graphicRef85718 graphicRef80452 graphicRef61526 \" href=\"mobipreview.htm?22/10/22697\">",
"       picture 40A-C",
"      </a>",
"      ), and half-and-half nails (apparent leukonychia) (",
"      <a class=\"graphic graphic_picture graphicRef85717 \" href=\"mobipreview.htm?40/18/41251\">",
"       picture 41",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H176463829\">",
"       'Nail signs of systemic diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rich P, Scher RK. Nail anatomy and basic science. In: An Atlas of Diseases of the Nail, Parthenon Publishing, New York 2003. p.7.",
"    </li>",
"    <li>",
"     Rich P. Nail Surgery. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby, New York 2006. p.2260.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/3\">",
"      Haneke E. Surgical anatomy of the nail apparatus. Dermatol Clin 2006; 24:291.",
"     </a>",
"    </li>",
"    <li>",
"     Haneke E. Surgical anatomy of the nail apparatus. In: Nail Surgery, Richert B, Di Chiacchio N, Haneke E (Eds), Informa Healthcare, New York 2011. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/5\">",
"      De Berker D, Mawhinney B, Sviland L. Quantification of regional matrix nail production. Br J Dermatol 1996; 134:1083.",
"     </a>",
"    </li>",
"    <li>",
"     Fleckman P. Structure and function of the nail unit. In: Nails: Diagnosis, Therapy, and Surgery, Scher RK, Daniel CR III, et al (Eds), Elsevier Saunders, 2005. p.13.",
"    </li>",
"    <li>",
"     Daniel CR. An approach to initial examination of the nail. In: Nails: Diagnosis, Therapy, and Surgery, Scher RK, Daniel CR III, et al (Eds), Elsevier Saunders, 2005. p.27.",
"    </li>",
"    <li>",
"     Rich P, Scher RK. Examination of the nail and work-up of nail conditions. In: An Atlas of Diseases of the Nail, Parthenon Publishing, New York 2003. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/9\">",
"      Bracho MA, Gonz&aacute;lez-Candelas F, Valero A, et al. Enterovirus co-infections and onychomadesis after hand, foot, and mouth disease, Spain, 2008. Emerg Infect Dis 2011; 17:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/10\">",
"      Wei SH, Huang YP, Liu MC, et al. An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis 2011; 11:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/11\">",
"      Tosti A, Andr&eacute; M, Murrell DF. Nail involvement in autoimmune bullous disorders. Dermatol Clin 2011; 29:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/12\">",
"      Piraccini BM, Iorizzo M, Tosti A. Drug-induced nail abnormalities. Am J Clin Dermatol 2003; 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/13\">",
"      Hardin J, Haber RM. Idiopathic sporadic onychomadesis: case report and literature review. Arch Dermatol 2012; 148:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/14\">",
"      Mehra A, Murphy RJ, Wilson BB. Idiopathic familial onychomadesis. J Am Acad Dermatol 2000; 43:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/15\">",
"      Hoy NY, Leung AK, Metelitsa AI, Adams S. New concepts in median nail dystrophy, onychomycosis, and hand, foot, and mouth disease nail pathology. ISRN Dermatol 2012; 2012:680163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/16\">",
"      Gordon KA, Vega JM, Tosti A. Trachyonychia: a comprehensive review. Indian J Dermatol Venereol Leprol 2011; 77:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/17\">",
"      Holzberg M. Common nail disorders. Dermatol Clin 2006; 24:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/18\">",
"      Sakata S, Howard A, Tosti A, Sinclair R. Follow up of 12 patients with trachyonychia. Australas J Dermatol 2006; 47:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/19\">",
"      Haneke E, Baran R. Longitudinal melanonychia. Dermatol Surg 2001; 27:580.",
"     </a>",
"    </li>",
"    <li>",
"     Baran R, Haneke E. Tumours of the nail apparatus and adjacent tissues. In: Diseases of the Nails and their Management, 2nd ed, Baran R, Dawber RP (Eds), Blackwell, Oxford 1994. p.417.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/21\">",
"      Sladden MJ, Mortimer NJ, Osborne JE. Longitudinal melanonychia and pseudo-Hutchinson sign associated with amlodipine. Br J Dermatol 2005; 153:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/22\">",
"      Sachdeva S, Sachdeva S, Kapoor P. Laugier-hunziker syndrome: a rare cause of oral and acral pigmentation. J Cutan Aesthet Surg 2011; 4:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/23\">",
"      Andr&eacute; J, Lateur N. Pigmented nail disorders. Dermatol Clin 2006; 24:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/24\">",
"      Baran R, Kechijian P. Hutchinson's sign: a reappraisal. J Am Acad Dermatol 1996; 34:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/25\">",
"      Tosti A, Piraccini BM, de Farias DC. Dealing with melanonychia. Semin Cutan Med Surg 2009; 28:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/26\">",
"      Tosti A, Baran R, Piraccini BM, et al. Nail matrix nevi: a clinical and histopathologic study of twenty-two patients. J Am Acad Dermatol 1996; 34:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/27\">",
"      Lateur N, Andre J. Melanonychia: Diagnosis and treatment. Dermatol Ther 2002; 15:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/28\">",
"      Jellinek N. Nail matrix biopsy of longitudinal melanonychia: diagnostic algorithm including the matrix shave biopsy. J Am Acad Dermatol 2007; 56:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/29\">",
"      Goettmann-Bonvallot S, Andr&eacute; J, Belaich S. Longitudinal melanonychia in children: a clinical and histopathologic study of 40 cases. J Am Acad Dermatol 1999; 41:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/30\">",
"      Ruben BS. Pigmented lesions of the nail unit: clinical and histopathologic features. Semin Cutan Med Surg 2010; 29:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/31\">",
"      Ronger S, Touzet S, Ligeron C, et al. Dermoscopic examination of nail pigmentation. Arch Dermatol 2002; 138:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/32\">",
"      Koga H, Saida T, Uhara H. Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia. J Dermatol 2011; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/33\">",
"      Iorizzo M, Tosti A, Di Chiacchio N, et al. Nail melanoma in children: differential diagnosis and management. Dermatol Surg 2008; 34:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/34\">",
"      de Berker DA, Perrin C, Baran R. Localized longitudinal erythronychia: diagnostic significance and physical explanation. Arch Dermatol 2004; 140:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/35\">",
"      Jellinek NJ. Longitudinal erythronychia: suggestions for evaluation and management. J Am Acad Dermatol 2011; 64:167.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/36\">",
"      Baran R, Perrin C. Longitudinal erythronychia with distal subungual keratosis: onychopapilloma of the nail bed and Bowen's disease. Br J Dermatol 2000; 143:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/37\">",
"      Baran R, Perrin C. Focal subungual warty dyskeratoma. Dermatology 1997; 195:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/38\">",
"      Cohen PR. Longitudinal erythronychia: individual or multiple linear red bands of the nail plate: a review of clinical features and associated conditions. Am J Clin Dermatol 2011; 12:217.",
"     </a>",
"    </li>",
"    <li>",
"     Baran R, Dawber RPR, Richert B. Physical signs. In: Baran and Dawber&rsquo;s Diseases of the nails and their management, 3rd ed, Baran R, Dawber RPR, De Berker DAR, Haneke E, Tosti A (Eds), Blackwell Science, Malden, MA 2001. p.48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/40\">",
"      Zaias N, Ackerman AB. The nail in Darier-White disease. Arch Dermatol 1973; 107:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/41\">",
"      Siragusa M, Schepis C, Cosentino FI, et al. Nail pathology in patients with hemiplegia. Br J Dermatol 2001; 144:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/42\">",
"      Baran R, Dawber RP, Perrin C, Drape JL. Idiopathic polydactylous longitudinal erythronychia: a newly described entity. Br J Dermatol 2006; 155:219.",
"     </a>",
"    </li>",
"    <li>",
"     Daniel CR III. Simple Onycholysis. In: Nails: Diagnosis, Therapy, and Surgery, Scher RK, Daniel CR III, et al (Eds), Elsevier Saunders, 2005. p.97.",
"    </li>",
"    <li>",
"     Rich P, Scher RK. Nail signs and their definitions: non-specific nail dystrophies. In: An Atlas of Diseases of the Nail, Parthenon Publishing, New York 2003. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/45\">",
"      Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000; 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     Lawry M, Daniel CR III. Nonfungal Infections and Acute Paronychia. In: Nails: Diagnosis, Therapy, and Surgery, Scher RK, Daniel CR III, et al (Eds), Elsevier Saunders, 2005. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/47\">",
"      Scheinfeld NS. Is blistering distal dactylitis a variant of bullous impetigo? Clin Exp Dermatol 2007; 32:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/48\">",
"      Hays GC, Mullard JE. Blistering distal dactylitis: a clinically recognizable streptococcal infection. Pediatrics 1975; 56:129.",
"     </a>",
"    </li>",
"    <li>",
"     Rich P, Scher RK. Infectious causes of Nail Disorders. In: An Atlas of Diseases of the Nail, Parthenon Publishing, New York 2003. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/50\">",
"      Rubright JH, Shafritz AB. The herpetic whitlow. J Hand Surg Am 2011; 36:340.",
"     </a>",
"    </li>",
"    <li>",
"     Abimelec P, Dumontier C. Basic and Advanced Nail Surgery (Part 2: Indications and Complications). In: Nails: Diagnosis, Therapy, and Surgery, Scher RK, Daniel RC III, et al (Eds), Elsevier Saunders, 2005. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/52\">",
"      Baran R, Perrin C, Baudet J, Requena L. Clinical and histological patterns of dermatofibromas of the nail apparatus. Clin Exp Dermatol 1994; 19:31.",
"     </a>",
"    </li>",
"    <li>",
"     Rich P, Scher RK. Nail Tumors. In: An Atlas of Diseases of the Nail, Parthenon Publishing, New York 2003. p.83.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/54\">",
"      Cahn RL. Acquired periungual fibrokeratoma. A rare benign tumor previously described as the garlic-clove fibroma. Arch Dermatol 1977; 113:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/55\">",
"      Ca&ntilde;ueto J, Santos-Briz &Aacute;, Garc&iacute;a JL, et al. Onychomatricoma: genome-wide analyses of a rare nail matrix tumor. J Am Acad Dermatol 2011; 64:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/56\">",
"      Baran R, Richert B. Common nail tumors. Dermatol Clin 2006; 24:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/57\">",
"      Gaertner EM, Gordon M, Reed T. Onychomatricoma: case report of an unusual subungual tumor with literature review. J Cutan Pathol 2009; 36 Suppl 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/58\">",
"      Perrin C, Goettmann S, Baran R. Onychomatricoma: clinical and histopathologic findings in 12 cases. J Am Acad Dermatol 1998; 39:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/59\">",
"      Fayol J, Baran R, Perrin C, Labrousse F. Onychomatricoma with misleading features. Acta Derm Venereol 2000; 80:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/60\">",
"      Raison-Peyron N, Alirezai M, Meunier L, et al. Onychomatricoma: an unusual cause of nail bleeding. Clin Exp Dermatol 1998; 23:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/61\">",
"      Goettmann S, Zaraa I, Moulonguet I. Onychomatricoma with pterygium aspect: unusual clinical presentation. Acta Derm Venereol 2006; 86:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/62\">",
"      Perrin C, Baran R. Onychomatricoma with dorsal pterygium: pathogenic mechanisms in 3 cases. J Am Acad Dermatol 2008; 59:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/63\">",
"      Perrin C, Baran R, Balaguer T, et al. Onychomatricoma: new clinical and histological features. A review of 19 tumors. Am J Dermatopathol 2010; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/64\">",
"      Fraga GR, Patterson JW, McHargue CA. Onychomatricoma: report of a case and its comparison with fibrokeratoma of the nailbed. Am J Dermatopathol 2001; 23:36.",
"     </a>",
"    </li>",
"    <li>",
"     Richert B. Surgery of the distal interphalangeal joint. In: Nail Surgery, Richert B, Di Chiacchio N, Haneke E (Eds), Informa Healthcare, New York 2011. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/66\">",
"      de Berker D, Goettman S, Baran R. Subungual myxoid cysts: clinical manifestations and response to therapy. J Am Acad Dermatol 2002; 46:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/67\">",
"      Drap&eacute; JL, Idy-Peretti I, Goettmann S, et al. MR imaging of digital mucoid cysts. Radiology 1996; 200:531.",
"     </a>",
"    </li>",
"    <li>",
"     Tosti A, Richert B, Massimiliano P. Tumors of the nail apparatus. In: Nails: Diagnosis, Therapy, and Surgery, Scher RK, Daniel RC, et al (Eds), Elsevier Saunders, 2005. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/69\">",
"      Gombos Z, Zhang PJ. Glomus tumor. Arch Pathol Lab Med 2008; 132:1448.",
"     </a>",
"    </li>",
"    <li>",
"     Richert B, Haneke E, Di Chiacco N. Surgery of the nail bed. In: Nail Surgery, Richert B, Di Chiacchio N, Haneke E (Eds), Informa Healthcare, New York 2011. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/71\">",
"      Bhaskaranand K, Navadgi BC. Glomus tumour of the hand. J Hand Surg Br 2002; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/72\">",
"      Cigna E, Carlesimo B, Bistoni G, et al. The value of clinical diagnosis of digital glomus tumors. Acta Chir Plast 2008; 50:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/73\">",
"      Marchadier A, Cohen M, Legre R. [Subungual glomus tumors of the fingers: ultrasound diagnosis]. Chir Main 2006; 25:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/74\">",
"      Wortsman X, Jemec GB. Role of high-variable frequency ultrasound in preoperative diagnosis of glomus tumors: a pilot study. Am J Clin Dermatol 2009; 10:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/75\">",
"      Drap&eacute; JL, Idy-Peretti I, Goettmann S, et al. Subungual glomus tumors: evaluation with MR imaging. Radiology 1995; 195:507.",
"     </a>",
"    </li>",
"    <li>",
"     Haneke E, Di Chiacco N, Richert B. Surgery of the bony phalanx. In: Nail Surgery, Richert B, Di Chiacchio N, Haneke E (Eds), Informa Healthcare, New York 2011. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/77\">",
"      Baran R, Goettmann S. Distal digital keratoacanthoma: a report of 12 cases and a review of the literature. Br J Dermatol 1998; 139:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/78\">",
"      Montes CM, Maize JC, Guerry-Force ML. Incontinentia pigmenti with painful subungual tumors: a two-generation study. J Am Acad Dermatol 2004; 50:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/79\">",
"      de Berker DA, Dahl MG, Malcolm AJ, Lawrence CM. Micrographic surgery for subungual squamous cell carcinoma. Br J Plast Surg 1996; 49:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/80\">",
"      Young LC, Tuxen AJ, Goodman G. Mohs' micrographic surgery as treatment for squamous dysplasia of the nail unit. Australas J Dermatol 2012; 53:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/81\">",
"      Dalle S, Depape L, Phan A, et al. Squamous cell carcinoma of the nail apparatus: clinicopathological study of 35 cases. Br J Dermatol 2007; 156:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/82\">",
"      Thai KE, Young R, Sinclair RD. Nail apparatus melanoma. Australas J Dermatol 2001; 42:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/83\">",
"      Saida T, Ohshima Y. Clinical and histopathologic characteristics of early lesions of subungual malignant melanoma. Cancer 1989; 63:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/84\">",
"      Levit EK, Kagen MH, Scher RK, et al. The ABC rule for clinical detection of subungual melanoma. J Am Acad Dermatol 2000; 42:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/85\">",
"      Thomas L, Dalle S. Dermoscopy provides useful information for the management of melanonychia striata. Dermatol Ther 2007; 20:3.",
"     </a>",
"    </li>",
"    <li>",
"     Tosti A, Piraccini BM. Dermatological Diseases. In: Nails: Diagnosis, Therapy, and Surgery, Scher RK, Daniel RC, et al (Eds), Elsevier Saunders, 2005. p.105.",
"    </li>",
"    <li>",
"     Rich P, Scher RK. Nail manifestations of cutaneous disease. In: An Atlas of Diseases of the Nail, Parthenon Publishing, New York 2003. p.51.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/88\">",
"      Baran R. Retinoids and the nails. J Dermatol Treat 1990; 1:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/89\">",
"      Szepietowski JC, Salomon J. Do fungi play a role in psoriatic nails? Mycoses 2007; 50:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/90\">",
"      Richert B, Andr&eacute; J. Nail disorders in children: diagnosis and management. Am J Clin Dermatol 2011; 12:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/91\">",
"      Scher RK. Lichen planus of the nail. Dermatol Clin 1985; 3:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/92\">",
"      Tosti A, Peluso AM, Fanti PA, Piraccini BM. Nail lichen planus: clinical and pathologic study of twenty-four patients. J Am Acad Dermatol 1993; 28:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/93\">",
"      Juhlin L, Baran R. On longitudinal melanonychia after healing of lichen planus. Acta Derm Venereol 1990; 70:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/94\">",
"      Goettmann S, Zaraa I, Moulonguet I. Nail lichen planus: epidemiological, clinical, pathological, therapeutic and prognosis study of 67 cases. J Eur Acad Dermatol Venereol 2012; 26:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/95\">",
"      Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998; 134:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/96\">",
"      Piraccini BM, Saccani E, Starace M, et al. Nail lichen planus: response to treatment and long term follow-up. Eur J Dermatol 2010; 20:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/97\">",
"      Tosti A, Morelli R, Bardazzi F, Peluso AM. Prevalence of nail abnormalities in children with alopecia areata. Pediatr Dermatol 1994; 11:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/98\">",
"      Tosti A, Fanti PA, Morelli R, Bardazzi F. Trachyonychia associated with alopecia areata: a clinical and pathologic study. J Am Acad Dermatol 1991; 25:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/99\">",
"      Sharma VK, Dawn G, Muralidhar S, Kumar B. Nail changes in 1000 Indian patients with alopecia areata. J Eur Acad Dermatol Venereol 1998; 10:189.",
"     </a>",
"    </li>",
"    <li>",
"     Lawry M, Daniel CR III. Nails in Systemic Disease. In: Nails: Diagnosis, Therapy, and Surgery, Scher RK, Daniel CR III, et al (Eds), Elsevier Saunders, 2005. p.147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/101\">",
"      Santoro F, Sloan SB. Nail dystrophy and bony involvement in chronic sarcoidosis. J Am Acad Dermatol 2009; 60:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/102\">",
"      Ciastko AR. Onychomadesis and Kawasaki disease. CMAJ 2002; 166:1069.",
"     </a>",
"    </li>",
"    <li>",
"     Rich P, Scher RK. Nail Signs of systemic disease. In: An Atlas of Diseases of the Nail, Parthenon Publishing, New York 2003. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/104\">",
"      SAMMAN PD, WHITE WF. THE \"YELLOW NAIL\" SYNDROME. Br J Dermatol 1964; 76:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/105\">",
"      Maldonado F, Ryu JH. Yellow nail syndrome. Curr Opin Pulm Med 2009; 15:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/106\">",
"      Hoque SR, Mansour S, Mortimer PS. Yellow nail syndrome: not a genetic disorder? Eleven new cases and a review of the literature. Br J Dermatol 2007; 156:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/107\">",
"      Maldonado F, Tazelaar HD, Wang CW, Ryu JH. Yellow nail syndrome: analysis of 41 consecutive patients. Chest 2008; 134:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/108\">",
"      Spicknall KE, Zirwas MJ, English JC 3rd. Clubbing: an update on diagnosis, differential diagnosis, pathophysiology, and clinical relevance. J Am Acad Dermatol 2005; 52:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/109\">",
"      Onelmis H, Sener S, Sasmaz S, Ozer A. Cutaneous changes in patients with chronic renal failure on hemodialysis. Cutan Ocul Toxicol 2012; 31:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/110\">",
"      Martinez MA, Greg&oacute;rio CL, Santos VP, et al. Nail disorders in patients with chronic renal failure undergoing hemodialysis. An Bras Dermatol 2010; 85:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/111\">",
"      Lindsay PG. The half-and-half nail. Arch Intern Med 1967; 119:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/15/36090/abstract/112\">",
"      Saray Y, Se&ccedil;kin D, G&uuml;le&ccedil; AT, et al. Nail disorders in hemodialysis patients and renal transplant recipients: a case-control study. J Am Acad Dermatol 2004; 50:197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13682 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36090=[""].join("\n");
var outline_f35_15_36090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H399961\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176463636\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176463643\">",
"      ANATOMY AND PHYSIOLOGY OF THE NAIL UNIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39940124\">",
"      NAIL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39940132\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39940139\">",
"      Nail examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565492\">",
"      SIGNS OF NAIL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3161596\">",
"      Transverse grooves (Beau lines and onychomadesis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565532\">",
"      Longitudinal grooves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23576022\">",
"      Onychorrhexis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3161608\">",
"      Pitting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3161650\">",
"      Trachyonychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549321\">",
"      Leukonychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549604\">",
"      Longitudinal melanonychia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2728225\">",
"      - Melanocytic activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2728232\">",
"      - Melanocytic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39940661\">",
"      - When to biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2728344\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H429302\">",
"      Longitudinal erythronychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H429742\">",
"      Splinter hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H429649\">",
"      Onycholysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H429734\">",
"      Subungual hyperkeratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176463680\">",
"      INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463698\">",
"      Fungal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463705\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57682911\">",
"      - Acute paronychia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57682918\">",
"      - Blistering distal dactylitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57682925\">",
"      - Felon (pulp space infection)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57682932\">",
"      - Green nail syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10917221\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10917231\">",
"      - Warts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10917254\">",
"      - Herpetic whitlow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176463719\">",
"      BENIGN TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463727\">",
"      Fibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463734\">",
"      Onychomatricoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463741\">",
"      Digital myxoid cyst or myxoid pseudocyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463748\">",
"      Pyogenic granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463763\">",
"      Glomus tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463770\">",
"      Subungual exostosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176463777\">",
"      MALIGNANT TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463785\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463792\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176463799\">",
"      SKIN DISEASES WITH NAIL INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463808\">",
"      Psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75739458\">",
"      Parakeratosis pustulosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463815\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463822\">",
"      Alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343070\">",
"      Darier disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343077\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176463829\">",
"      NAIL SIGNS OF SYSTEMIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463994\">",
"      Yellow nail syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463837\">",
"      Clubbing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176463844\">",
"      Half-and-half nails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369081736\">",
"      Koilonychia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H399961\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13682|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/11/43187\" title=\"figure 1\">",
"      Nail anatomy 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/48/40706\" title=\"figure 2\">",
"      Nail growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/36/26191\" title=\"figure 3\">",
"      Felon cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/58/43951\" title=\"figure 4\">",
"      Clubbing of the fingers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13682|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/18/36132\" title=\"picture 1\">",
"      Nail anatomy 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/23/6516\" title=\"picture 2A\">",
"      Beau lines 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/10/18592\" title=\"picture 2B\">",
"      Beau line on the toe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/58/43940\" title=\"picture 2C\">",
"      Median nail dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/52/15169\" title=\"picture 3A\">",
"      Beau lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/50/17187\" title=\"picture 3B\">",
"      Onychomadesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/8/40067\" title=\"picture 4\">",
"      Onychorrhexis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/7/15474\" title=\"picture 5A\">",
"      Nail psoriasis pits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/37/16976\" title=\"picture 5B\">",
"      Nail pits aa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/48/40704\" title=\"picture 5C\">",
"      Trachyonychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/17/17685\" title=\"picture 6\">",
"      Trachyonychia - twenty nail dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/16/19715\" title=\"picture 7\">",
"      Leukonychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/6/23653\" title=\"picture 8\">",
"      Melanonychia ethnic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/52/15170\" title=\"picture 9\">",
"      Nail melanoma Hutchinson sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/55/16240\" title=\"picture 10\">",
"      Longitudinal melanonychia pseudo Hutchinson",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/6/27745\" title=\"picture 11A\">",
"      Longitudinal melanonychia - thumbs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/29/3540\" title=\"picture 11B\">",
"      Longitudinal melanonychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/7/30832\" title=\"picture 11C\">",
"      Melanonychia hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/20/17728\" title=\"picture 12A\">",
"      Lentigo nail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/42/33445\" title=\"picture 12B\">",
"      Nail nevus child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/39/21106\" title=\"picture 13\">",
"      Melanoma nail dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/59/30640\" title=\"picture 14A\">",
"      Longitudinal erythronychia melanoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/27/39344\" title=\"picture 14B\">",
"      Squamous cell carcinoma erythronychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/28/43458\" title=\"picture 14C\">",
"      Squamous cell carcinoma nail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/44/34502\" title=\"picture 14D\">",
"      Periungual Bowen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/48/40709\" title=\"picture 14E\">",
"      Periungual Bowen 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/31/30195\" title=\"picture 15A\">",
"      Splinter hemorrages 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/39/35442\" title=\"picture 15B\">",
"      Nail psoriasis onycholysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/51/33585\" title=\"picture 15C\">",
"      Nail psoriasis oil drop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/29/29138\" title=\"picture 15D\">",
"      Nail psoriasis hyperkeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/63/16369\" title=\"picture 16\">",
"      Splinter hemorrhages in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/52/31553\" title=\"picture 17A\">",
"      Subungual onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/22/14690\" title=\"picture 17B\">",
"      Distal subungual onychomycosis - toenail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/1/3089\" title=\"picture 17C\">",
"      Proximal subungual onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/24/38275\" title=\"picture 17D\">",
"      Proximal subungual onychomycosis - fingernails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/10/44195\" title=\"picture 17E\">",
"      Proximal subungual onychomycosis - toenails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/42/673\" title=\"picture 18A\">",
"      Acute paronychia 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/44/37571\" title=\"picture 18B\">",
"      Acute paronychia lateral nail fold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/9/24721\" title=\"picture 19A\">",
"      Blistering distal dactylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/50/7971\" title=\"picture 19B\">",
"      Blistering distal dactylitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/48/43777\" title=\"picture 19C\">",
"      Blistering distal dactylitis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/22/9581\" title=\"picture 20\">",
"      Felon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/50/13091\" title=\"picture 21\">",
"      Pseudomonas nail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/51/27454\" title=\"picture 22\">",
"      Periungual warts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/31/31231\" title=\"picture 23\">",
"      Herpetic whitlow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/3/30770\" title=\"picture 24A\">",
"      Subungual fibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/33/7700\" title=\"picture 24B\">",
"      Nail fibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/5/4180\" title=\"picture 24C\">",
"      Acquired ungual fibrokeratoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/19/21813\" title=\"picture 24D\">",
"      Koenen tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/62/21473\" title=\"picture 25\">",
"      Onychomatricoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/29/21972\" title=\"picture 26\">",
"      Onychomatricoma pincer nail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/31/13812\" title=\"picture 27A\">",
"      Digital myxoid cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/24/20867\" title=\"picture 27B\">",
"      Digital myxoid cyst nail plate depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/42/22177\" title=\"picture 28\">",
"      Pyogenic granuloma periungual",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/25/2449\" title=\"picture 29A\">",
"      Glomus tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/39/43636\" title=\"picture 29B\">",
"      Glomus tumor subungual 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/34/5667\" title=\"picture 29C\">",
"      Glomus tumor subungual 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/34/44578\" title=\"picture 29D\">",
"      Glomus tumor nail dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/8/35969\" title=\"picture 30\">",
"      Subungual exostosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/19/39231\" title=\"picture 31A\">",
"      Acral lentiginous melanoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/33/43536\" title=\"picture 31B\">",
"      Subungual melanoma - finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/63/1011\" title=\"picture 32\">",
"      Melanoma subungual amelanotic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/60/14273\" title=\"picture 33\">",
"      Nail melanoma dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/63/42996\" title=\"picture 34\">",
"      Parakeratosis pustulosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/22/4452\" title=\"picture 35A\">",
"      Nail lichen planus longitudinal fissuring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/12/30915\" title=\"picture 35B\">",
"      Lichen planus trachyonychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/58/27560\" title=\"picture 35C\">",
"      Lichen planus nail pterigium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/24/39297\" title=\"picture 36\">",
"      Nail lichen planus pterygium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/36/26178\" title=\"picture 37\">",
"      Darier disease - nails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/12/18626\" title=\"picture 38\">",
"      Nail sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/6/23649\" title=\"picture 39\">",
"      Yellow nail syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/31/19952\" title=\"picture 40A\">",
"      Digital clubbing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/7/19570\" title=\"picture 40B\">",
"      Hypertrophic osteoarthropathy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/40/26242\" title=\"picture 40C\">",
"      Hypertrophic osteoarthropathy 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/18/41251\" title=\"picture 41\">",
"      Half-and-half nails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/44/36546\" title=\"picture 42A\">",
"      Koilonychia 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/7/39025\" title=\"picture 42B\">",
"      Koilonychia 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13682|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/10/1197\" title=\"table 1\">",
"      Nail questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/46/18155\" title=\"table 2\">",
"      Pseudo-Hutchinson sign causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/63/13308\" title=\"table 3A\">",
"      Melanonychia drug induced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/15/13565\" title=\"table 3B\">",
"      Causes of longitudinal melanonychia 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/46/1768?source=related_link\">",
"      Clinical manifestations and diagnosis of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/20/19786?source=related_link\">",
"      Cutaneous manifestations of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26249?source=related_link\">",
"      Cutaneous warts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24776?source=related_link\">",
"      Darier disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/0/36869?source=related_link\">",
"      Nail biopsy: Indications and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12758?source=related_link\">",
"      Nail surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1973?source=related_link\">",
"      Nail-patella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=related_link\">",
"      Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27993?source=related_link\">",
"      Overview of hand infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37846?source=related_link\">",
"      Paronychia and ingrown toenails",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/51/38713?source=related_link\">",
"      Principles and overview of nail surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29785?source=related_link\">",
"      Pyogenic granuloma (Lobular capillary hemangioma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_15_36091="Causes of Q waves on the electrocardiogram";
var content_f35_15_36091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of Q waves on the electrocardiogram",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physiologic or positional factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal variant \"septal\" q waves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal variant Q waves in leads V1,V2, aVL, III, and aVF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left pneumothorax or dextrocardia: loss of lateral precordial R wave progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Myocardial injury or infiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute processes: myocardial ischemia or infarction, myocarditis, hyperkalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic processes: myocardial infarction, idiopathic cardiomyopathy, myocarditis, amyloidosis, tumor, sarcoid, scleroderma, Chagas' disease, echinococcus cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ventricular hypertrophy or enlargement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left ventricle: slow R wave progression in which there are small or absent R waves in the mid-precordial leads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right ventricle: reversed R wave progression in which there is a progressive decrease in R wave amplitude from V1 to the mid-lateral precordial leads, or slow R wave progression, particularly with chronic obstructive lung disease or acute pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertrophic cardiomyopathy - may simulate anterior, inferior, posterior, or lateral infarcts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Conduction abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left bundle branch block - slow R wave progression in which there are small or absent R waves in the mid-precordial leads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wolff-Parkinson-White patterns",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36091=[""].join("\n");
var outline_f35_15_36091=null;
var title_f35_15_36092="Frequency common birth defects";
var content_f35_15_36092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Leading categories of birth defects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Birth defects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated incidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Structural/metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heart and circulation",
"       </td>",
"       <td>",
"        1 in 115 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscles and skeleton",
"       </td>",
"       <td>",
"        1 in 130 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Club foot",
"       </td>",
"       <td>",
"        1 in 735 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cleft lip/palate",
"       </td>",
"       <td>",
"        1 in 930 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genital and urinary tract",
"       </td>",
"       <td>",
"        1 in 135 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nervous system and eye",
"       </td>",
"       <td>",
"        1 in 235 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anencephaly",
"       </td>",
"       <td>",
"        1 in 8,000 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spina bifida",
"       </td>",
"       <td>",
"        1 in 2,000 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chromosomal syndromes",
"       </td>",
"       <td>",
"        1 in 600 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Down syndrome (trisomy 21)",
"       </td>",
"       <td>",
"        1 in 900 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory tract",
"       </td>",
"       <td>",
"        1 in 900 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic disorders",
"       </td>",
"       <td>",
"        1 in 3,500 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PKU",
"       </td>",
"       <td>",
"        1 in 12,000 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Congenital infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital syphilis",
"       </td>",
"       <td>",
"        1 in 2,000 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital HIV infection",
"       </td>",
"       <td>",
"        1 in 2,700 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital rubella syndrome",
"       </td>",
"       <td>",
"        1 in 100,000 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rh disease",
"       </td>",
"       <td>",
"        1 in 1,400 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fetal alcohol syndrome",
"       </td>",
"       <td>",
"        1 in 1,000 births",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Note: all numbers are based on the best available estimates, which underestimate the incidence of many birth defects.",
"    </div>",
"    <div class=\"reference\">",
"     Unpublished review of the literature and information from various state and regional birth defects surveillance systems (California, Iowa, Metropolitan Atlanta, New York, and Texas). file://www. marchofdimes.com/aboutus/680_2164.asp Copyright &copy; 2000 March of Dimes Perinatal Data Center. Used by permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36092=[""].join("\n");
var outline_f35_15_36092=null;
var title_f35_15_36093="Reduction of proteinuria on renal survival in IgA nephropathy";
var content_f35_15_36093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Effect of reduction of proteinuria on renal survival in IgA nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 431px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Impact of reduction of proteinuria on renal survival. Patients attaining partial remission (&lt;1 g/d), regardless of peak proteinuria, had a similar favorable outcome (NS). Group 1, 1 to 2 g/d peak proteinuria; group 2, 2 to 3 g/d peak proteinuria; group 3, &gt;3 g/d peak proteinuria. p = NS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18:3177. Copyright &copy; 2007 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36093=[""].join("\n");
var outline_f35_15_36093=null;
var title_f35_15_36094="Microbiology of preseptal and orbital cellulitis";
var content_f35_15_36094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Microbiology of preseptal and orbital cellulitis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Preseptal cellulitis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Orbital cellulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Chaudhry, et al",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Botting, et al",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        McKinley, et al",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Seltz, et al",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Nageswaran, et al",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Botting, et al",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Goytia, et al",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of patients",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        227",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of patients with a positive culture (except",
"        <sup>",
"         &bull;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        53",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        11",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        29",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &Delta;",
"       </td>",
"       <td class=\"sublist1_start\">",
"        32",
"       </td>",
"       <td class=\"sublist1_start\">",
"        11",
"       </td>",
"       <td class=\"sublist1_start\">",
"        8",
"       </td>",
"       <td class=\"sublist1_start\">",
"        3",
"       </td>",
"       <td class=\"sublist1_start\">",
"        7",
"       </td>",
"       <td class=\"sublist1_start\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        MSSA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NR",
"       </td>",
"       <td class=\"sublist_other\">",
"        NR",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"       <td class=\"sublist_other\">",
"        NR",
"       </td>",
"       <td class=\"sublist_other\">",
"        NR",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        MRSA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NR",
"       </td>",
"       <td class=\"sublist_other\">",
"        NR",
"       </td>",
"       <td class=\"sublist_other\">",
"        8",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        NR",
"       </td>",
"       <td class=\"sublist_other\">",
"        NR",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha-hemolytic streptococci (including",
"        <em>",
"         S. pneumoniae",
"        </em>",
"        ) or non-hemolytic streptococci",
"       </td>",
"       <td>",
"        &Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta-hemolytic streptococci (including",
"        <em>",
"         S. pyogenes",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        &Delta;",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococcus anginosus",
"        </em>",
"        (formerly",
"        <em>",
"         S. milleri",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Rothia mucilaginosa",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Haemophilus parainfluenzae",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Klebsiella pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Moraxella catarrhalis",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Arcanobacterium",
"        </em>",
"        spp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Eikenella corrodens",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaerobes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin flora/contaminant",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        11",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        12",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible pathogen",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sites of culture",
"       </td>",
"       <td>",
"        Blood, wound, abscess",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Blood, orbital abscess, eye, sinus, epidural abscess, nose",
"       </td>",
"       <td>",
"        Blood, sinus/orbit, subdural space",
"       </td>",
"       <td>",
"        Orbital abscess, subperiostial abscess, sinus",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Blood, endoscopic sinus, subperiosteal, intraorbital",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MSSA: methicillin-susceptible",
"     <em>",
"      Staphylococcus aureus",
"     </em>",
"     ; MRSA: methicillin-resistant",
"     <em>",
"      Staphylococcus aureus",
"     </em>",
"     ; NR: not reported.",
"     <br>",
"      * Results are reported as the number of cultures that grew a given organism. Some cultures grew &gt;1 organism and some patients had &gt;1 positive culture.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Results are reported as number of positive cultures (rather than number of patients with a positive culture); some patients may have had &gt;1 positive culture.",
"       <br>",
"        &Delta;",
"        <em>",
"         Staphylococcus",
"        </em>",
"        spp and",
"        <em>",
"         Streptococcus",
"        </em>",
"        spp were recovered from 26 (72 percent) of cultures, but the authors did not report the number of positive cultures for individual species.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         In McKinley, et al",
"         <sup>",
"          [3]",
"         </sup>",
"         , coagulase-negative",
"         <em>",
"          Staphylococcus",
"         </em>",
"         spp was reported as a recovered organism, but in Seltz, et al",
"         <sup>",
"          [4]",
"         </sup>",
"         , this organism was classified as a contaminant. We have classified it as a contaminant for both studies.",
"         <br>",
"          &sect; The authors of this study classifed some (but not all) sinus/orbit cultures as possible pathogens rather than true pathogens.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Chaudhry IA, Shamsi FA, Elzaridi E, et al. Inpatient preseptal cellulitis: experience from a tertiary eye care centre. Br J Ophthalmol 2008; 92:1337.",
"       </li>",
"       <li>",
"        Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases. A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol 2008; 72:377.",
"       </li>",
"       <li>",
"        McKinley SH, Yen MT, Miller AM, Yen KG. Microbiology of pediatric orbital cellulitis. Am J Ophthalmol 2007; 144:497.",
"       </li>",
"       <li>",
"        Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566.",
"       </li>",
"       <li>",
"        Nageswaran S, Woods CR, Benjamin DK Jr, et al. Orbital cellulitis in children. Pediatr Infect Dis J 2006; 25:695.",
"       </li>",
"       <li>",
"        Goytia VK, Giannoni CM, Edwards MS. Intraorbital and intracranial extension of sinusitis: comparative morbidity. J Pediatr 2011; 158:486.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36094=[""].join("\n");
var outline_f35_15_36094=null;
var title_f35_15_36095="FAST subxiphoid tamponade";
var content_f35_15_36095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/75313/FAST_subxiphoid_tamp_movie.mp4?title=FAST+subxiphoid+tamponade\" style=\"width:480px;height:320px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Subxiphoid view of cardiac tamponade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This subxiphoid view of the heart shows a large pericardial effusion causing tamponade.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_15_36095=[""].join("\n");
var outline_f35_15_36095=null;
